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A b s t r a c t
The evaluation o f vaccines for human use requires reliable models o f infection, that are predictive of 
protective efficacy. Traditionally whole cell pertussis vaccines (Pw) have been controlled using the 
Kendrick test, which measures protection following intracerebral challenge with B o rd e te lla  p ertu ssis . 
However, this test is unsuitable for assessing the potency o f the new acellular pertussis vaccines (Pa). 
In this study, it was demonstrated that protection in a murine respiratory challenge model correlates 
with the protective efficacy o f Pa and Pw in children, but vaccine potency could not be predicted on the 
basis o f antibody responses against individual antigens. Furthermore, the murine model was shown to 
be a reliable method for the determination of consistency between different batches o f Pa and Pw. This 
study highlights the possible applications o f the murine model in the regulatory control and future 
development o f pertussis vaccines.
The murine model o f infection has been used in the elucidation o f the protective mechanisms 
induced following immunization with Pw or Pa, revealing roles for both antibody and T-cells in 
protection against B. p ertu ssis . It has been demonstrated that children still appear to be protected 
against infection, despite a rapid decline in antibody levels after vaccination. In the murine model, 
antibody levels quickly decline after immunization, but significant levels o f protection were observed 
following aerosol challenge. Recall T-cell responses detectable for prolonged periods after 
immunization, together with an anamnestic antibody response post-challenge suggest that 
immunological memory is more significant in protection, than the induction of immediate antibody 
responses in vaccine-induced protection against B. p ertu ssis .
It has been demonstrated that Thl responses and particularly the cytokine IFN-y, play a 
critical role in immunity to B. p ertu ssis . In the present study, the role o f IL-12 and IL-18 in the 
induction o f a protective Thl response to B. p ertu ss is  was examined. Lack o f IL-12 during primary 
and secondary infection effected protection only at the early stages o f infection, suggesting that IL-12 
plays an important role at the induction stage o f the immune response to B. p ertu ss is , but also suggests 
that other cytokines may be involved. IL-18 is rapidly produced in the lungs of B. p ertu ssis  infected 
IL-1 2~'~ and wild-type mice , which may compensate for the lack o f IL-12 at the later stages of 
infection.
The importance o f Thl responses and IFN-y were fiirther highlighted in this study, through the 
investigation o f the effect o f helminth infection on the outcome o f B. p ertu ssis  infection, or 
immunization with Pw. Infection with the parasite F a s c io la  h ep a tic a , was shown to suppress B. 
p ertu ssis -specific Thl responses, and delay bacterial clearance from the lungs, and was also shown to 
inhibit this Thl response after it had become established. Furthermore, it was demonstrated that 
infection with F. h ep a tic a  was capable o f downregulating the Thl response induced by systemic 
immunization with Pw, and reducing its protective efficacy. In addition, a role for IL-4 was 
demonstrated in the parasite-induced immunoregulation.
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❖  C h a p t e r  1  ❖  
G e n e r a l  In t r o d u c t io n
In t r o d u c t i o n
1 .1  In n a t e  I m m u n i t y
Protective immunity results from the interplay o f  two cardinal systems: non-specific 
innate immunity and antigen-specific adaptive immunity. Innate immunity involves 
a set o f disease-resistance mechanisms that are not specific to a particular pathogen. 
Cells o f the innate system recognize non-processed antigens, such as 
lipopolysaccharide (LPS), carbohydrates and nucleic acids expressed on pathogens, 
using a variety o f receptors (Fearon & Locksley, 1996, Palucka & Banchereau, 
1999) . This type o f immunity provides the first line o f defense after the host’ s 
exposure to the pathogen. Apart from the anatomical barriers such as the skin, and 
physiological barriers, such as temperature and pH which can restrict the growth o f 
microorganisms, other components o f innate immunity include complement, 
interferons a/p, NK cells and phagocytic cells.
Initiation o f both the classical and alternative pathways o f complement 
activation can contribute to innate immunity. A collection o f germ-line encoded 
antigen recognition molecules, known as natural antibody, is important in the 
recognition o f pathogens and activates the innate system via the classical pathway 
o f complement activation (Carroll & Prodeus, 1998). Furthermore, cell wall 
constituents o f both gram positive and gram negative bacteria, some viruses, fungal 
and yeast cell walls, and LPS are all initiators o f the alternative pathway o f 
complement activation, resulting in lysis o f cells, bacteria and viruses and 
opsonization o f antigen.
IFN-a and IFN-P play a particularly important role in the innate immune 
response to viral infection. Binding o f  IFN-a or IFN-P to the IFN-a/p receptor 
activates the synthesis o f several factors responsible for the degradation o f viral 
RNA and inhibition o f viral replication. IFN-a enhances MHC class I expression, 
resulting in increased susceptibility to cytotoxic T-lymphocytes (CTL), and plays a 
role in the activation o f macrophages (Palucka & Banchereau, 1999). The binding 
o f IFN-a and IFN-P to NK cells induces lytic activity, making them very effective in 
killing virally infected cells. The activity o f NK cells is also greatly enhanced by IL- 
12 and IL-18. Very early in infection IL-12 is produced and induces IFN-y 
production from NK cells, which contributes to phagocytic cell activation and
2
inflammation. IL-12 has also been shown to act as a growth factor for NK cells and 
enhance their cytotoxicity (Trinchieri, 1995). IL-18 also induces IFN-y production 
and enhances NK activity, activating the perforin/granzyme system (Okamura et ah, 
1998), an action which does not require endogenous IL-12 (Akira, 2000). The IL- 
18 receptor is constitutively expressed on NK cells (Hyodo et ah, 1999), and 
functional NK cells can develop in the absence o f IL-12. IL-12 and IL-18 also act 
in synergy in the development o f Thl cells, which are involved in cell-mediated 
responses necessary for clearance o f intracellular microorganisms.
Of the many components o f innate immunity perhaps the most important is 
the role played by phagocytic cells. Macrophages, neutrophils and other phagocytic 
cells are key components o f the antimicrobial immune response. Organisms attach 
to long membrane evaginations on the phagocyte, called pseudopodia. Ingestion o f 
the organism forms a phagosome which fuses with a lysosome. This fusion results 
in the release if lysosomal enzymes into the phagosome, destroying the ingested 
organism, by oxidative or non-oxidative mechanisms (Bogdan et ah, 2000).
1 .2  A d a p t i v e  I m m u n i t y
In general, most o f the microorganisms encountered by a healthy individual are 
cleared within a few days by non-specific defense mechanisms. However, if the 
pathogen eludes innate immunity, then the specific immune response o f adaptive 
immunity is triggered to completely eradicate the pathogen. A defining feature o f 
adaptive immunity is the development o f immunological memory. This occurs once 
the immune system has recognized and responded to a specific antigen(s) on the 
infectious agent. Thus not only is acquired immunity responsible for the elimination 
o f the invading pathogen, but it also ensures subsequent immunity to re-infection. 
Adaptive immunity is mediated by lymphocytes, that have the ability to recognize 
specific epitopes on a given pathogen. Lymphocytes are classified into two 
categories, B lymphocytes and T lymphocytes.
1 .2 .1  B -L y m p h o c y t e s
The B-lymphocyte derived it’s letter designation from it’ s site o f maturation, in the 
bursa o f Fabricius in birds, a name which is also apt for bone marrow, it’ s major site
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o f maturation in many mammalian species. B-lymphocytes or B-cells are the 
primary cell type involved in antibody production, although they can also serve as 
potent antigen-presenting cells for CD4+ T-cells and can produce a large number o f 
cytokines (Pistoia, 1997). Mature B-cells are distinguished from other lymphocytes 
by their synthesis and display o f membrane-bound immunoglobulin (antibody) 
molecules, which serve as antigen receptors. Antigen-specific proliferation o f B- 
cell clones is elicited by the interaction o f membrane antibody with antigen. 
Antibody molecules have a common structure o f four peptide chains; two identical 
light (L) chains and two identical heavy (H) chains. Each chain contains constant 
(C) and variable (V) regions, the latter determining antibody specificity. 
Immunoglobulins (Ig) can be divided into five isotypes; IgG, IgM, IgA, IgE, and 
IgD, which participate in distinct effector functions.
1. IgG antibodies are the most abundant class in serum. There are four IgG 
subclasses in both humans and mice. This isotype has a wide variety o f functions 
including activation o f complement and opsonization o f antigen. IgG readily 
crosses the placenta and plays an important role in protecting the developing 
foetus.
2. IgM is the first Ig class produced in primary response to antigen. Because o f  it’ s 
large size (pentamer), IgM does not diffuse well and is restricted almost entirely 
to the bloodstream. IgM is efficient in the agglutination o f antigen and the 
activation o f complement.
3. IgA is the predominant Ig class in mucosal secretions such as saliva, tears and 
mucus o f the bronchial, genitourinary and digestive tracts. It plays an important 
role in prevention o f bacterial/viral attachment at mucous membrane surfaces.
4. IgE antibodies mediate the immediate hypersensitivity reactions associated with 
allergic type responses. IgE binds to Fc receptors on basophils and mast cells. 
Cross-linkage o f receptor-bound IgE with antigen causes the cells to release 
various mediators o f allergic reactions, such as histamine.
5. No biological effector function has been identified for IgD, other than it’s action 
as a membrane receptor for immunocompetent B-cells.
Mature B-cells can be activated by antigen that contains epitopes specifically 
recognized by their cell surface Ig. B-cell activation proceeds by two different
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routes depending on the nature o f  the antigen. Thymus-independent antigens 
stimulate B-cells directly, and is dependent upon the cross-linking o f membrane- 
bound Ig on B-cells. Most thymus-independent antigens are mitogens, and are able 
to activate B-cells regardless o f their antigenic specificity. Thymus-dependent 
antigens require interaction with a T-helper cell to stimulate B-cells in the 
production o f antibody. B-cells bind this type o f antigen through their specific 
antigen receptors, and then process the antigen into peptides following endocytosis. 
The peptides are then exported to the cell surface where they are displayed in 
association with MHC class II molecules. CD4+ T-cells with receptors specific for 
this class II-peptide complex interact with the B-cell. The T-cell in turn promotes 
B-cell activation, both by releasing cytokines and by direct intercellular contact. 
This contact between the T-cell and B-cell occurs through a number o f molecules 
and plays an important role in B-cell activation. CD40 ligand (CD40L) and CD28 
on T-cells bind to CD40 and B71/B72 respectively on B-cells. This crosslinking 
induces B-cell proliferation and antibody production (Clark & Ledbetter, 1994). 
Once activated, B-cells proliferate and differentiate into antibody-producing plasma 
cells. The cytokines produced by T-cells play a major role in the antibody isotype 
that is produced by the B-cell. In the mouse, IFN-y promotes IgG2a production, 
but inhibits IgGl and IgE production, the Ig classes associated with Th2 responses. 
On the other hand, the Th2-derived cytokine, IL-4, promotes production o f IgGl 
and IgE and suppresses production o f  IgM, IgG2a and IgG2b (Coffman, et al., 
1993, Purkerson & Isakson, 1992).
1 .2 .2  T -L y m p h o c y t e s
T-lymphocytes, or T-cells, arise in the bone marrow and derive their name from 
their site o f maturation in the thymus, where they undergo development and 
differentiation. Maturation in the thymus occurs along several developmental 
pathways, which generate functionally distinct subpopulations o f mature T-cells, 
that migrate to peripheral lymphoid organs. During development in the thymus, T- 
cells come to express a unique antigen-binding molecule called the T-cells receptor 
(TCR) - a complex o f polypeptides that includes CD3. T-cells can be divided into 
two distinct lineages based on the cell surface receptor expression. In humans and
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most animals the vast majority o f  T-cell express a TCR composed o f  an a chain and 
a p chain, but there also exists a much smaller population o f T-cells which possess a 
TCR comprising y and 8 chains, a/p T-cells can be further divided into 
subpopulations o f cells, based on their expression o f the co-receptors CD4 or CD8. 
These cells are fundamentally distinct from each other in their recognition of antigen 
and effector functions (Mills, 1989).
T-cell receptors do not recognize free antigen, but respond only to an 
antigenic peptide that is bound to cell membrane proteins called major 
histocompatibility complex (MHC) molecules. There are two types o f MHC 
molecules: Class I MHC molecules are expressed on virtually all nucleated cells, 
whereas class II molecules are restricted to cells o f the immune system. T-cells that 
express the membrane glycoprotein molecule CD8 are restricted to recognition of 
antigen bound to class I MHC molecules, whereas T-cells expressing CD4 are 
restricted to recognizing antigen bound to class II molecules. The class I antigen 
pathway typically begins with internally synthesized proteins, such as those from an 
invading virus, being reduced to peptides in proteasomes. These peptides are then 
carried to the endoplasmic reticulum where they are loaded onto MHC class I 
molecules to form a MHC-peptide complex. This complex is routed through the 
golgi apparatus and exported to the cell surface, where it can be recognized by 
CD8 T-cells with the appropriate TCR. In contrast, MHC class II molecules 
utilize an endocytic antigen pathway. Antigen-presenting cells (APC) ingest 
exogenous antigen, which is internalized by endocytosis. The antigen is degraded 
into peptides within endosomes. Peptides are then transported to the plasma 
membrane in association with MHC class II molecules, where they can be 
recognized by CD4+ T-cells.
CD8+ and CD4+ T-cells have distinct immunological functions. CD4+ T-cells 
or T-helper (Th) cells provide help for B-cells in antibody production. They also 
secrete a range o f cytokines which activate macrophages and are involved in 
regulating immune responses. CD8+ T-cells are cytotoxic to cells infected with 
bacteria or viruses and are referred to as cytotoxic T-lymphocytes (CTL). The 
CTL-mediated response involves a carefully orchestrated sequence o f events 
culminating in the destruction o f the target cells. There are two proposed
6
mechanisms o f cell mediated cytotoxicity; one mechanism depends upon contact- 
mediated transmembrane signaling and the other on the exocytosis o f toxic products 
by the CTL. The granule-exocytosis pathway is characterized by the secretion o f 
the lytic protein perforin. This protein polymerizes to form a pore in the host cell, 
allowing the entry o f the cosecreted granule contents, including granzymes, leading 
to apoptosis o f the target cell. The second pathway is non secretory and instead 
involves the crosslinking o f a surface-membrane ligand (Fas ligand) present on some 
antigen-activated CTL and a death receptor (Fas) on the target cell, which initiates 
a cascade o f proteolytic enzymes, resulting in target cell apoptosis and lysis 
(Stenger & Modlin, 1998).
1.3 CD4+ T - c e l l  S u b s e t s
CD4+ T-cells are considered to be the major regulators o f the immune response 
during infection, and their developmental regulation is critically important to the 
form and effectiveness o f acquired immunity. CD4+ T-cells can be divided into two 
distinct subsets o f effector cells based on their functional capabilities and the profile 
o f cytokines they produce. These subsets, designated Thl and Th2 cells, originally 
described by Mosmann and colleagues in 1986, have classically been considered to 
mediate cellular and humoral immunity respectively. Each subset produces 
cytokines that serve as its own autocrine growth factor, and promote differentiation 
o f naïve T-cells to that subset. Mouse Thl cells produce IL-2, IFN-y, and TNF-P 
(lymphotoxin), whereas Th2 cells secrete IL-4, IL-5, IL-6, IL-10 and IL-13 
(Mosmann & Coflman, 1989). Human Thl and Th2 cells produce similar patterns, 
although the synthesis o f IL-2, IL-6, IL-10 and IL-13 is not as tightly restricted to a 
single subset as in mouse T cells. Several other cytokines are secreted by both 
subsets, including IL-3, TNF-a, and GM-CSF (Mosmann & Sad, 1996). Thl cells 
are responsible for the induction o f cell-mediated immunity, but are also associated 
with antibody production and Ig class switching. IFN-y, a defining cytokine o f the 
Thl subset, activates macrophages; it stimulates these cells to increase microbicidal 
activity, to up-regulate the level o f class II MHC, and to secrete cytokines such as 
IL-12, which induces Th cells to differentiate into the Thl subset. IFN-y secretion 
also induces antibody class-switching to IgG classes (such as IgG2a in the mouse),
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that support phagocytosis and the fixation o f complement. Thl cells are associated 
with inflammatory phenomenon such as delayed type hypersensitivity, due to their 
secretion o f cytokines that mediate inflammation such as IFN-y and TNF-p. Th2 
cytokines are associated with the induction o f humoral immunity, promoting 
antibody production. The signature cytokines o f Th2 cells are IL-4 and IL-5. IL-4 
is the major inducer o f B-cell switching to IgE production and is therefore a key 
initiator of IgE-dependent, mast-cell mediated reactions. IL-5 is the principal 
eosinophil-activating cytokine which play an important role in immunity to helminth 
parasites. The production o f these two cytokines by the same Th subset accounts 
for the frequent presence o f both IgE and activated eosinophils in Th2-dominated 
immune reactions, such as in allergies and helminthic infection. Th2 cells also 
stimulate antibody production very efficiently, such as IgGl in mice, or it’s 
homologue, IgG4, in humans.
A third subset o f CD4+ T-cells, called ThO cells, have also been described, 
which produce a mixture o f  the two patterns o f cytokine secretion exhibited by Thl 
and Th2 cells (Firestein et al., 1989). The overlapping cytokine profiles associated 
with this subset, however, may be due to the presence o f mixed populations o f 
CD4+ T-cell subsets rather than derived from individual Th cell clones. Analyses 
using in situ mRNA hybridization (Carding et al., 1989) and intracellular protein 
staining (Openshaw et al., 1995) in which cytokines can be detected in individual 
cells, favour the mixed population explanation.
1 .4  F a c t o r s  a f f e c t i n g  t h e  d e v e l o p m e n t  o f  T h  s u b s e t s  
Studies o f numerous animal and human models have revealed that the ability o f a 
host to effectively eradicate an invading organism, depends on the class o f effector- 
specific immune response that is mounted, and in particular the type o f Th response 
elicited. Type-1 and type-2 immunity involve fundamentally different and opposing 
effector functions. T-cells, and the cytokines they produce, play a crucial role in 
determining the outcome o f infections in terms of both protective immunity and 
immunopathology. The development o f  a particular Th subset has important 
implications for the outcome o f infection, and has been demonstrated in disease 
conditions where the development o f one Th subset is associated with susceptibility
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to disease, whereas development o f the corresponding Th subset is associated with 
disease resistance. The dual regulatory and effector roles o f CD4+ T-cells are best 
understood in murine Leishmania major infection. Cutaneous infection o f most 
inbred strains with L. major results in a lesion that heals spontaneously and confers 
resistance to infection. However, in BALB/c mice, the infection progresses to a 
disseminated visceral disease that is usually fatal. Susceptible BALB/c mice 
develop a Th2 response and succumb to infection, whereas resistant strains such as 
C57BL/6 mice develop a Thl response and survive (Scott et al., 1989, Sher & 
Coffinan, 1992). Therefore, the factors which are involved in the differentiation of 
naïve T-cells into either Thl or Th2 subsets are critical. The selective 
differentiation o f either subset is established during priming and the major variable 
in this differentiation is the cytokine environment (O’Garra & Murphy, 1994). 
However, many studies indicate that other factors including the APC type, co­
stimulation and the nature and dose o f antigen play a role in the selective 
development o f a particular Th subset and are crucial to the progression towards 
either humoral or cell-mediated immunity (Constant & Bottomly, 1997).
1.4.1 C y t o k i n e s  t h a t  s e l e c t i v e l y  i n d u c e  T h I  c e l l s  
A large body o f evidence has accumulated over recent years to indicate that IL-12 is 
one o f the most important cytokines in the differentiation o f naïve CD4+ T-cells to 
the Thl subset (Germann et al., 1993, Schmitt et al., 1994, Manetti et al., 1993, 
Abbas et al., 1996, Trinchieri, 1994, Seder et al., 1993). It’ s main function is to 
induce the canonical Thl cytokine, IFN-y. IL-12 is produced by macrophages and 
other APC (Hall, 1995), and serves to enhance proliferation, IFN-y secretion and 
cytotoxic function by T-cells and NK cells (Gately et al., 1998). IL-12 and IL-12- 
induced IFN-y promotes the generation o f Thl cells by priming CD4+ T-cells for 
high IFN-y production and by favouring the expansion o f  Thl cells (Wu et al., 
1993, Seder et al., 1993). In doing so, IL-12 acts in antagonistic equilibrium with 
IL-4, which stimulates the development o f Th2 cells. Both IL-12 and a functional 
IL-12 receptor are required for the development o f fully competent Thl cells, and 
IFN-y mediates both IL-12RJ32 expression (Szabo et al., 1997), and actively
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induces IL-12 production from macrophages (Ma el al., 1996). The Thl response 
modality is thus stabilized by a positive feedback loop.
Thl responses are considered most relevant for the elimination o f 
intracellular pathogens, and therefore it may also be assumed that IL-12, which 
favours the development o f Thl cells would play a role in the resolution o f 
intracellular infections. Indeed, in experimental infections with intracellular 
pathogens such as Leishmania, Toxoplasma and Listeria, attenuation o f the Thl 
response through the elimination of IL-12 has revealed a compulsory role for this 
cytokine in the production o f IFN-y, and for the establishment o f a Thl-type 
response (Mattner et al., 1996, Gazzinelli et al., 1993, Scharton-Kersten et al.,
1995). It has also been shown to be an important mediator in the generation o f  the 
type 1 response to Mycobacterium leprae in humans (Sieling et al., 1994). In other 
systems, lack o f IL-12 function resulted in a failure to produce a cytokine profile 
characteristic o f a Thl response, but rather directed the immune response towards 
Th2 responsiveness (Seder et al., 1993). Thus, IL-12 seems to promote Thl 
differentiation indirectly through the induction o f IFN-y. However, the status o f 
IFN-y as an inducer o f  the Thl phenotype during primary Th stimulation remains 
controversial.
It is still unclear whether IL-12 can act directly on Th cells to cause them to 
differentiate and secrete IFN-y, or whether the effect on Th cells is indirect, for 
example, NK derived. Several models have failed to provide a consensus view, 
with some indicating that the mechanism is IFN-y independent, whilst others 
suggest a requirement for IFN-y. A study by Scott (1991) revealed that treatment 
of mice with anti-IFN-y antibody at the time o f challenge with Leishmania major, 
resulted in reduced IFN-y production from lymph node cells restimulated in vitro, 
suggesting a requirement for IFN-y in the priming o f Thl cells. In contrast to this, 
Mountford and colleagues (1999) reported that Thl differentiation can occur 
without the presence o f NK-cell derived IFN-y in an in vivo model o f pulmonary 
granuloma formation, indicating that IL-12 can act independently o f IFN-y for the 
induction o f Thl cells. Similarly, in another study, it was shown that during 
infection with Leishmania major, Thl cells, which are crucial in protection against
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this parasite, can differentiate in vivo without exposure to IFN-y from other cells, 
such as NK cells (Wakil et al., 1998). Nevertheless, in vitro the presence of 
endogenously synthesized IFN-y during the priming o f naïve CD4+ T-cells both 
accelerates and enhances the Thl-differentiating effects o f IL-12 (Wenner et al., 
1996, Bradley et al., 1996). In addition, IFN-y and IL-12 can indirectly promote 
the induction o f Thl cells by inhibiting IL-4 production, thus generating optimal 
conditions for the priming o f IFN-y producing cells.
Not only does IL-12 synergize with IFN-y in the development o f Thl cells, 
but it also acts in concert with another IFN-y-inducing factor - IL-18. IL-18 is 
produced by a variety o f different cells types including macrophages and T-cells and 
shares many biological properties with IL-12, such as IFN-y induction, enhancement 
o f cytotoxic function o f NK cells and stimulation o f  Thl differentiation. However, 
naïve T-cells only begin to express the IL-18 receptor (IL-18R) after IL-12 
stimulation (Akira et al., 2000). So, although IL-18 is a potent stimulus for the 
induction o f IFN-y from T-cells, it’s function completely depends on the presence o f 
IL-12, in the context o f a second stimulus (Okamura et al., 1995, Ushio et al., 
1996, Okamura et a l, 1998, Micallef et al., 1996, Ahn et al., 1997). In this way 
IL-18 potentiates IL-12-driven Thl development. IL-18 has been shown to play a 
role in the development o f  a protective response to a variety o f organisms including 
Mycobacterium tuberculosis, Yersinia enterocolitica (a gram negative bacterium 
which causes enteritis and enterocolitis), Leishmania major and Salmonella 
typhimurium (Sugawara et al., 1999, Bohn et al., 1998, Ohkusu et al., 2000, 
Mastroeni et al., 1999), all o f which are associated with the generation o f Thl 
responses.
1 .4 .2  C y t o k i n e s  t h a t  s e l e c t i v e l y  i n d u c e  T h 2  c e l l s  
The development o f Th2 cells from naïve precursor CD4+ T-lymphocytes is induced 
by IL-4, through it’s ability to activate signal transducer and activator o f 
transcription (STAT) 6, a transcription factor which binds to the IL-4 gene 
(Murphy et al., 2000). Although IL-4 induces Th2 cells and IL-12 induces Thl 
cells, when both cytokines are present in the same culture, the effect o f  IL-4 is
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dominant and Th2 cells develop in the presence o f  IL-12 (Seder et al., 1993, Hsieh 
et al., 1993). The critical role o f signals from IL-4 in Th2 development is shown by 
the observation that knocking out the gene that encodes IL-4 prevents the 
development o f this T-cell subset (Kuhn et al., 1991, Kopf et al., 1993). Similarly 
in STAT 6 knockout mice, IL-4 mediated processes are severely inhibited or absent 
(Kaplan et al., 1996, Takeda et al., 1996, Shimoda et al., 1996).
Although Th2 cells are themselves a major source o f IL-4, the source o f 
early IL-4 production that mediates the development o f Th2 cells remains to be 
clearly defined. It has been suggested that a number o f different cell types including 
mast cells, basophils, eosinophils and NK1.1+ T-cells (an atypical subset o f T-cells 
not restricted by class I MHC), may serve as a source o f early IL-4. However there 
is more convincing evidence to suggest that Th2 differentiation can be supported 
solely by IL-4 produced by antigen-primed (Schmitz et al., 1994) or memory CD4+ 
lymphocytes (Gollob & Coflman, 1994). Given the ability o f threshold amounts o f 
IL-4 to override signals for Thl differentiation, even small amounts o f IL-4 early in 
the immune response may be sufficient to direct the development o f Th2 cells.
IL-13 has also been shown to play a role in the development o f Th2 cells. 
Knocking out the gene that encodes for IL-13 has been shown to impair the 
development o f Th2 responses (McKenzie et al., 1998). In another study using a 
Th2-driven lung granuloma model induced with Schistosoma mansoni eggs, it was 
demonstrated that IL-4 and IL-13 act in concert with each other to initiate rapid 
Th2 responses, and that combined disruption o f these cytokines can either abolish 
these responses or delay their onset, resulting in an inappropriate Thl response 
(McKenzie et al., 1999).
1 .4 .3  T h 1 / T h 2  C r o s s r e g u l a t i o n
The critical cytokines produced by Thl and Th2 subsets have three characteristic 
effects on Th subset development. Firstly, they act as autocrine growth factors for 
the subset that produces them. IL-2 acts as a growth factor for Thl cells, 
promoting their proliferation, and IL-4 promotes the expansion o f Th2 cells. 
Secondly, they make members o f the T-cell subset that releases them, less 
responsive to the cytokine that directs the differentiation o f the other T-cell subset.
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IL-4 enhances Th2 cell development by downregulating the (32 subunit o f the IL-12 
receptor, thereby making T-cells unresponsive to IL-12, which would direct Thl 
development. On the other hand, IFN-y upregulates the expression o f this (32 
subunit making T-cells more responsive to IL-12, and hence overriding the effects 
o f IL-4 and favouring the differentiation and activity o f Thl cells (Gillespie et al., 
2000, Wu et al., 2000). Finally, they inhibit the development and activity o f the 
opposing subset, an effect known as cross-regulation. During many immune 
responses, antibody production and DTH responses are mutually exclusive. Since 
Th2 and Thl cells appear to be at least partially responsible for antibody and DTH 
responses respectively, it is possible that the reciprocal relationship between these 
two responses is that Thl and Th2 cells are mutually inhibitory and self-stimulatory. 
The signature Thl cytokine IFN-y, preferentially inhibits the proliferation o f the Th2 
subset (Manetti et al., 1993), and IL-4 and IL-10 (secreted by Th2 cells) 
downregulate secretion o f IL-12, the critical cytokine for Thl differentiation, by 
both macrophages and dendritic cells (Sher et al., 1992). Similarly, these cytokines 
have opposing effects on antibody-producing B-cells. IFN-y promotes IgG2a 
production, but inhibits IgGl and IgE production, the Ig classes associated with 
Th2 responses. On the other hand, IL-4 promotes production o f IgGl and IgE and 
suppresses production o f IgG2a. Thus, the balance between IFN-y, IL-12 and IL-4 
plays a critical role in determining the outcome o f the CD4 effector T-cell response 
(Nakamura et al., 1997), and the net effect o f  this is that once a T-cell immune 
response begins to develop along either the Thl or Th2 pathway, from a common 
precursor, it tends to become increasingly polarized in that direction
The crossregulation o f Thl cells by IL-10, secreted from Th2 cells and 
regulatory T-cells (Tr), appears to inhibit cytokine responses through an effect on 
macrophages and monocytes, rather than a direct interaction with T-lymphocytes. 
IL-10 interferes with the ability o f APC to activate the Thl subset to produce IFN-y 
(Mosmann & Moore, 1991, Fiorentino et al., 1991). This interference is thought to 
result from the ability o f IL-10 to downregulate the expression o f class II MHC 
molecules on APC, but has also been shown to inhibit costimulatory activity and B7 
expression (Ding et al., 1993). IL-10 can also downregulate IFN-y dependent 
immunity by blocking this cytokine’s ability to activate macrophages for the killing
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o f intra- and extra-cellular parasites (Gazzinelli et al., 1992). This suppression is 
due to inhibition o f IFN-y-induced production o f  nitric oxide and other bactericidal 
metabolites known to be involved in parasite killing (Gazzinelli et al., 1992). Since 
IFN-y is an important mediator o f the protective immune response against infection, 
downregulation o f it’s production by a Th2 cytokine maybe an important strategy 
promoting the survival o f infectious agents. In this regard, IL-10 production has 
been shown to be associated with the decreased IFN-y responsiveness 
accompanying helminth infection (Sher et al, 1991), and with the exacerbated 
disease occurring in BALB/c mice infected with L. major (Heinzel et al., 1991).
1.4.4 d o s e  o f  A n t i g e n  a n d  R o u t e  o f  A d m i n i s t r a t i o n  
Reports in vivo and in vitro have provided much evidence that the nature and 
availability o f antigen, can participate in the commitment o f CD4+ T-cells to 
production o f restricted or polarized patterns o f cytokines. However, there is little 
consensus regarding a universal model o f differentiation, with data suggesting that 
both low and high antigen dose favours Th2 responses. Some have suggested that 
this process not only involves the nature and dose o f antigen, but also that the time 
period over which differentiation occurs can also be a major factor (Rogers & 
Croft, 1999). In vitro experiments have implicated antigen dose as an important 
factor in the Thl/Th2 decision. However, interpretation o f these results is complex 
as increasing antigen dose may switch the immune response from Thl to Th2 and 
visa versa, and when a wide range o f doses is used a double switch can occur from 
Th2 to Thl to Th2 (Mosmann & Sad, 1996).
Early in vivo studies showed that both high and low amounts o f antigen 
primed for DTH, whereas moderate levels stimulated antibody production (Parish, 
1972). Similar effects occur in infectious models and suggest that priming with high 
doses o f an immunogen will induce humoral responses, whereas lower doses will 
lead to cell-mediated immunity. This particular dichotomy was demonstrated by 
Bretscher et al. (1992), by immunizing susceptible BALB/c mice with different 
numbers o f Leishmania major parasites. They showed that immunization with low 
numbers o f parasites induced DTH responses that protect mice against subsequent 
L. major infection. However, immunization with increasingly higher numbers of
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parasites led to the progressive loss o f DTH responses and protection. Similar to 
the L. major studies, low-level infections with the intestinal nematode Trichuris 
muris, polarize CD4+ T-cell responses towards the Thl phenotype (Bancroft et al.,
1994). In addition, low-dose infections with the parasitic helminth F. hepatica, 
gives rise to a more mixed Thl/Th2 cytokine profile compared with a high dose 
infection, which generates a highly polarized Th2 response (O’Neill et ah, 2000).
Other studies have demonstrated that priming to different doses o f an 
immunogen can induce the opposite effect, with high doses o f antigen inducing Thl 
responses and low doses o f antigen priming for the development o f Th2 cells. For 
example Pfeiffer et al. (1995) immunized mice using a peptide antigen derived from 
the sequence o f  human collagen IV protein and demonstrated that immunization 
with 50pg o f peptide led to the generation o f Thl cells, whereas 2pg induced the 
development o f the reciprocal T-cell subtype.
These studies with seemingly contradictory conclusions, however, have one 
key difference, which is the type o f antigen used. Most o f the studies in which high 
doses o f antigen induced Th2-like responses used parasites as immunogens 
(Bretscher et al., 1992, Bancroft et al., 1994, O’Neill et al., 2000), whereas high 
doses of soluble peptide tended to skew toward the Thl phenotype (Pfeiffer et al.,
1995). Therefore, it may be that the soluble or particulate nature o f  the antigen 
itself can influence the type o f response initiated. At low concentrations o f a 
soluble antigenic peptide, each APC should present a low-density o f peptide-MHC 
complexes. In contrast, although relatively low numbers o f APC will capture an 
infectious agent at a low dose, each successful APC will present a large amount o f 
antigen because o f the digestion o f a whole particle.
The route o f immunization may also be critical in influencing the type 
immune response that develops, which has important implications for disease 
outcome and protection against infection. It has been demonstrated that a pertussis 
vaccine administrated via the intraperitoneal route resulted in an enhanced Thl 
response, whereas immunization by the subcutaneous route produced a 
predominantly Th2 response (Barnard et al., 1996). Immunization by mucosal 
routes also appears to favour the induction o f Th2 cells (Conway et al., 2001).
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1 .4 .5  C O -STIM U LA T O R Y  M OLECULES
Naïve T-cells use the CD3-associated TCR a /(3 complex to recognize bound 
antigen to MHC molecules on the surface o f the APC. The engagement o f the TCR 
provides the first activation signal to the T-cell. However, for optimal activation to 
occur, a second activating signal, or co-stimulus is required. The development o f 
both Thl and Th2 cells is dependent on co-stimulation. The most studied co­
stimulatory molecules in T-cell activation are the B7 family o f molecules. B7-1 
(CD80) and B7-2 (CD86) molecules can be expressed on activated B- and T-cells, 
dendritic cells (DC) and activated monocytes. It has been shown in some systems 
that B7-1 and B7-2 may differentially regulate Th cell differentiation (Kuchroo et 
al., 1995, Lenschow et al., 1995). It has been suggested that the dominant 
expression o f B7-2 during priming may direct T-cell activation towards the Th2 
phenotype (Bottomly et al., 1997). However, other studies have reported that B7-1 
and B7-2 can have the opposite or no effect on Thl/Th2 differentiation (Lanier et 
al., 1995, Lenschow et al., 1995).
Of the ligands for B7-1 and B7-2, CD28 is found on both resting and 
activated T-cells, whereas the other, cytotoxic T-lymphocyte antigen 4 (CTLA-4), 
is only found on activated T-cells (Clark & Ledbetter, 1994). The binding o f B7 
molecules to CD28 on T-cells previously stimulated through their antigen receptors 
stimulates IL-2 production and T-cell proliferation and the generation o f cytotoxic 
activity (Zhang et al., 1997). Analysis o f CTLA-4'7' T-cells have revealed an 
important role for CTLA-4 in the regulation o f Th cell differentiation. In the 
absence o f  CTLA-4, naïve CD4+ T-cells differentiate into Th2 cells, producing large 
amounts o f IL-4, IL-5 and IL-10 (Oosterwegel et al., 1999). This skewing towards 
Th2 differentiation does not appear to be dependent on the strength o f the TCR 
signal, as the effect can be observed over a broad range o f antigen concentration 
(Oosterwegel et al., 1999).
It is well known that CD40-CD40L interactions are required for B-cell 
activation (Clark & Ledbetter, 1994), but it is now accepted that they are also 
essential for the initiation o f antigen-specific T-cell responses (Grewal & Flavell,
1996). CD40L is a type II membrane protein, and is preferentially expressed on 
activated T-cells and mast cells. CD40 is expressed on DC, activated macrophages,
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follicular dendritic cells (FDC) and activated B-cells. CD40-CD40L interaction 
during T-cell activation by APC results in IL-12 production (Grewal & Flavell,
1996). It is widely accepted that IL-12 plays a crucial role in the development o f 
Thl cells, and thus it can be concluded that the CD40-CD40L interaction is 
important in this process.
The CD4 activation antigen, 0X40 and its ligand (OX40L) are upregulated 
during CD4+ T-cell priming and it has been shown that this molecule may also play 
a role in directing Th differentiation. One model suggests that the CD28 signal 
upregulates 0X40 after antigen activation o f CD4+ T-cells, and that both molecules 
may act in synergy to induce the rapid expansion o f CD4+ T-cells and the 
preferential production o f  Th2 cytokines (Lane, 2000).
1 .4 .6  A n t i g e n -P r e s e n t i n g  C e l l s
In addition to the other contributory factors that determine Thl/Th2 commitment, 
the type o f APC present at the site o f T-cell activation plays a central, but not 
mutually exclusive role in Th cell differentiation. APC which express both TCR and 
co-stimulatory molecules, inform naive Th cells about invading organisms, 
providing an antigen-specific ‘signal 1’ and a co-stimulatory ‘signal 2’ . 
Macrophages, DC and B-cells all have the ability to perform this important 
function.
The major variable in the differentiation o f precursor T-cells towards either 
the Thl or Th2 phenotype, as discussed earlier, is the cytokine environment. 
However, due to the relatively low frequency o f specific T-cells secreting either 
Thl-inducing IFN-y, or Th2-inducing IL-4, present in the local milieu during 
priming, the cytokines produced by APC are considered to play an important role in 
this process. Macrophages are potent producers o f IL-12 and also produce IL-18, 
both o f which favour the development o f Thl cells (Abbas et al., 1996, Trinchieri, 
1994, Micallef et al., 1996). It has been suggested that some intracellular 
pathogens may inhibit the production o f IL-12 by macrophages, and hence delay or 
prevent the development o f cell-mediated immunity in order to potentiate their own 
survival (Mosser & Karp, 1999). They mechanism by which this occurs is thought 
to involve the crosslinking o f surface receptors on the macrophages, such as CR3,
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and confirms the importance o f macrophage-secreted IL-12 in the development o f 
Thl responses. DC are also capable o f producing IL-12, and stimulating Thl 
responses (Macatonia et al., 1995). Furthermore, DC can influence Th cell 
differentiation by preferentially inducing Thl or Th2 type responses. This 
differential polarization o f CD4+ T-cells appears to be mediated by two discrete DC 
subsets; DC’s o f lymphoid origin induce Thl differentiation and DC’s o f the 
myeloid lineage induce Th2 differentiation (Pulendran et al., 1999, Rissoan et al., 
1999, Reid et al., 2000).
1 .5  B o r d e t e l l a  p e r t u s s is . H i s t o r i c a l  o v e r v i e w
B. pertussis is a Gram negative bacterium and the causative agent o f pertussis or 
‘whooping cough’ , a respiratory disease which remains a significant cause of 
morbidity and mortality in infants worldwide. Pertussis was not differentiated from 
other respiratory entities with any certainty until 1578 when Guillaume de Baillou 
described the first epidemic (Linneman, 1979), which primarily affected young 
children, and was characterized by paroxsyms o f cough occurring about every five 
hours. His depiction is dramatic:
The lung is so irritated be every attempt to expel that which is causing the 
trouble it neither admits the air nor again easily expels it. The patient is 
seen to swell up and as if strangled holds his breath tightly in the middle o f  
his throat....For they are without the troublesome coughing for the space o f  
four or five hours at a time, then this paroxsym o f coughing returns, now so 
severe that blood is expelled with force through the nose and through the 
mouth. Most frequently an upset stomach follows....For we have seen so 
many coughing in such a manner, in whom after a vain attempt semiputrid 
matter in an incredible quantity was ejected.
In 1679 Sydenham (Lapin, 1943), writing about the disease gave it the name 
“pertussis”, meaning “a violent cough”. However it was not until 1906 when 
Bordet and Gengou first isolated the causative agent o f pertussis, from the sputum 
o f children suffering from the disease. They used a medium consisting o f potato
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starch infusion, glycerol, and defibrinated blood, which is still frequently used for 
the isolation o f B. pertussis today. The bacterium was initially known as 
Haemophilus pertussis, but later became the type species o f the genus Bordetella 
(Pittman, 1984). All members o f the genus Bordetella have an absolute 
requirement for niacin or nicotinamide. Unsaturated fatty acids are toxic to the 
organism and, therefore media usually contain substances that absorb fatty acids 
such as starch, charcoal, ion exchange resins, or albumin. In Bordet-Gengou 
medium blood is used as a source o f albumin.
1 .6  B. p e r t u s s i s .  C l a s s i f i c a t i o n  a n d  m o r p h o l o g y  
B. pertussis belongs to the genus Bordetella in the family Alcaligenaceae, which 
contains several species o f  closely related bacteria with similar morphology. The 
genus Bordetella contains six species: B. pertussis which is the agent responsible 
for human pertussis; B. parapertussis, which causes a mild pertussis-like disease in 
humans; B. hronchiseptica, which is primarily a veterinary pathogen that causes 
atrophic rhinitis in swine and kennel cough in dogs, but may infect humans; B. 
avium and B. hinzii which both cause respiratory disease in poultry and are very 
rarely found in humans (Kersters et al., 1984, Cookson et ah, 1994). A recent 
addition to the genus is B. holmesii which has been shown to cause bactereremia in 
an immunocompromised individual without respiratory infection (Weyant et ah,
1995). The four species are differentiated from each other by their phenotypic 
characteristics. DNA homology studies have shown that B. pertussis, B. 
parapertussis and B. hronchiseptica are genetically similar and therefore, might 
more appropriately be designated biotypes o f the same species (Cherry et ah, 1988).
B. pertussis is a gram negative coccobacillus that measures 0.2 to 0.8pm in 
size. The bacillus has a slime sheath and filaments extruding from the cell wall. In 
1931, Leslie and Gardner noted four phases (phases I, II, III, IV) when B. pertussis 
was cultured on artificial medium. The antigenically competent, smooth virulent 
form (phase I) which requires 3 to 4 days to form colonies, can mutate to the 
antigenically incomplete, nonvirulent, rough form (phase IV). This spontaneous 
phase variation is associated with a loss o f capacity to synthesize pertussis toxin, 
filamentous haemagglutinin, heat-labile toxin, adenylate cyclase toxin, agglutinogens
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and certain outer membrane proteins, and a concomitant loss o f virulence in 
laboratory animals. There are also two intermediate forms, called phases II and III, 
but these are less well defined. The colonies when grown aerobically on Bordet- 
Gengou medium is small, punctiform, convex, glistening and translucent. A hazy 
zone o f hemolysis surrounds the colony.
1.7 V i r u l e n c e  f a c t o r s  o f  B. p e r t u s s i s
In this section the properties o f the bacterial components that contribute to the 
pathogenicity and immunogenicity o f B. pertussis will be described. Bordetella 
pertussis is a complex organism with multiple virulence determinants. To establish 
efficient colonization o f the respiratory tract, this bacterium produces a variety o f 
virulence factors that contribute to it’ s adherence to the respiratory epithelium, and 
to the development o f clinical pertussis. Recent studies have demonstrated that 
active or passive immunization o f mice with various B. pertussis antigens confers a 
high level o f protection against subsequent aerosol challenge (Mills et al., 1998a). 
The contribution of each o f these components to the disease process is presented 
below.
1.7.1 A g g l u t i n o g e n s
In the genus Bordetella the agglutinogens are highly immunogenic surface protein 
antigens, which induce the production o f antibodies that can cause bacterial 
agglutination. A total o f 14 agglutinogens are now recognized within the genus 
(Eldering et al., 1957, Anderson, 1953). Agglutinogens (aggs) 1 and 7 are found in 
all strains o f B. pertussis with agglutinogen 7 being common to all Bordetella 
species. It is now believed that in B. pertussis there are 3 major Aggs, 1, 2 and 3, 
and three minor Aggs, 4, 5, and 6 (Robinson et al., 1985 (a)). Aggs 1 is specific for 
pertussis and is associated with lipooligosaccharide. Although it is common to all 
strains the nature o f Aggs 1 is unclear, and it is not considered to be a significant 
mediator o f protection. Most interest has centred on Aggs 2 and 3 which have been 
identified as immunogenically distinct fimbriae (Ashworth et al., 1982, Irons et al., 
1985, Zhang et al., 1985a). Due to their fimbrial nature and given the proven 
involvement o f fimbriae in adherence o f other bacteria to mammalian cells, it has
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been suggested that agglutinogens 2 and 3 may act as adhesins. Antibodies to Aggs 
have been shown to block the binding o f bacteria to Vero cells (Gorringe et al., 
1985) and HeLa cells (Redhead et al., 1985). Alternatively, it has been found that 
non-fimbriated strains o f B. pertussis are capable o f binding to human ciliated cells 
(Tuomanen & Weiss, 1985).
Active immunization with purified Aggs 2 or mixtures o f Aggs 2 and 3 have 
protected mice against respiratory infection with B. pertussis (Robinson et al., 
1985b, Zhang et al., 1985b), and human antibodies to Aggs have been shown 
passively to protect mice from aerosol challenge (Oda et al., 1985). Probably the 
strongest evidence for Aggs being protective antigens stems from the Medical 
Research Council vaccine trials in England in the 1950’s. These trials revealed a 
good correlation between serum agglutinin titres in mice and vaccine efficacy in 
children (MRC, 1959). Taken together these findings suggest that agglutinogens 
may be important pertussis vaccine components as reflected by the WHO 
recommendation that vaccines should include the three major agglutinogens.
1.7.2 F i l a m e n t o u s  H a e m a g g l u t i n i n  (FHA)
FHA is a high molecular weight rod-shaped protein o f approximately 220 kDa, 
named for it’s ability to cause the agglutination o f  erythrocytes. It is a surface 
associated and secreted protein, easily purified in high yields from culture 
supernatants (Arai & Sato., 1976, Cowell et al., 1981, Arai & Munoz., 1979), and 
is unusually susceptible to breakdown into a number o f polypeptide species ranging 
from 95 kDa to 126 kDa (Arai et al., 1976, Cowell et al., 1981). When examined 
under an electron microscope, the protein appears as fine filaments measuring 2nm 
in diameter and 40-100nm in length (Arai et al., 1976). FHA is now considered to 
be the major attachment factor o f virulent Bordetella Spp. (Locht, 1993). Because 
FHA is not only a surface associated protein, but is also readily secreted from B. 
pertussis cells during growth (Tuomanen, 1988), raises an interesting possibility 
that FHA may play another role in the pathogenesis o f whooping cough. This 
secreted FHA may be a component o f an immunoevasive strategy o f B. pertussis. 
FHA contains an arginine-glycine-aspartic acid (RGD) sequence which promotes 
binding to the integrin CR3 expressed on macrophages, PMN and other cell types
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(Reiman et al., 1990). Ligation o f CR3 has recently been demonstrated to suppress 
IL-12 production by macrophages (McGuirk & Mills, 2000). Pre-incubation o f 
macrophages with FHA was shown to suppress IL-12 in response to LPS and low 
dose IFN-y. Furthermore injection o f mice with FHA suppressed IL-12 and IFN-y 
levels in the serum, and that this suppression was mediated by an IL-10 dependent 
mechanism (McGuirk & Mills, 2000). It is possible that FHA may play a role in 
inhibiting the development o f a cell-mediated response, which has been shown to be 
critical for the development of protection against B. pertussis (Mills et al., 1993, 
Redhead et al., 1993, Ryan et al., 1997).
Active or passive immunization with FHA has been shown to protect mice 
against lethal infection with virulent B. pertussis (Oda et al., 1984) and reduce the 
numbers o f bacteria infecting the lungs o f mice (Oda et al., 1984). Serum 
antibodies to FHA have been detected in children following immunization with 
acellular pertussis vaccines (Pa), or whole cell pertussis vaccines (Pw), and in 
pertussis convalescent children (Sato & Sato, 1984). Furthermore, the inclusion o f 
FHA in acellular vaccines has been correlated with lower rates o f initial infection 
(Storsaeter et al., 1990). Due to its non-toxicity, immunogenicity, and protective 
effects FHA is considered an important constituent o f all current acellular pertussis 
vaccine preparations.
1 .7 .3  P e r t a c t i n  (P R N )
Pertactin, originally known as “69 kDa protein” , is a non-fimbrial protein closely 
associated with the outer membrane o f B. pertussis. Although this protein can be 
detected and purified from the surface o f B. pertussis as a single polypeptide o f 
molecular mass close to 69 kDa, the pertactin gene was found to encode a 93 kDa 
protein (Charles et al., 1989), which is cleaved to give a mature protein o f 60.5 
kDa.(Makoff et al., 1990). The biological activities o f this component remain to 
fully defined, but it has been demonstrated that PRN may play a role in adherence to 
monocytes (Hazenbos et al., 1994). PRN, like FHA contains an RGD sequence 
which mediates binding to CR3, and it has been shown that PRN can augment the 
suppressive effect o f FHA on LPS-induced IL-12 production in vitro (McGuirk & 
Mills, 2000). Active or passive immunization o f mice with PRN has been shown to
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protect mice against respiratory and lethal challenge with B. pertussis (Shahin et al., 
1990, Mills et ah, 1998a). PRN is a component o f two Pa licensed for use in 
humans.
1.7.4 P e r t u s s i s  T o x i n  (PT)
Pertussis toxin is a protein exotoxin, secreted during in vivo and in vitro growth. 
The toxin is a hexamer o f five dissimilar subunits - SI, S2, S3, S4 and S5, present in 
the molar ratio o f 1:1:1:2:1. Although PT is synthesized solely by B. pertussis, both 
B. parapertussis and B. bronchiseptica possess genes for PT without expressing 
them. Like other bacterial AB toxins, pertussis toxin consists o f an A subunit that 
carries the biologic activity and a B subunit that binds the complex to the cell 
membrane. In pertussis toxin the SI subunit constitutes the A protomer which is 
linked to the remaining subunits that make up the pentameric binding or B 
oligomer. PT binds to cell receptors by two dimers, one consisting o f S2 and S4 
and the other o f S3 and S4 (Figure 1.1). Upon entry to the cell, SI ADP- 
ribosylates a cysteine residue located near the carboxyl terminus o f the a-subunit o f 
several heterotrimeric G proteins including Gi which is involved in the inhibitory 
control o f mammalian cellular adenylate cyclase. ADP-ribosylation uncouples signal 
transduction between G proteins and as a result the conversion o f ATP to cAMP 
cannot be checked and intracellular levels o f cAMP increase disrupting normal 
cellular function. This enzymatic activity also produces systemic effects, from 
which the toxin has acquired a number o f synonyms: elicitation o f a profound 
leucocytosis resulting from an accelerated maturation and release o f thymocytes 
into the periphery and inhibition o f migration o f lymphocytes and neutrophils to the 
white pulp o f the spleen (leucocytosis-promoting factor), stimulation o f pancreatic 
islet cells to secrete insulin which induces hypoglycemia (islet-activating protein), 
and sensitization to histamine (histamine-sensitizing factor) (Burnette, 1992).
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Figure 1.1 Binding o f pertussis toxin to cell membrane
It is now widely accepted that PT is a crucial factor in the pathogenesis of 
pertussis and is the major cause o f the harmful systemic affects (Pittman et al., 
1979, Pittman et al., 1984). In a chemically or genetically detoxified form PT is 
considered an essential component o f any effective vaccine. Active or passive 
immunization with PT is protective in animal models against respiratory infection 
with virulent B. pertussis (Oda et al., 1984, Mills et al., 1998a). Furthermore, 
serum antibodies to PT have been detected in children following immunization with 
Pa or Pw and in pertussis convalescent children (Sato & Sato, 1984).
1 .7 .5  T r a c h e a l  C y t o t o x i n  (T C T )
TCT is a low molecular weight disaccharide-tetrapeptide containing diaminopimelic 
acid and muramic acid (Cookson et al., 1989), and is secreted during the 
logarithmic growth o f  B. pertussis. This toxin is derived from the peptidoglycan of 
the bacterial cell envelope and induces ciliostasis and specific extrusion o f ciliated 
cells from the respiratory epithelium (Goldman et al., 1982). In the absence of 
ciliary activity, coughing becomes the only means in which to clear the airways of 
bacteria and inflammatory debris. Thus, TCT-mediated destruction o f ciliated cells 
may trigger the violent coughing episodes symptomatic o f pertussis. In addition, 
the destruction o f cilia predisposes patients to secondary pulmonary infections
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which are major causes o f pertussis mortality. Furthermore, recent studies by Heiss 
et al. (1994) have shown that the deleterious effects o f TCT are dramatically 
attenuated by nitric oxide synthase inhibitors, which suggests that TCT toxicity in 
the lung may be mediated through the induction o f  nitric oxide production. While 
TCT is almost certainly an important virulence factor, no immune response to it in 
animal or human infections has been reported and its possible value in a vaccine 
formulation is unknown.
1.7.6 H e a t - L a b i l e  T o x i n  (HLT)
HLT, also known as dermonecrotising toxin, is a heat-sensitive (56°C for 10 min) 
toxin first described in 1909 by Bordet and Gengou and is now known to be 
produced by all species o f Bordetella. This toxin is a simple protein with a total 
molecular weight o f 102 kDa with sub-units o f  20 and 30 kDa (Endoh et al., 1986). 
HLT may be responsible for some o f the symptoms associated with pertussis but no 
defined role has been established for it in the pathogenesis o f the disease and 
evidence o f a protective role is lacking.
1.7.7 A d e n y l a t e  C y c l a s e  T o x i n  (ACT)
ACT is an extracytoplasmic enzyme that is released by B. pertussis organisms into 
the surrounding medium during exponential growth. The activity o f the enzyme is 
markedly enhanced by calmodulin, a protein that is unique to eukaryotic cell 
systems (Wolff et al., 1980). On entering cells, ACT catalyses the production o f 
extremely high levels o f cyclic adenosine monophosphate (cAMP), lfom 
endogenous cellular ATP, which then interferes with normal cellular metabolism 
and cell function (Confer & Eaton, 1982). ACT has been found to inhibit the 
phagocytic activity o f macrophages and neutrophils (Confer & Eaton, 1982) in this 
way, and has also been linked to the induction o f apoptosis in macrophages infected 
with B. pertussis (Guierard et al., 1998). Molecular analysis has shown the gene 
for ACT to encode for a 200 kDa protein, with a calmodulin-sensitive adenylate 
cyclase domain at the N-terminus, and a hemolysin domain at the C-terminus 
(Glaser et al., 1988a, Glaser et al., 1988b). The hemolysin domain functions in the 
internalization o f ACT into the cell. It has since been demonstrated that B.
2 5
pertussis mutants devoid o f ACT, or those that lack either the adenylate cyclase 
activity or the hemolysin activity display a dramatic reduction in the pathogenicity 
o f the bacterium (Weiss et al., 1984, Gross et al., 1992). Mutants deficient in 
hemolysin had a reduced virulence in the infant mouse respiratory infection model 
(Weiss & Goodwin, 1989). Active and passive immunization o f mice with ACT has 
been shown to protect mice from lethal infection with B. pertussis (Brezin et al., 
1987). Furthermore, antibodies to ACT have been detected in the sera o f children 
who had been vaccinated with a Pw, thus implicating a role for ACT in immunity to 
pertussis (Arciniega et al., 1991). ACT is not present in any current Pa and further 
studies will be required before it is possible to determine whether it should be 
considered for inclusion.
1 .7 .9  L i p o p o l y s a c c h a r i d e  (L P S )
The LPS o f B. pertussis possesses many o f the properties common to LPS o f other 
Gram-negative bacteria in being heat stable, antigenic, pyrogenic and toxic (Ayme 
et al., 1980). However, B. pertussis LPS is composed o f two chemically and 
immunologically distinct lipids, lipid A and lipid X, and two different 
oligosaccharide chains (type I and type II) containing 12-16 monosaccharide units 
each (Ayme et al., 1980). B. pertussis LPS is immunogenic and anti-LPS 
antibodies have been detected in animals and humans following vaccination with Pw 
or infection (Ashworth et al., 1983, Li et al., 1988). Nevertheless, LPS is not 
considered to be a protective antigen and has been shown to contribute directly to 
the reactogenicity o f the whole cell vaccine in humans (Baraff et al., 1989). 
Therefore, it is the current view that LPS be excluded from any Pa preparations.
1 .8  P a t h o g e n e s i s  o f  B. p e r t u s s i s
Pertussis has two phases, the first being colonization and the second, disease. It is a 
highly contagious disease, and can occur at any age, though severe illness is more 
common in young unimmunized children. The bacterium is spread by aerial 
transmission, and infection starts with it’ s arrival in the upper respiratory tract o f a 
susceptible host. In vivo B. pertussis has a marked tropism for ciliated cells o f the 
respiratory epithelium. Bacteria attach and multiply at the tips of, between, and at
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the base o f the cilia and this leads to ciliostasis, cell death and the shedding o f the 
epithelial cells. Consequently, secondary infections are very common following B. 
pertussis infection, because the damaged respiratory epithelium may be more easily 
colonized by other respiratory pathogens. Bordetella organisms are thought to be 
non-invasive and remain on the respiratory surfaces where they multiply, but B. 
pertussis does have the ability to survive within alveolar macrophages and other 
mammalian cells types, which may contribute to the persistence o f infection 
(Friedman et al., 1992, Saukkonen et al., 1991). B. pertussis adherence to cilia is 
mediated primarily by two non-fimbrial bacterial proteins, filamentous 
haemagglutinin (FHA) and pertussis toxin (PT) which are thought to act in synergy 
(Figure 1.2), each acting as a bivalent bridge between the bacterium and the ciliary 
receptor (Reiman et al., 1990, Locht et al., 1993). Pertussis toxin mediates binding 
through the S2 and S3 subunits. The S2 subunit binds to lactosylceramide found 
primarily on ciliated cells, while S3 binds to a glycoprotein found mainly on 
phagocytic cells (Saukkonen et al., 1992). FHA binds to galactose-containing 
glycoconjugates on both cilia and macrophages (Locht et al., 1993, Reiman et al., 
1990).
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Figure 1.2
Synergy between PT and FHA in binding o f B. p ertu ssis  to ciliated 
respiratory epithelial cells
2 7
In addition, the FHA gene contains an arginine-glycine-aspartate (RGD) sequence, 
which promotes adherence o f B. pertussis to the macrophage integrin CR3 
(CD1 lb/CD18) (Reiman et al., 1990). Although the non-fimbrial protein pertactin 
contains an RGD sequence like FHA, its exact role in adherence has yet to be 
clearly defined. One study has shown that PRN can mediate bacterial adhesion, 
even in the absence o f a functional RGD motif and that Salmonella strains 
expressing PRN were significantly more invasive than isogenic parental strains 
(Everest et al., 1995). Agglutinogens may also be important in attachment, 
whereas HLT, in association with TCT and ACT may be important in the cause of 
local tissue damage in the respiratory tract during infection.
Generally, the typical clinical disease can be divided into four phases: 
incubation, catarrhal, paroxysmal and convalescent. The incubation period involves 
adherence o f the bacterium to the cilia o f respiratory tract epithelial cells where it 
multiplies, and then colonizes the ciliated mucosa o f both the upper and lower 
respiratory tract. The length o f this phase can vary from between 6 to 20 days 
(Friedman, 1988). The onset o f disease is subtle, resembling a mild upper 
respiratory tract infection. This is known as the catarrhal phase, and lasts from 
seven to 14 days. Initially the infection induces cold-like symptoms including a mild 
cough, sneezing, rhinorrhea and a mild fever, and is the most infectious period, with 
a high risk o f transmission. It is during this phase that organisms can frequently be 
cultured from nasopharyngeal swabs. The use o f antibiotics, such as erythromycin, 
can reduce the duration and severity o f disease if administered at this stage o f 
infection. However, due the difficulty in identifying the disease prior to the 
development o f the characteristic paroxysmal cough, pertussis is rarely diagnosed in 
the early stages o f infection. The simple dry cough develops, gradually increases in 
frequency and intensity, leading to the paroxysmal phase. This phase can last up to 
six weeks and is typified by episodes o f violent coughing, or paroxysms, which are 
more frequent at night. The characteristic “whoop” , from which the disease gets 
it’s name, immediately follow these paroxysms, and is due to rapid inspiration 
through a narrowed glottis. Antibiotic treatment is not effective at this stage 
(MRC, 1953). A wide range o f complications are associated with pertussis during 
the paroxysmal phase. Violent coughing may result in umbilical or inguinal hernias,
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and subconjuctival or cerebral hemorrhages. In addition, severe anoxia during 
paroxysms can lead to seizures, coma, encephalopathy, and in rare cases permanent 
brain damage (Cherry et al., 1988). Paroxysms decline in frequency and severity, as 
the disease enters the convalescent stage, although a residual cough may persist 
even in the absence o f B. pertussis organisms during this phase.
Therapeutic treatment o f pertussis is only a viable option in the treatment of 
pertussis before the onset o f the onset o f the paroxysmal cough. Thus, because of 
the difficulty in identifying the disease before this stage, the most applicable control 
measure for the prevention o f the disease is now considered to be through the 
development and widespread use o f safe and effective vaccines.
1 .9  P e r t u s s i s  W h o l e - C e l l  V a c c i n e s
Following the initial isolation o f B. pertussis in 1906, attempts to produce a 
pertussis vaccine quickly followed. The majority o f vaccines developed after this 
time contained intact bacteria, killed or inactivated by physical or chemical methods. 
This form became known as whole cell pertussis vaccine. It is generally accepted 
that the current Pw are effective at providing protection and are o f substantial 
benefit to the recipient. The first studies to demonstrate significant protection 
against pertussis were carried out by Madsen (1933) in the Faroe islands. These 
studies clearly showed that a significant degree o f protection was provided with Pw 
prepared from freshly isolated strains. This was an important observation in light of 
the discovery by Leslie and Gardner (1931) that phase I strains (which were used by 
Madsen) undergo phase variation and become avirulent in phase IV. Clinical trials 
conducted by the Medical Research Council in the 1950’s showed that Pw was 
effective in children (MRC, 1959). A striking observation o f pertussis efficacy 
resulted from reduced vaccine uptake in the UK, Japan and Sweden in the mid to 
late 1970’s (Cherry et al., 1988). Adverse publicity concerning pertussis vaccine 
reactions or efficacy caused a sudden fall in vaccine acceptance rates. The 
incidence o f pertussis following this increased dramatically, resulting in two major 
epidemics in England and a huge increase in the incidence o f disease and death in 
Japan and Sweden (Pollard, 1980). As acceptance rates rose again, case 
notifications o f whooping cough fell to extremely low levels.
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Although whole-cell vaccines are highly effective in controlling pertussis, 
they have been associated with a variety o f adverse reactions. Local reactions such 
as pain, swelling and redness at the site o f injection are usually mild and transitory. 
Mild to moderate systemic reactions include vomiting, fever, persistent crying and 
spasm, but a more serious cause o f concern has been severe reactions such as 
shock, febrile and non-febrile convulsions, permanent brain damage and death. It 
has been suggested that residual active toxins, especially PT and LPS are 
responsible for vaccine reactogenicity (Cherry et al., 1988, Sidley et al., 1989). A 
recent study by Loscher et al. (1998) has suggested that these neurological 
reactions may be due to the presence o f proinflammatory cytokines, such as IL-ip 
in the brain following parenteral immunization with Pw (Loscher et al., 1998). 
Furthermore, immunization with Pw is associated with the induction o f antigen- 
specific Thl cells, which are critical in host resistance to infection (Redhead et al., 
1993, Ryan et al, 1997).
1 .1 0  P e r t u s s i s  A c e l l u l a r  V a c c i n e s
The reactogenicity and toxicity o f the whole-cell vaccine has prompted the 
development o f non-toxic acellular pertussis vaccines, from purified components o f 
the bacteria. The adhesion molecules FHA, PRN and FIM are suitable for inclusion 
in the vaccine because o f  their availability and immunogenicity. PT is also highly 
immunogenic and is the only toxin used in acellular vaccines.
The first Pa was developed by Yugi and Hirko Sato in the mid 1970’s and 
since 1981 Japan has used this form o f vaccine for routine primary immunization. 
Pa are produced by six manufactures in Japan, using slightly varying processes. 
Four manufactures produce the T-type (named after the manufacturer Takeda) 
vaccines which contain formalin treated preparations o f FHA, PT, pertactin, and 
agglutinogen 2 in an approximately 90:10:10:1 ratio. One manufacture (Biken) 
produces a B-type vaccine, containing equal parts o f formalin treated FHA and PT 
with the remaining manufacturer (Kitasato) producing a formalin-toxoided PT and 
FHA in a ratio o f 1:4 (Aoyama, 1996).
Although the safety profile o f Pa are considerably improved, when 
compared with Pw, in general the level o f protection induced with most Pa does not
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surpass that achieved with potent Pw. In fact, the residual toxins PT and LPS 
which are largely responsible for the reactogenicity o f Pw, are also the same 
components that enhance the efficacy o f the vaccine, but are absent from Pa. 
Immunization with Pa induces Th2 responses in mice (Redhead et al., 1993, Mills et 
al., 1998a, Barnard et al., 1996) and a mixed Thl/Th2 response in children (Ryan et 
al., 1997, Ausiello et al., 1997). However, one study has shown that it is possible 
to mimic the effect o f the toxins by adding exogenous IL-12 to Pa. This improves 
the protective efficacy o f the vaccine by activating IFN-y secreting cells (Mahon et 
al., 1996). Recent field trials in Sweden, Italy, Senegal, Munich and Mainz o f 
various Pa preparations have yielded estimated efficacies o f 84%- 93%, (Gustafsson 
et al., 1996, Greco et al., 1996, Simondon et al., 1997, Belohtadsky, 1997, 
Schmitt, 1997). The results o f these and other trials suggest that routine 
immunization with Pa with the gradual elimination o f whole cell vaccine, may be 
more beneficial to the recipient, with less adverse reactions and acceptable efficacy.
1 .1 1  I m m u n i t y  t o  B . p e r t u s s is
Acquired immunity to B. pertussis develops after natural infection and confers 
relatively long-lived protection against subsequent infection. However, it has not 
been possible to correlate protection against disease with a quantifiable immune 
response against a single protective antigen, or indeed with a single arm o f the 
immune response. B. pertussis not only binds and multiplies extracellularly in the 
respiratory tract, but can occupy an intracellular niche within macrophages and other 
cells types. Therefore, it is not surprising that optimal immunity to B. pertussis is 
considered to be conferred by both cellular and humoral mechanisms.
1 .1 1 .1  H u m o r a l  Im m u n i t y
Antibody may function in immunity to B. pertussis by neutralizing toxins, inhibiting 
the binding o f the bacteria to the ciliated epithelial cells o f the respiratory tract, and 
by enabling bacterial uptake and destruction by macrophages and neutrophils. 
Levels o f circulating antibodies that are critical for protection induced with certain 
vaccines such as Haemophilus influenzae type b (Hib), tetanus, diphtheria and polio 
(Robbins et al., 1995, Kayhty et al., 1998), have been identified. Consequently,
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many studies have been carried out with the aim o f also defining a level o f 
protective antibody against B. pertussis. Although it has not been possible to 
correlate protection with a quantifiable immune response against a single protective 
antigen, recent studies have suggested that antibody to a number o f antigens may 
confer protection (Storsaeter et al., 1998, Cherry et al., 1998).
In a murine model o f respiratory infection with B. pertussis, where 
protection correlates with pertussis vaccine efficacy in children, it has been shown 
that pertussis vaccine efficacy could not be predicted on the basis o f ELISA 
antibody responses against individual components o f the vaccine (Mills et al., 
1998b). Immunization o f mice with Pa induced high antibody titres against each 
component o f the vaccine. The strongest response was detected against PT, even in 
the lower efficacy vaccine. On the other hand, antibodies to PT were low or 
undetectable in mice immunized with Pw. These data shows that there is no clear 
relationship between antibody responses and protection against infection. These 
results are consistent with the findings from human clinical trails which have also 
failed to demonstrate an immunological correlate o f protection in children based on 
monotypic antibody responses against putative protective antigens (Greco et al„ 
1996, Simondon et al., 1997, Gustafsson et al., 1996, Olin et al., 1997).
The results o f passive immunization experiments have demonstrated that 
antibodies raised against PT and one or more additional antigens can confer a 
reasonable level o f protection against respiratory challenge (Mills et al., 1998a). 
However an active immunization schedule which induced the same levels o f 
antibody in the circulation at the time o f challenge conferred higher levels o f 
protection, especially with the Pw vaccine (Mills et al., 1998a). Furthermore, B 
cells have been shown to be required to confer immune mediated protection 
(Mahon et al., 1997, Mills et al., 1998a, Leef et al., 2000). For example, B. 
pertussis challenge o f naïve Ig mice results in the development o f a chronic 
infection; mice fail to clear the bacteria from their lungs for at least 6 months post­
challenge, compared to wild-type mice which clear the infection after 8-10 weeks 
(Mahon et al., 1997). Moreover, immunization with Pa or Pw does not induce a 
significant protective effect in Ig'A mice (Mills et al., 1998a). However, Ig"/_ mice do 
not make mature B-cells, and T-cell responses in these mice are defective, it cannot
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be excluded that impairment o f protection was due to a failure to produce 
antibodies. This is supported by a study by Leef and colleagues (2000), who 
demonstrated that intranasal immunization o f Ig’/_ mice with formal-fixed B. 
pertussis did not protect mice against aerosol challenge, which was restored by 
transfer o f pertussis-immune B-cells. These results suggest an alternative role in for 
B-cells in protection against B. pertussis other than the production o f antibody 
(Leef et ail., 2000).
1 .1 1 .2  C e l l u l a r  Im m u n i t y
The first evidence o f  the importance o f a direct role for T-cells in acquired 
resistance the B. pertussis was the demonstration that nude mice (which are 
deficient in T-cells), fail to clear an infection with B. pertussis, whereas normal 
BALB/c mice resolve the infection after 35 days (Mills et al., 1993). Antibody 
responses in normal BALB/c mice did not develop until the infection was almost 
cleared, indicating that another mechanism o f immunity was involved. It was 
subsequently shown that T-cell responses to PT, FHA PRN and B. pertussis sonic 
extract are induced earlier in infection. Furthermore, adoptive transfer o f enriched 
T-cells or purified CD4+ T-cells, but not CD8+ T-cells from immune convalescent 
mice into nude or irradiated recipient mice conferred a high level o f protection, in 
the absence o f a detectable antibody response. The protective T-cells were shown 
to secrete IFN-y and IL-2, but not IL-4, a cytokine profile characteristic o f Thl 
cells (Mills et al., 1993). This characteristic response has been confirmed by the 
generation o f B. pertussis-specilie T-cell lines and clones (Barnard et al., 1996). 
Since then it has also been demonstrated that PBMC from acutely infected or 
convalescent children secrete type 1 cytokines in response to B. pertussis antigens, 
indicating the preferential induction o f CD4+ Thl cells by B. pertussis following 
infection in humans (Ryan et al., 1997). In addition to this, other studies have 
indicated that the signature Thl cytokine IFN-y, can be detected in serum and 
bronchoalveolar lavage fluid o f B. pertussis-infected mice (Torre et al., 1993), and 
this cytokine has been shown to be critical in the appropriate control o f bacterial 
dissemination, pathology and bacterial clearance after aerosol pertussis infection o f 
adult mice (Mahon et al., 1997, Barbie et al., 1997). Furthermore exogenous
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administration o f recombinant IFN-y and IL-12 has been shown to enhance 
resistance o f  mice to B. pertussis infection, either by the direct activation o f  alveolar 
macrophages by IFN-y, or through IL-12-induced generation o f Thl cells (Torre et 
al., 1995).
A role for cellular immunity in vaccine-induced immune responses has also 
been defined. Studies in mice have shown that spleen cells from mice immunized 
with Pw, or from convalescing mice secreted cytokines with the typical Thl profile, 
with high levels o f IFN-y and IL-2, but not IL-4 or IL-5 (Redhead et al., 1993). In 
contrast, immunization with Pa was shown to induce a Th2 response with the 
production o f IL-4 and IL-5 from spleen cells in the absence o f IFN-y and IL-2. 
Following aerosol challenge with B. pertussis, Pw-immunized mice eliminated the 
bacteria from the lungs at a much faster rate than Pa-immunized mice. The authors 
concluded that the protracted clearance o f bacteria reflected the failure o f Pa to 
induce a potent Thl response. It was suggested that high antibody levels induced by 
Pa resulted in an early decline in the numbers o f viable bacteria in the lungs, but that 
complete and rapid clearance was dependent on cell-mediated immunity. A study by 
Mahon et al. (1996), is in agreement with this hypothesis, showing that addition o f 
recombinant IL-12 to Pa significantly enhanced vaccine efficacy by promoting the 
induction o f Thl cells. In another study, Leef and co-workers (2000) defined specific 
roles for both B- and T-cells in protective immunity to B. pertussis following intranasal 
immunization with formalin-fixed B. pertussis. Following immunization, athymic nu/nu 
mice (lacking TCR-a/p+ T-cells) and mice lacking all TCRs were aerosol challenged and 
bacterial recoveries from the lungs were assessed. Both athymic mice and mice lacking 
TCR were unable to clear the bacteria, indicating an important role for T-cells in the 
generation o f protective immunity. Furthermore, CD4-depleted or CD4/CD8-depleted 
mice were shown to have significantly higher bacterial counts in the lungs and tracheae 
compared with controls, following aerosol challenge. B-cells were also shown to play 
an important role in the development o f protective immunity as assessed by clearance of 
bacteria from the lungs and tracheas o f B-cell knockout mice. Intranasal immunization 
o f B-cell knockout mice with killed bacteria, or pertussis antigens in microspheres did 
not protect against aerosol challenge, with significantly higher numbers o f bacteria 
recovered from the lungs and tracheae o f knockout mice compared with controls.
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B. pertussis-specific T-cell responses have also been defined in humans 
following immunization with Pw or Pa. One o f the first studies to compare cytokine 
profiles after primary vaccination o f children with Pw or Pa, suggested that 
pertussis vaccines induce a basic type 1 response in infants with constitutive 
expression o f IFN-y, which is accompanied by some production o f type 2 cytokines 
(Ausiello et al., 1997). They proposed that Th2 cytokines are expressed to a 
greater extent following immunization with Pa, and minimally expressed after 
immunization with Pw. A study by Ryan et al. (1998) further clarified the nature o f 
B. pertussis-specific immune responses following immunization o f children with Pw 
and Pa, and provided convincing evidence that these vaccines activate different 
populations o f T-cells. Using peripheral blood lymphocytes isolated from children 
vaccinated with Pw or Pa, Ryan et al. (1998) examined the production o f T-cell 
cytokines and proliferative responses specific for the B. pertussis antigens, PT, 
FHA, and PRN. They demonstrated that immunization with Pw, like natural 
infection, selectively induced the activation o f pertussis-specific T cells that secreted 
high levels o f IFN-y but not IL-5, a cytokine profile indicative o f Thl cells. In 
contrast immunization with Pa was found to induce a more mixed Thl/Th2 or ThO 
response.
1 .1 2  A n i m a l  m o d e l s  f o r  B . p e r t u s s is  i n f e c t i o n
Humans are the only natural host for B. pertussis, but a number o f animal species 
including mice, rats, rabbits and monkeys can be infected with B. pertussis, and 
have been used for studies in immunity to this bacterium. However, these animal 
model systems are generally regarded as models o f infection rather than disease, 
since B. pertussis is not a natural pathogen o f animals.
A coughing rat model o f B. pertussis infection, where the animals are 
challenged by intrabronchial challenge with B. pertussis embedded in fine agarose 
beads, resembles the human disease in the relationship between the time course o f 
infection and cough production (Hall et al., 1999). Pa and Pw have been found to 
be protective against paroxysmal coughing and leucocytosis (Hall et al., 1998) 
indicating that this model may be useful for the comparative testing o f different 
formulations o f pertussis vaccines before they reach clinical trials.
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The use o f murine models o f infection have played an important role in 
defining the mechanisms o f protective immunity to B. pertussis, and have also been 
utilized to assess the efficacy o f pertussis vaccines. Kendrick (1947) devised the 
original active mouse protection test for Pw, which measured survival following 
intracerebral (i.e.) challenge o f immunized mice. Kendrick and colleagues 
demonstrated that protection in this model correlated with Pw efficacy in clinical 
trails (MRC, 1959). Since then the i.c. model or Kendrick test has been used to 
assess the potency o f Pw. However, it has several disadvantages in that it does not 
predict the efficacy o f the new generation Pa. Furthermore, the route o f challenge 
and the lack o f similarity to many aspects o f the human model o f disease is o f little 
use to dissect the immune mechanisms to B. pertussis.
Respiratory challenge by aerosol or intranasal (i.n.) administration o f the 
bacteria has been extensively used for studies o f pathogenesis and immunity to B. 
pertussis. In the aerosol challenge model, animals are subjected to an aerosol 
containing concentrated live virulent B. pertussis bacteria, which has been reported 
to induce a more uniform and reproducible infection compared with the intranasal 
model (Peterson et al., 1995). In the intranasal model o f  infection, live B. pertussis 
organisms are administered as droplets onto the nasal cavity. Although the 
characteristic cough or “whoop” is absent in these models o f infection, the course 
o f infection and many o f the systemic effects, including leucocytosis and CNS 
effects, are similar to that observed in infants (Pittman et al., 1980, Sato et al., 
1980, Loscher et al., 2000). It has also been demonstrated that bacterial clearance 
from the lungs o f mice immunized with Pa or Pw, following aerosol challenge, 
correlates with pertussis vaccine efficacy in children (Mills et al., 1998a, Mills et al., 
1998b). Furthermore, measurement o f antibody responses to pertussis vaccines in 
the murine respiratory challenge model, failed to show a correlation between 
antibody responses and vaccine efficacy (Mills et al., 1998b). Similarly, results 
from human clinical trails have failed to demonstrate an immunological correlate o f 
protection in children based on monotypic antibody responses against putative 
protective antigens (Greco et al„ 1996, Simondon et al., 1997, Gustafsson et al., 
1996, Olin et al., 1997). These observations further validate the respiratory 
challenge model for studies on the mechanisms o f immunity to B. pertussis.
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1 .1 3  F A S C IO L A  H E P A T IC A : A n  IN TR O D U C TIO N
Fasciola hepatica, and obligate, endoparasitic trematode is the causative agent of 
fasciolosis or liver fluke disease. The disease has worldwide distribution but is 
located primarily in the temperate zones (Europe, the Americas and Asia). The 
most common definitive hosts are sheep and cattle, but F. hepatica is also 
considered to be an important pathogen o f humans, with approximately 2.5 million 
people infected worldwide (Spithill & Dalton, 1998). Fasciolosis can be a chronic 
disease with adult worms surviving for up to 12 years in the host, and is also 
associated with susceptibility to secondary infection. Infection in mice results in 
100% mortality within approximately 2-6 weeks, depending on worm burden. The 
major pathology caused by F. hepatica includes fibrosis due to severe trauma 
induced by juvenile worms migrating through the liver, and inflammation, edema 
and fibrosis o f the bile ducts due to the presence o f the adult flukes. F. hepatica 
also secretes a number o f excretory-secretory products like many other parasites.
1 .1 4  T h e  L i f e  C y c l e  o f  F a s c io l a  h e p a t ic a
The life cycle o f Fasciola hepatica is both cyclical and indirect, requiring an 
invertebrate intermediate host, the snail Lymnaea truncatula, and a definitive 
mammalian host (Fig. 1.3). The monoecious adult lives in the biliary tracts where it 
feeds on the lining o f the biliary ducts. It is here that the sexually mature adult lays 
eggs which are carried by bile into the intestine. Although flukes are hermaphroditic 
and can self-fertilize, it’s preferred means o f reproduction is by cross fertilization. 
Eggs are void with the faeces and embryonation will only occur in the presence o f 
suitable conditions. Moreover eggs must be liberated from faecal matter as it 
inhibits embryonation.
Free-swimming phototropic miracidia are liberated from the egg and must 
invade the secondary host within 24 hours (Hope-Cawdery el al., 1978). It is 
believed that this adaptation has developed in order that the miracidia have the 
advantage o f always continually migrating to the edge o f the water source where 
the amphibious intermediate host resides. Once present in the host’ s habitat it is 
attracted to the snail by chemotaxis. Transmission into the intermediate host is 
active and may require proteolytic enzymes to penetrate the body wall.
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On reaching the snail the miricidia attach to the intermediate host by it’ s 
apical gland. The final penetration is by a young sporocyst which migrates via the 
lymph o f blood vessels to the digestive gland. In favourable conditions one 
sporocyst develops into 5-8 first generation rediae. First generation rediae in turn 
give rise to about 40 daughter rediae. Further development occurs and the rediae 
develop into approximately 600 cercariae which are shed via the birth pore 
(Andrews, 1998). The development o f  larval stages in the snail is temperature 
dependent.
After the release o f cercariae some will encyst at the waters surface but 
most attach to aquatic plants below the water level. The tails from the cercariae are 
shed and the cyst wall is secreted within two minutes to two hours to form 
metacercariae, the infectious stage o f the life cycle (Smyth and Halton, 1983). 
Transmission to the definitive host is passive, by the ingestion o f aquatic plants or 
by drinking contaminated water.
Metacercariae excystment is initiated in the stomach o f the mammalian host 
in the presence o f high concentrations o f carbon dioxide, reducing conditions and 
high temperatures (Fried, 1994). Liberation o f the newly encysted juvenile (NEJ) 
fluke migrate through the intestinal wall into the peritoneal cavity, subsequently 
penetrating the gilsons capsule and migrating across the liver parenchyma to the 
biliary passages. It is during this phase that the parasite causes extensive damage. 
Once present in the bile duct the worms become sexually mature in four-five weeks 
and commence egg production.
1 .1 5  I m m u n o l o g y  o f  F . h e p a t ic a  i n f e c t i o n
The physiological components o f the innate immune system, such as the skin, 
mucous layers and gastric acid may provide resistance to some infectious agents, 
but they are generally ineffective against helminth infections. The metacercariae o f 
F. hepatica can not only have the ability to survive the acid environment o f the 
stomach, but the gastric acid actually aids in the excystment process o f the parasite 
(Mulachy et al., 1999). With regard to acquired immunity, helminth infections are 
generally considered to induce a cytokines polarized to the Th2 subtype. It has 
been demonstrated that mice infected with F. hepatica display an early and
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persistently polarized Th2 response (O’Neill et al., 2000), with highly elevated 
levels o f IL-4 and IL-5, and an absence o f the type 1 cytokines IFN-y and IL-2. In 
addition, it was found that mice produced antifluke IgGl antibodies, without the 
production o f the Thl-associated subtype, IgG2a, which is also indicative o f a Th2 
response (O’Neill et al., 2000). The induction o f type 2 responses in mice are in 
agreement with earlier studies which collectively suggest that type 2 responses 
predominate in F. hepatica-infected rats, sheep and cattle (Mulcahy et al., 1999). 
Furthermore, F. hepatica infection has been shown to be accompanied by high 
levels o f IgE and eosinophilia (Mulcahy et al., 1999, Finkelman et al., 1991). The 
induction o f cytokines characteristic o f the Th2 subtype involves the early 
production o f IL-4. The cells that produce this early IL-4 remain to be elucidated, 
but it has been suggested that mast cells, basophils, eosinophils or NK1.1+ T-cells, 
may be capable o f fulfilling this role.
The induction o f a Th2 response in many helminth infections is frequently 
accompanied by a downregulation in Thl responses or cell-mediated immunity 
(Sher et al., 1992). Inhibition o f lymphocyte proliferative responses has been 
reported during nematode infections (Allen et al., 1998). Similarly, infection with 
F. hepatica has also been associated with impaired proliferative responses (Cervi et 
al., 1998), and the downregulation o f  Thl cytokine responses in mice (Brady et al., 
1999, O’Neill et al., 2000). The parasite-induced production o f IL-4 is believed to 
play a role in this suppression, but may not be mediated solely by the production o f 
inhibitory cytokines. Immunomodulatory molecules secreted by the liver fluke may 
also be critical in suppressing a potentially protective Thl response and prolonging 
survival o f the parasite. Cervi et al. (1996) showed that excretory-secretory 
antigens o f F. hepatica suppressed the delayed hypersensitivity responses, which 
are regulated by Thl cytokines, both specifically and non-specifically. Other 
candidate immunosuppressive molecules include glycoconjugates sloughed from the 
parasite surface glycocalyx (Mulcahy et al., 1999), and/or cysteine proteinases 
(Smith et al., 1993, Carmona et al., 1993).
During the migratory phases, the flukes survive even though they are in 
contact with the host circulation. It was demonstrated that during these phases the 
flukes secrete a proteolytic enzyme capable o f cleaving immunoglobulin (Chapman
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& Mitchell, 1982). They proposed that in vivo, this enzyme may cleave anti-fluke 
antibody, and hence prevent the adherence o f immune effector cells, such as 
macrophages and eosinophils, protecting the flukes from immune destruction. 
Since then it has been shown that F. hepatica secretes approximately 11 different 
proteinases (Dalton & Heffeman, 1989). One o f these proteinases (cathepsin LI) 
was shown to cleave IgG at or near the hinge region, and to prevent the antibody- 
mediated attachment o f immune effector cells to the parasite (Smith et al., 1993, 
Carmona et al., 1993). This effect can be blocked in vitro by the addition o f anti- 
cathepsin L antibodies (Smith et al., 1994). Another cathepsin L proteinase 
(cathepsin L2), with a different substrate specificity was also purified (Dowd et al., 
1994). The authors suggested that the action o f both o f these enzymes may be the 
prime mechanism by which the parasites penetrate tissue, but that they may also 
play an immunoevasive role due to their ability to cleave host Ig (Smith et al., 1993, 
Carmona et al., 1993).
1 .1 6  P a r a s i t e - i n d u c e d  i m m u n o s u p p r e s s i o n
Possibly the most distinguishing feature if parasitic infection is its chronicity. In 
endemic areas, parasitic infection implies a lifelong intimate association, where 
individuals are infected from a very young age, and can expect to harbour worms 
for most o f their lives, due to an inability to develop protective immunity. In both 
filarial and schistosome infections, adult worms are, in general, more resistant to 
immune effector mechanisms than the larval stages. This phenomenon is known as 
concomitant immunity and is considered a general feature o f helminth infection 
(Maizels et al., 1993). In concomitant immunity the host is protected against newly 
invading larvae while tolerating an established adult worm load. This suggests that 
adult worms have developed immune evasion strategies, such as stage-specific 
antigen expression, and/or an ability to counteract immune effector mechanisms that 
would kill immature forms.
Many parasitic infections are associated with the induction o f Th2 type 
responses (Finkelman et al., 1991, Grencis, 1993, O’Neill et al., 2000). However, 
whether the production o f these cytokines plays a role in protection against 
infection remains controversial. The cytokines produced in response to parasitic
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protozoa and helminths can have opposing effects on the parasite, resulting in the 
resolution o f infection or promotion o f disease and immunopathology (Finkelman et 
al., 1991, Grencis, 1993, Scott et al., 1989, Sher & Coffman, 1992). Despite this 
apparent paradox regarding protection and immunopathology, type 2 cytokines 
induced by parasitic infection have been implicated in the process o f 
immunosuppression, which is a frequently encountered feature o f parasitic infection 
(Pearce et al., 1991, Mosmann & Moore, 1991, Kullberg et al., 1992, Maizels et 
al., 1993, Actor et al., 1993, Cervi et al., 1997, Allen et al., 1998, Cervi et al., 
1998, O’Neill et al., 2000), and is almost certainly responsible for the long-term 
survival o f parasites.
Parasite-induced cytokines produced by the Th2 subset, have the ability to 
suppress the production or activity o f Thl cytokines. The establishment o f this 
state o f cross-regulation has particular relevance where individuals may be exposed 
to multiple infections, or when vaccines are administered during chronic parasitic 
infection. Indeed, there have been several reports o f a downregulation o f Thl 
cytokines to both parasite and non-parasite antigens during helminth infection with 
S. mansoni and F. hepatica (Kullberg et al., 1992, Pearce et al., 1991, O’Neill et 
al., 2000), and an exacerbation o f concurrent infections (Actor et al., 1993, Njunda 
et al., 1996, Brady et al., 1999). IL-4, IL-10 and TGF-P, have all been implicated 
in the downregulation o f cell-mediated immune responses (Sher et al., 1992). 
These cytokines have well-defined effects on Th lymphocyte responses. IL-4 
promotes the expansion o f the Th2 subset, and acts as an antagonist to IL-12, 
therefore inhibiting Thl development (Abbas et al., 1996). IL-10 impairs ability o f 
APC to activate the Thl subset to produce IFN-y (Mosmann & Moore, 1991, 
Fiorentino et al., 1991), and can also inhibit macrophage activation and IFN-y- 
induced nitric oxide production, which is involved in parasite killing (Gazzinelli et 
al., 1992). Studies with the helminth S. Mansoni have implicate IL-10 in the 
suppression o f Thl responses (Sher et al., 1991), and may also be responsible for 
immune suppression in F. hepatica infection (O’Neill et al., 2000). IL-4 and IL-10 
can act synergistically to inhibit the production o f reactive nitrogen oxides, which 
are known to upregulate inflammatory responses (Liew, 1993). IL-4, IL-10 and 
TGF-p all downregulate macrophage functions involved in the effector phase o f
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cell-mediated immunity to L. major, Trypanosoma cruzi and Toxoplasma gondii 
(Sher et al., 1992).
Immunosuppression by parasites may not be mediated solely by the 
production o f inhibitory cytokines. Molecules contained in the excretory-secretory 
products o f parasites may also play a critical role in immunoevasion and 
immunomodulation. These include phosphorlycholine (Harnett and Harnett, 1999), 
which has been shown to modulate lymphocyte responsiveness, immunosuppressive 
glycoconjugates (Mulcahy et al., 1999), and cysteine proteinases, which have been 
implicated in tissue degradation, hemoglobin digestion (Dalton et al., 1995), the 
induction o f allergenic-like reactions (Dowd et al., 1994), and antibody cleavage 
(Smith et al., 1993, Chapman & Mitchell, 1982).
4 2
O bjectives
The aims o f this project were to demonstrate that the murine respiratory challenge 
model o f infection with Bordetella pertussis is a reliable method for the assessment 
o f pertussis vaccine potency, the determination o f consistency between different 
clinical batches o f Pa and Pw, and in the elucidation o f the mechanisms mediating 
protection. This model was utilized to define the contributions o f B- and T-cells in 
long term protection against B. pertussis, following immunization with Pa and Pw. 
In addition, because IFN-y and Thl cells have been shown to be critical in host 
protection to B. pertussis, the contribution o f the IFN-y-inducing cytokines IL-12 
and IL-18 to protection was investigated. Finally, as Thl and Th2 cells produce 
cytokines that are mutually inhibitory for the differentiation and effector functions 
o f the reciprocal phenotype, it was examined whether the cross-regulation o f Thl 
and Th2 cells occurs in vivo, using a coinfection model with a Th2 inducing parasite 
F. hepatica and the Thl-inducing bacterium B. pertussis.
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Figure 1.3 The Life Cycle of Fasciola hepática
❖  C h a p t e r  2  ❖  
M a t e r ia l s  a n d  M e t h o d s
2.1 P r e p a r a t i o n  O f  M e d i a  A n d  B u f f e r s
2.1.1 B o r d e t - G e n g o u  M e d iu m  
250 ml ddH20 (distilled/deionised water)
2.5 ml Glycerol
7.5 g Bordet Gengou Agar (Difco)
The medium was then autoclaved (121°C for 20 mins.), allowed to cool and 
supplemented with 1 ml o f cephalexin (Sigma, 10 mg/ml) and 50 mis o f pre-warmed 
sterile defribrinated horse blood (E+O Laboratories, Bonnybridge, Scotland). The 
medium was then poured into 9 cm petri dishes (20 ml aliquots) and stored at 4°C 
for up to 5 weeks.
Cephalexin
0.1 g Cephalexin dissolved in ddH20 and then filter sterilized.
1% Casein
6.0 g Sodium Chloride (NaCl)
10.0 g Casamino acids
Dissolved in 1 Litre ddH20 pH 7.2 and autoclaved 115°C for 20 mins.
2.1.2 P h o s p h a t e - B u f f e r e d  S a l i n e  (PBS)
80 g Sodium Chloride (NaCl)
11.6 g Sodium hydrogen phosphate (Na2HP0 4 )
2 g Potassium dihydrogen phosphate (KH2P04)
2 g Potassium Chloride (KC1)
Dissolved in 1 L o f ddH20 and pH adjusted to 7.0.
2.1.3 T r i s - B u f f e r e d  S a l i n e  (PBS)
2.42g Trizma base
8.76g Sodium Chloride (NaCl)
Dissolved in 1 L o f ddH20  and pH adjusted to 7.3
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2.1.4 S t a i n e r  a n d  S c h o l t e  M e d iu m  
Basal M edium
10.72 g L-Glutamic acid (monosodium salt)
0.24 g L-Proline
2.5 g NaCl 
0.5 g KH2P04 
0.2 g KC1
0.3 g Magnesium Chloride (MgCl2.6H20)
0.4 g Calcium Chloride (CaCl2.2H20)
1.525 g Tris (hydroxymethyl) methylamine
Dissolved in 1 L ddH20 and pH adjusted to 7.2. The medium was then autoclaved 
at 121°C for 20 minutes, allowed to cool and 1 ml o f supplement added per 100 ml 
o f basal medium before use.
Supplem ent
0.4 g L-Cysteine (dissolved first in 1 ml o f concentrated HC1)
0.5 g Ferrous Sulphate (FeSC>4.7H20)
0.6 g Ascorbic acid 
0.7 g Nicotinic acid
1.0 g Glutathione
Dissolved in 100 ml o f ddH20 and filter sterilized and stored at 4°C for up to 5 
weeks.
2.1.5  C e l l  C u l t u r e  M e d i u m
Complete RPMI medium: Roswell Park Memorial Institute (RPMI)-1640 medium 
(Gibco BRC, Life Technologies, Paisley, Scotland), was used to culture all cell 
lines, and primary cells isolated from murine spleens and lymph nodes. This was 
supplemented with 8% heat inactivated (56°C for 30 mins) foetal calf serum (FCS), 
lOOmM L-Glutamine, 100 U/ml penicillin, 100 pg/ml streptomycin and 50 pM 2- 
Mercaptoethanol.
4 6
2 .1 .6  D i e t h a n o l a m i n e  B u f f e r  
97 ml Diethanolamine
0.1 g Magnesium Chloride (MgC12.6H20)
0.2 ml 1M Sodium Azide (NaN3)
made up to 1 L with ddH20 and pH adjusted to 7.2
2 .1 .7  S o d iu m  a c e t a t e  b u f f e r  
Acetic acid (0.2M)
11.55ml o f glacial acetic acid was added to 1 L o f ddH20
Sodium acetate (0.2M) (CHsCOONa)
16.4 g o f sodium acetate was added to 1 L o f ddH20
Sodium acetate buffer
This was prepared by adding 148ml o f 0.2M acetic acid to 352ml o f 0.2M sodium 
acetate. The volume was brought up to 1 L with ddHzO and the pH adjusted to 5.0
2 .1 .8  3 -A M IN O -9-E T H Y L C A R B A Z O L E  ( A E C )  SUBSTRATE BUFFER 
10mg of AEC
lml dimethylformamide (DMF)
30ml 0.1M sodium acetate buffer (pH 5.0)
15pl 30% Hydrogen peroxide (H2O2)
First, the AEC was dissolved well in lml o f DMF in a glass tube. 30ml o f sodium 
acetate buffer (pH 5.0) was then added, and the resulting solution was then passed 
through a 45 pm filter. Finally 15 pi o f hydrogen peroxide was added. This 
substrate was freshly prepared prior to use.
2 .2  B a c t e r i a l  a n t i g e n s
B. pertussis Wellcome 28 phase 1 stocks were provided by Keith Redhead at the 
National Institute for Biological Standards and Control (NIBSC), Herts, UK. Heat 
killed B. pertussis for use in T-cell assays were prepared by incubation o f cells at
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90°C for 20 mins- Purified native pertussis toxin (PT), filamentous haemagglutinin 
(FHA) and pertactin (PRN) for use in T-cell assays were provided by Connaught 
Laboratories Ltd., Ontario, Canada. Purified filamentous haemagglutinin (FHA), 
pertactin (PRN) and non-toxic recombinant pertussis toxin (PT-9K/129G), were 
also provided by Chiron Corporation, Siena, Italy. PT was inactivated by heating at 
80°C for 20 minutes. This abolished mitogenic activity prior to use in T-cell assays 
in vitro. All other antigens were used as native preparations without chemical or 
heat-inactivation.
2.3 P r e p a r a t i o n  o f  L i v e r  F l u k e  H o m o g e n a t e  (LFH)
Adult liver flukes were obtained from infected livers o f slaughtered cattle at a local 
abbatoir. In order to remove bile and debris the flukes were washed in sterile PBS. 
Mature liver flukes were homogenised in 10 ml o f sterile PBS. The liver fluke 
homogenate was centrifuged at 13,000 g for 30 min. The supernatant containing 
soluble antigens was removed and aliquoted into 1 ml vials and stored at -20°C 
until use. Protein concentration was determined using bicinchoninic protein assay 
(BCA). This assay was used to quantitatively determine protein concentrations 
from 20pg/ml to 2000(o.g/ml. Bovine serum albumin, at a concentration range of 
25pg/ml to 2000pg/ml were used to plot a standard curve.
2.4 M o u s e  S t r a i n s
Specific pathogen-free BALB/c (H-2d), C57BL/6 (H-2b), and mutant C57/BL6 mice 
deficient in the IL-4 gene (IL-4'') were bred and maintained under the guidelines of 
the Irish Department o f Health and were 8-12 weeks old at the initiation o f 
experiments. IL-12 knockout (IL-12-/-) mice were purchased from Harlan Olac 
Ltd., Blackthorn, United Kingdom.
2 .5  A n t i b o d i e s
The specificities and source o f monoclonal and polyclonal antibodies used are 
detailed in Table 2.1
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2.6 C y t o k i n e  S t a n d a r d s
Murine cytokines were obtained from the Division o f Immunobiology in NIBSC 
and from commercial sources as outlined in Table 2.2
2 .7  C e l l  l i n e s
The adherent murine macrophage cell line J774 and the IL-2 dependent T-cell line 
CTLL-2 were obtained from the American Type Culture Collection (ATCC) 
Rockville, USA.
2 .8  CTLL C e l l  C u l t u r e
CTLL cells were cultured under sterile conditions in RPMI-1640 medium (as 
described in 2.2.5), supplemented with 5 U/ml o f recombinant IL-2 at 37°C and 
95% humidity in a C02 incubator. Cells were seeded at a density o f 2 x 105/ml and 
passaged every two to three days o f culture.
2 .9  C r y o p r e s e r v a t i o n  o f  c e l l s  i n  l i q u i d  n i t r o g e n
Cells were frozen in RPMI-1640 medium containing 10% (v/v) dimethysulphoxide 
(DMSO) and 20% FCS (v/v). The cells to be cryopreserved were first pelleted by 
centrifiigation, resuspended with the freezing mix at 4°C and then transferred to 
cryo tubes in 1.2 ml volumes. Cells were frozen under conditions that permitted a 
gradual reduction o f  temperature (l°C/min) before transferral to liquid nitrogen. 
Recovery o f viable cells from liquid nitrogen was performed by thawing the cells 
quickly in a 37°C water bath. The cells were then transferred to 10 ml centrifuge 
tubes and washed 3 times in RPMI-1640 to ensure that all traces o f DMSO were 
removed from the cell suspension. A viability count was performed and cells 
resuspended in complete medium and cultured at 37°C in a C02 incubator as 
described above.
2 .1 0  A s s e s s m e n t  o f  c e l l  v i a b i l i t y
A staining solution was prepared by dissolving 0.1 mg o f Acridine Orange and 0.1 
mg o f Ethidium Bromide (Sigma) in 100 ml o f PBS and stored at 4°C. To assess 
cell viability 980 pi, 180 pi, or 20 pi (1/50, 1/20, !4 dilution, depending on cell
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density) o f this stain was mixed with 20 pi o f cell suspension and placed in a 
haemocytometer. The number o f viable cells (green) and non-viable cells (orange) 
were counted using a fluorescent microscope.
2 .1 1  F o r m a l d e h y d e  d e t o x i f i c a t i o n  o f  b a c t e r i a l  a n t i g e n s
The detoxification o f bacterial antigen was achieved by addition o f Gelatin (0.02%, 
v/v) and Tween 20 (0.05%, v/v) to the antigen preparation followed by addition of 
formaldehyde (0.2%, v/v) and incubated overnight at 37°C. Following this 
treatment the sample was exhaustively dialysed against 0.01% formaldehyde/PBS. 
The concentration o f protein in the formaldehyde treated antigen sample was then 
assessed by the Bio-Rad protein assay.
2 .1 2  B i o -R a d  p r o t e i n  m i c r o a s s a y
Protein concentrations were determined by the use o f the Bio-Rad protein assay 
(Bio-Rad, Herts, UK). 800 pi o f either the test sample, a serially diluted protein 
standard (Bovine serum albumin (BSA)), or PBS were mixed with 200 pi o f Bio- 
Rad dye reagent. After 5 minutes, absorbance at 595nm was measured against the 
reagent blank and protein concentration o f the test sample was determined after 
reference to a standard curve prepared using BSA in the range o f 0 to 200 pg/ml.
2 .1 3  U V - S t e r i l i z a t i o n
Protein antigens or other preparations were sterilized by exposure to UV-irradiation 
at 254nm for 10 minutes at a distance o f 8 cm from the light source. Only 
preparations in medium free reagents were UV-irradiated as the phenol red dye 
present in RPMI-1640 medium generates toxic free radicals upon exposure to UV 
light.
2 .1 4  P r e p a r a t i o n  o f  a c e l l u l a r  v a c c i n e s
Alum adsorbed antigens were prepared by mixing 5pg each o f FHA, pertactin and 
PTd to 150pg o f alhydrogel and incubated overnight at 4°C with constant agitation. 
All other acellular vaccines used were provided as freeze dried preparations which 
were reconstituted in sterile PBS, or as full liquid formulations.
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2 .1 5  P r e p a r a t i o n  o f  w h o l e  c e l l  v a c c i n e s
0.2 human dose o f whole cell vaccines (88/522) or (94/532) reconstituted in sterile 
PBS were used for all immunizations, except where otherwise stated.
2 .1 6  Im m u n i z a t i o n s
All mice were 8-12 weeks old at the initiation o f experiments. Mice immunized by 
the intraperitoneal (i.p.) route received a maximum volume o f 0.3 ml per mouse. In 
experiments to assess the protective efficacy o f pertussis vaccines mice received 
two i.p. immunizations (weeks 0 and 4) and were aerosol challenged with B. 
pertussis (as described in section 2.14) 2 weeks after the second immunization.
2 .1 7  A e r o s o l  i n f e c t i o n  o f  m i c e
Respiratory challenge o f mice was induced by aerosol challenge using a modified 
version o f the method described by Sato et al., 1980. B. pertussis Wellcome 28 
phase 1 was grown at 37°C under agitation conditions in Stainer-Scholte liquid 
medium (Stainer and Scholte, 1971). Bacteria from a 48hr. culture were 
concentrated by centrifugation to 2 x 1010 CFU/ml in physiological saline containing 
1% casein. Mice were exposed for 15 minutes to the challenge inoculum using a 
nebulizer directed into an aerosol chamber containing groups o f 20-30 mice. Four 
mice form each experimental group were sacrificed two hours after aerosol 
challenge and at various other times to assess the number o f viable bacteria in the 
lungs.
2 .1 8  E n u m e r a t i o n  o f  v i a b l e  b a c t e r i a  i n  t h e  l u n g
Lungs were removed aseptically and homogenized in 1 ml o f sterile PBS with 1% 
casein on ice. One hundred microlitres o f  neat or serially diluted homogenate were 
plated out on Bordet-Gengou plates. The plates were incubated at 37°C for 4 days 
and the numbers o f colony forming units (CFU) were estimated. Results are given 
as the mean number o f B. pertussis CFU for individual lungs from four mice from 
each experimental group.
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2 .1 9  F a s c io l a  h e p a t ic a  i n f e c t i o n  o f  m ic e
Metacercariae were obtained from Compton Paddock Laboratories, Berkshire, UK. 
Mice were infected by placing a very small amount o f cotton wool which contained 
10 metacercariae into the mouth, followed by a few drops o f water to aid 
swallowing.
2 .2 0  D e t e c t i o n  o f  T - C e l l  c y t o k i n e s
Spleen mononuclear cells (2 x 106/ml) were stimulated in vitro with B. pertussis 
antigens, mitogens (positive control) or medium alone (negative control). 
Alternatively, lymph node cells (1 x 106/ml) were cultured in vitro using the same 
stimuli. Supernatants were removed after 24h for analysis o f IL-2 concentrations 
and after 72h for IL-4, IL-5 and IFN-y. IL-2 was assayed by testing the ability o f 
supernatants from antigen stimulated T-cells to support the growth o f the IL-2 
dependent CTLL-2 cell line. 50pl o f test supernatants, removed after 24hrs o f 
culture were added in triplicate to 96-well microtiter plates and incubated with 50pl 
o f CTLL-2 cells (1 x 105/ml). Cells were cultured for 24hrs and pulsed with [3H]- 
thymidine for the final 4hrs o f culture. Following the 4h pulse period, the wells 
contents were harvested onto glass fiber paper with an automatic cell harvester. 
The filters were then dried using an IR lamp and placed in plastic bags with non- 
aqueous scintillation fluid and [3H]-thymidine incorporation measured using a Beta- 
plate counter (Wallac). The levels o f IL-2 were determined after reference to a 
standard curve prepared with recombinant murine IL-2 and results expressed as 
international units per milliliter (IU/ml).
The concentrations o f IL-4, IL-5 and IFN-y were measured by enzyme 
linked immunosorbent assay (ELISA) using the antibodies described in table 2.1 
Cytokine specific capture antibodies (50)0,1/well at lpg/ml in PBS) were added to 
96-well microtitre plates (Nunc) and incubated overnight at 4°C. The plates were 
washed 4-5 times with wash solution (PBS/0.05% Tween 20) and then incubated 
with 200p 1/well o f blocking solution (PBS supplemented with 10% w/v o f dried 
milk (marvel®)) at room temperature for 2h to block non-specific binding sites. 
Following washing, plates were incubated overnight at 4°C with 50pFwell o f the
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test supernatant or the corresponding cytokine standard. The plates were then 
washed and incubated with 50pi/well o f a biotinylated anti-cytokine antibody and 
lpg/ml in PBS at room temperature for lh. After washing, the plates were 
incubated for 20 minutes at room temperature with 50pl/well o f extravidin alkaline 
phosphatase (Sigma Chemical Co. Ltd, Poole, Dorset, UK) at 1/2500 dilution in 
PBS. Finally, after washing, the plates were incubated with lOOpl/well o f p- 
nitrophenyl phosphate (pNPP) substrate (Sigma) at 1 mg/ml in 1M diethanolamine 
buffer pH 9.8. The O.D. value o f test samples and cytokine standards were 
measured at 405nm using a microtiter plate reader (Titertex) and cytokine 
concentrations for test samples determined after reference to a standard curve 
prepared from recombinant cytokines o f known concentration and potency. The 
limits o f the assays were 0.5 ng/ml for IFN-y and 20 pg/ml for IL-4 and IL-5.
2.21  I s o l a t i o n  o f  PBMC f r o m  m u r i n e  b l o o d
A stock solution o f (35.3% w/v) o f analytical grade metrizamide (Nyegaard) was 
prepared in distilled water. This was filter sterilized and kept in the dark at 4°C. 
Prior to use the stock metrizamide solution was diluted to 18% v/v in PBS. Fresh 
blood samples obtained by thoracic bleed were collected into tubes containing 1M 
EDTA (lOpl/tube). This was to prevent the blood from clotting. Blood was then 
carefully layered onto the metrizamide gradient (2 ml) and centrifuged at 1500 rpm 
for 30 mins. PBMC were removed from the interface, washed twice and 
resuspended in RPMI-1640 (8% FCS), and a viable cell count was performed
2.22  D e t e c t i o n  o f  c y t o k i n e - s e c r e t i n g  c e l l s  b y  ELISPOT
Antibody-forming cells were quantified by an insoluble substrate B. pertussis- 
specific Enzyme-Linked Immunospot assay (ELISPOT). The wells o f 96-well 
nitrocellulose plates (Multiscreen HA: Millipore, Bedford, MA) were coated 
overnight at 4°C with lOOpl o f IFN-y or IL-5 capture antibody, at a concentration 
o f 2pg/ml. The plate and the supporting manifold were washed 5 times aseptically 
with PBS and then were blocked for 2hr with RPMI, 8%FCS (vol/vol). 
Supernatants were removed from spleen cells (lxl 05 cells/ml), which had been
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stimulated for 72 hours with B. pertussis antigens, and the cells were resuspended 
in fresh medium. Resuspended cells were added to the nitrocellulose plates and 
incubated overnight at 37°C with 5% C02. Plates were washed three times with 
PBS, followed by a further three washes with PBS/Tween. After washing, 
lOOpl/well biotinylated detection antibody in PBS/Tween/ 1% BSA, was added at a 
concentration o f 1 pg/ml for IFN-y and 5pg/ml for IL-5, and plates were incubated 
overnight at 4°C. Following incubation, plates were washed with PBS and 
peroxidase-conjugated polyclonal goat-anti-biotin (PAB) antibody was added at 
lOOpl/well, and at a concentration o f 1 mg/ml in PBA/Tween/1% BSA for both 
cytokines, and plates were again incubated for 24 hours at 4°C. Plates were then 
washed 3 times more with PBS/Tween, before the addition o f 200pl/well 3-amino- 
9-ethylcarbazole substrate buffer (AEC). After maximal spot development (5-30 
minutes), this was removed, and the plates were washed once with distilled water 
and allowed to air-dry. Spots representing individual cytokine-secreting cells were 
counted using a zoom stereo microscope.
2.23 ELISPOT a s s a y  f o r  t h e  i d e n t i f i c a t i o n  o f  a n t i b o d y - s e c r e t i n g
CELLS
Antibody-forming cells were quantified by an insoluble substrate B. pertussis- 
specific ELISPOT. The wells o f 96-well nitrocellulose plates were coated 
overnight with lOOpl o f  sonicated B. pertussis or inactivated pertussis toxin 
(5pg/ml). Both surfaces o f the membrane were washed 5 times aseptically with 
PBS and then were blocked for 2hr with RPMI, 8%FCS (vol/vol). After blocking, 
spleen or peripheral blood mononuclear cell preparations were added to 
quadruplicate wells at concentrations from 1 x 104 to 1 x 107 cells/ml and were 
incubated at 37°C with 5% C02 for 2 days. After washing 6 times in sterile PBS, 
horseradish peroxidase-conjugated goat anti-mouse IgG (Sigma, Dorset, UK) was 
added for 2 hours. Plates were then washed 3 times more before the addition o f 
200(j.l/well 3-amino-9-ethylcarbazole substrate buffer (AEC). After 45 min, this 
was removed, and the plates were washed once with distilled water and allowed to
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air-dry. Spots representing individual antibody-forming cells were counted by use 
o f a zoom stereo microscope.
2 .2 4  D e t e r m i n a t i o n  o f  s e r u m  I g G  a n t i b o d y  l e v e l s
Serum samples were prepared from peripheral blood o f mice removed from the 
thoracic cavity after sacrifice. Blood was allowed to clot for 1 hour at room 
temperature and then placed at 4°C for 2-4 hours. Serum was then removed into 
fresh tubes and stored at -20°C. The levels o f antigen-specific IgG antibodies in the 
sera o f naïve, immunized or infected mice was determined by ELISA. PT, FHA and 
PRN (lpg/ml in PBS) or B. pertussis sonicate (5pg/ml in PBS), was added to 96- 
well microtiter plates and incubated overnight at 4°C. Excess antigen was washed 
with wash buffer (PBS/0.05% Tween 20) and non-specific binding sites were 
blocked by incubating the plates with PBS supplemented with 10% w/v o f dried 
milk for two hours. Sera were serially diluted in PBS on the washed plates to 
determine the endpoint titres. The initial dilution used for analysis o f total IgG 
titres depended on the number o f immunizations and the time after immunization or 
infection. In general, an initial dilution o f 1/75 or 1/100 was used for serum from 
mice which were infected or which had received two immunizations. The plates 
with the serum samples were incubated overnight at 4°C or for 2h at room 
temperature. After washing, plates were incubated for lh at room temperature with 
50pl/well o f an alkaline phosphatase conjugated rat anti-mouse IgG monoclonal 
antibody (1/10,000 dilution in PBS/2%FCS), with a specificity for the whole IgG 
molecule. The plates were then washed and incubated with 1 OOpl/well o f p- 
nitrophenyl phosphate in diethanolamine buffer. The absorbance was measured at 
405nm. Results are expressed as logio endpoint antibody titres determined by 
extrapolation to the OD405nm value o f the control, naïve serum. Control wells in 
which the antigen, serum sample or detection antibodies were omitted gave 
negligible absorbances with range 0.1-0.2.
2 .2 5  T h e  d e t e c t i o n  o f  I L -1 2  b y  i m m u n o a s s a y
IL-12 was detected by immunoassay using commercially available antibodies 
(Genzyme) specific for the IL-12 p40 subunit. These antibodies recognise IL-12
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p40 either as a monomer, heterodimer, or as part o f the p70 heterodimer. 96-well 
microtiter plates were coated with 50pi/well o f a capture anti-IL-12 monoclonal 
antibody (as described in Table 2.1) at a concentration o f 2pg/ml in PBS and 
incubated overnight at 4°C. Following washing non-specific binding sites were 
blocked at room temperature for 2hr using 200pl/well o f PBS with 10% w/v dried 
milk. After washing 50pl o f the test sample or diluted IL-12 standards in the range 
o f 0-5000pg/ml were added and incubated overnight at 4°C. The plates were then 
washed and incubated with the detecting antibody (rat anti-mouse IL-12) at a 
concentration o f 2pg/ml in PBS (50pl/well) for lhr at room temperature. An 
alkaline phosphatase conjugated mouse anti-rat IgG2a (PharMingen) antibody was 
then used to detect the second anti-IL-12 antibody. Plates were incubated with 
50pl/well o f a 1/1000 dilution o f the alkaline phosphatase antibody for 2hr at room 
temperature. Finally, plates were washed and incubated with 1 OOpPwell o f pNPP 
substrate at 1 mg/ml prepared in diethanolamine buffer (pH 9.8). OD values were 
measured at 405nm and IL-12 concentrations were determined from a standard 
curve prepared using recombinant murine IL-12 o f known concentration.
2.26 IL-18 ELISA
The concentrations o f IL-18 were determined using an enzyme-linked 
immunosorbent assay (ELISA), using the antibodies described in Table 2.1. IL-18 
specific capture antibody (50pl/well at lpg/ml in PBS) was added to 96-well 
microtitre plates and incubated overnight at 4°C. The plates were washed 5 times 
with PBS/0.05% Tween 20 and then incubated with 200pl/well o f blocking solution 
(1%BSA, 5% sucrose, and 0.05% NaN3 in PBS) for 2 hours at room temperature, 
to block non-specific binding sites. Following washing, plates were incubated 
overnight with 50pFwell o f the test supernatant, or lung homogenates, and the 
appropriate cytokine standard. The plates were then washed again and incubated 
with 50pl/well o f a biotinylated detection antibody at 200ng/ml in Tris Buffered 
Saline (TBS) pH 7.3, at room temperature for 2 hours. After washing the plates 
were incubated with for 30mins at room temperature with 100pl/well streptavidin 
(horseradish peroxidase conjugated) (Sigma chemical Co. Ltd., Poole, Dorset, UK),
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at a 1/1000 dilution in TBS as recommended by the manufacturer. Finally, after 
washing, the plates were incubated with lOOpl/well o f tetramethylbenzidine (TMB) 
substrate (Sigma). The plates were allowed to develop for approximately 20mins, 
and then the reaction was stopped with the addition o f 1M H2SO4. The O. D. value 
o f test samples and cytokine standards were measured at 450nm using a microtiter 
plate reader (SpectraMax, Gemini) and cytokine concentrations for test samples 
determined after reference to a standard curve prepared from recombinant cytokines 
o f known concentration and potency. The limit o f the assay was 31 pg/ml.
2 .2 7  S t a t i s t i c s
Statistical analysis o f data was performed using the computer based statistical 
package StatWorks. Statistical significance o f difference was assessed using the 
Mann Whitney U test or Student’ s t test as indicated in the text and figure legends.
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T a b l e  2 . 1  T h e  o r i g i n  a n d  s p e c i f i c i t i e s  o f  a n t i b o d i e s
A n tibody clone S p ecific ity C onjugate Supplier
RA-6A2 mouse IFN-y - PharMingen, San Diego, USA
XMG1.2 » IFN-y biotin 1
11-B-ll IL-4 - National Institute o f Health, USA
BVD6-24G2 IL-4 biotin PharMingen, San Diego, USA
TRFK5 IL-5 - II
TRFK4 IL-5 biotin »!
C17.8 IL-12 - Genzyme Diagnostics, MA, USA
C15.6 IL-12 - »!
R19-15 IgG2a AKP PharMingen, San Diego, USA
51817.111 IL-18 - R&D Systems, UK
- IL-18 biotin II
goat Biotin peroxidase Sigma Chemical Co. Ltd, Poole, 
Dorset, UK
T a b l e  2 .2  R e c o m b i n a n t  c y t o k i n e s
C ytokine Source
Mouse IFN-y 
" IL-2 
" IL-4 
" IL-5 
" IL-12 
" IL-18
NIBSC, Herts, UK 
NIBSC, Herts, UK 
NIBSC, Herts, UK 
PharMingen, San Diego, USA 
Stanley Wolf, Genetics Institute Inc., Mass., USA 
R&D Systems, UK
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❖ Chapter 3 ❖
A  RESPIRATORY CHALLENGE MODEL FOR INFECTION WITH
Bo r d e t e l l a  pe r tu ssis  : A p p l i c a t i o n  in  t h e  a s s e s s m e n t
OF PERTUSSIS VACCINE POTENCY AND IN DEFINING THE 
MECHANISM OF PROTECTIVE IMMUNITY
3 .1  I n t r o d u c t i o n
The last decade has seen the emergence o f an abundance o f information regarding 
pathogenesis and immunity to B. pertussis; data which has improved our current 
understanding o f the disease, and contributed to the development o f new less 
reactogenic vaccines. Although immune responses elicited following vaccination or 
infection in humans has provided important insights on immunological correlates o f 
protection, a more precise examination o f the mechanisms o f protective immunity is 
very often dependent on the utilization o f animal models. Furthermore, licensure o f 
vaccines usually requires an evaluation o f potency and safety in pre-clinical models 
o f infection. Studies in a murine respiratory challenge model o f infection with B. 
pertussis have made a significant contribution to the understanding o f the 
immunological mechanisms that determine the resolution o f infection or progression 
to disease.
Aerosol inoculation o f mice with B. pertussis results in a uniform, self- 
limiting infection with many similarities to that observed in children. Although the 
characteristic cough is absent in this model, other disease manifestations such as 
local pathology, systemic reactions, including leucocytosis and CNS effects have 
been documented (Pittman et ol., 1980, Sato et al., 1980, Loscher et al., 2000). 
Because B. pertussis does not occupy a purely extracellular niche, but can invade 
and survive within several mammalian cell types, protection in both mice and 
children involves a complex dual T-cell and antibody mechanism. The murine 
model o f B. pertussis infection has provided vital information on the roles o f both 
humoral and cell-mediated immunity (Mills et al., 1993, Mills et al., 1998a, 
Redhead et al., 1993, Barnard et al., 1996, Mahon et al., 1996, Mahon et al., 1997, 
McGuirk et al., 1998) to B. pertussis during infection and immunization. Antibody 
may be important for limiting infection and disease by preventing bacterial 
adherence to ciliated epithelial cells, may play a role in the neutralization o f toxins, 
and may also be required for the elimination o f bacteria through opsonization. Thl 
cells and particularly the cytokine IFN-y, appears to be required for the activation o f 
macrophages to kill intracellular bacteria. However, despite the numerous reports 
on different aspects o f immunity to B. pertussis after infection or immunization, in 
both mice and humans, there is still no clear consensus as to what constitutes a
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protective immune response to B. pertussis. Not only does protection involve both 
humoral and cellular mechanisms, but optimum immunity to B. pertussis also 
appears to incorporate multiple protective antigens. However, a major goal o f 
clinical studies on pertussis to correlate a critical level o f  antibody, or a quantifiable 
T-cell response against a single antigen or combination o f antigens, with protection 
against B. pertussis, has to date remained unattainable.
The active mouse protection test originally devised by Kendrick (1947) has 
been used to assess the potency o f Pw. This involves intracerebral (i.c) challenge o f 
mice 2-3 weeks post immunization with decreasing doses o f the vaccine. Although 
studies in the U.K. in the 1950’s revealed that protection against i.c challenge in 
mice correlated with the estimated efficacy o f Pw in clinical trials (MRC, 1959), the 
Kendrick test fails to predict the efficacy o f Pa in humans, and is unsuitable for 
dissecting the mechanisms o f immunity to B. pertussis, due to the route o f challenge 
and the dissimilarity o f the model to human disease (Corbel & Xing, 1997). 
Prediction o f the potency o f Pa based on immunogenicity, especially antibody 
responses to individual B. pertussis antigens is also questionable. The measurement 
o f antibody to the putative protective antigens o f B. pertussis by ELISA following 
immunization o f children, have failed to correlate with the estimated vaccine 
efficacy in human clinical trials (Greco et al, 1996, Simondon et al., 1997, 
Gustafsson et al., 1996, Olin et al., 1997). Other drawbacks exist with regard to 
the evaluation o f pertussis vaccine efficacy based on the measurement o f antibody 
responses. Detection o f B. pertussis-specific antibodies by ELISA does not 
consequently mean that these antibodies are functionally relevant, or play a role in 
protection. It may be argued that antibody levels detected by this method 
demonstrate that the antigenic proteins are immunogenic and are capable of 
inducing an acquired immune response, but does not automatically indicate that the 
antibody elicited functions in limiting infection in vivo. Furthermore, measurement 
o f circulating IgG may not necessarily reflect what is happening at the local mucosal 
surface in the lung. It is reasonable to expect that antibodies to adhesins such as 
FHA will exert a stronger protective effect when present at the site o f attachment 
than in the circulatory system. In addition, measurement o f total IgG does not 
impart significant information on the induction o f  specific Th subtypes,
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immunological memory, or their role in protective immunity. The inherent 
disadvantages in using antibody responses as a predictor o f vaccine efficacy, 
together with the demonstration that cellular immunity has also plays a major role in 
the protective mechanisms against B. pertussis, suggests that murine respiratory 
challenge model, in which both T-cell and antibody responses to different 
components can be easily monitored, offers the most definitive method of 
evaluating pertussis vaccine potency. In this study, the murine respiratory challenge 
model was employed to evaluate the efficacy and immunogenicity o f a number of 
acellular and whole cell pertussis vaccines.
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3.2 R e s u l t s
3.2.1 S e r u m  a n t i b o d y  l e v e l s  d e t e c t e d  f o l l o w i n g  i m m u n i z a t i o n  
w i t h  Pa o r  Pw d o e s  n o t  p r e d i c t  p e r t u s s i s  v a c c i n e  e f f i c a c y  
It has previously been shown that there is a highly significant correlation between 
vaccine-induced protection against B. pertussis in children, and protection in the 
murine respiratory challenge model (Mills el al., 1998a). Mills and colleagues 
evaluated clinical lots o f different Pw and Pa using the murine respiratory challenge 
model, and demonstrated that the efficacy o f these vaccines, which had previously 
been evaluated in human clinical trials, were markedly similar when assessed in the 
murine model. Vaccines o f high efficacy in children were shown also to be highly 
protective in mice (Table 3.1). Immunization with PM Pw, which has an estimated 
efficacy o f  95%, conferred the highest level o f  protection in mice. The lower 
efficacy CLI Pw, which protected 36 and 48% o f children in the Italian and Swedish 
trials respectively (Greco et al., 1996, Gustafsson et al., 1996), also showed 
significantly poorer clearance in immunized mice. Mice immunized with the 3- 
component SmithKline Pa, had a higher rate o f bacterial clearance than in those 
immunized with SB Pa2. This correlated well with the results from the Italian and 
Swedish trials (Greco et al., 1996, Gustafsson el al., 1996), which showed an 
estimated effiacacy o f 84% for SB Pa3 and 59% for SB Pa2. The efficacy o f both 
the 5-component Pa manufactured by Connaught laboratories (CLL Pa5) and the 
Pasteur Merieux 2-component Pa (PM Pa2), was estimated at 85%, in the Swedish 
(Gustafsson et al., 1996) and Senegal (Simondon et al. 1997),and these vaccines 
generated an equivalent level on protection in immunized mice. The high level o f 
protection (84%) conferred by the CB Pa3a in the Italian trial (Greco et al., 1996), 
showed a similar level o f protection in the mouse model, which was comparable to 
the level o f protection afforded by a different clinical lot o f the same vaccine (CB 
Pa3b). Analysis o f T-cell responses following vaccination clearly showed that a 
higher level o f protection was provided through the induction o f a more polarized 
Thl response, both in children and mice (Table 3.1). In contrast, Pa induce a mixed 
Thl/Th2 cytokine profile in children and a more polarized Th2 response in mice 
(Table 3.1).
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Given that vaccine-induced protection in mice correlates with estimated 
pertussis vaccine efficacy in children, the serum antibody responses from immunized 
mice used in the study discussed above, were examined in an attempt to define the 
relative contribution o f  humoral immunity to vaccine-induced protection against B. 
pertussis, and to correlate levels o f B. pertussis-specific antibody with protection. 
The antibody response o f mice immunized with the Pasteur-Merieux (PM) 2- 
component Pa combined with Hepatitis-B, Hib and IPV vaccines either as a full 
liquid formulation (PM 94), or reconstituted before injection (PM 181) were also 
evaluated, in order to determine if the addition of other vaccines would effect 
antibody responses to B. pertussis. Mice were immunized with 0.2 human dose of 
either PM Pw, CLI Pw, SB Pa2, SB Pa3, PM Pa2, CLL Pa5, CB Pa3(a)/CB 
Pa3(b), or Pasteur Merieux (PM) 2-component Pa combined with Hepatitis-B, Hib 
and IPV vaccines, either as a full liquid formulation (PM 94) or reconstituted before 
injection (PM 181), and boosted 4 weeks later. Two weeks after the second 
immunization, blood was recovered from individual mice and serum antibody 
responses to killed B. pertussis, PT, FHA, PRN and FIM were evaluated by ELISA.
Antibody responses to the antigens in different lots o f the CB Pa3 vaccine 
were not significantly different (Fig. 3.2). Similarly different formulations o f the 
PM Pa2 combined with Hepatitis-B, Hib and IPV vaccines (PM 94 and PM 181) 
did not have a significant effect o f the induction o f antibody responses to PT and 
FHA. Antibody levels to full liquid formulation (PM 94) is almost identical to that 
o f reconstituted vaccine (PM 181) (Fig. 3.2). However, antibody levels to PT and 
FHA in these vaccines were slightly lower when compared with the PM Pa2 used in 
the Senegal trial, which was combined with diphtheria and tetanus vaccines. In 
general all the Pa induced potent antibody responses to each o f the antigens in the 
vaccine (Fig. 3.2). The strongest antibody responses observed were those to PT, 
however antibody levels to FHA were also quite considerable. In contrast, the 
antibody response to PT was weak in mice immunized with the higher efficacy PM 
Pw. FHA-specific antibody detected in the serum o f mice immunized with both 
high (PM Pw) and low (CLI Pw) efficacy Pw were comparable to those induced in 
mice immunized with Pa. Antibodies specific for FIM were detected at low levels 
in the high efficacy PM Pw. Similarly, immunization with the high efficacy 5-
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component Connaught Pa induced weak FIM-specific antibody responses. In 
contrast, a strong antibody response to FIM was observed in mice immunized with 
the low efficacy CLI Pw. These results clearly demonstrate that antibody responses 
detected by ELISA do not correlate with estimated pertussis vaccine efficacy, and 
an observation o f high levels o f antibody to the putative protective antigens o f B. 
pertussis following immunization does not necessarily indicate high efficacy.
3.2.2 A p p l i c a t i o n  o f  t h e  m u r i n e  r e s p i r a t o r y  c h a l l e n g e  m o d e l  in
THE EV ALU ATIO N  OF THE PROTECTIVE EFFICACY OF FIVE DIFFERENT PA 
The benefits o f animal models for vaccine evaluation and for dissecting the 
mechanism o f immunity are well illustrated by several studies using a murine model 
o f infection with B. pertussis. Experiments carried out using this model have shown 
that there is a significant correlation between pertussis vaccine efficacy in children 
and protection in mice (Mills et al., 1998a, Mills et al., 1998b), and identified that 
T-cells play a significant role in the protective mechanisms leading to the resolution 
o f infection with B. pertussis. It has been demonstrated that immunization with Pw 
induces a polarized Thl response (Redhead et al., 1993, Barnard et al., 1996, Mills 
et al., 1998a), whereas immunization with Pa induces a polarized Th2 response in 
mice and a more mixed Thl/Th2 response in children (Ausiello et al., 1997, Ryan et 
al., 1997, Ryan et al., 1998).
In this study, five different Pa, the efficacy o f which were previously 
evaluated in clinical trials (Greco et al., 1996, Gustaffson et al., 1996, Simondon et 
al., 1997), were received from the World Health Organization (WHO), to be 
evaluated in the murine respiratory challenge model as a blinded trial (it is important 
to note that the vaccines received were not the actual batches used in the clinical 
evaluations). This collaborative study was organized to examine whether the 
murine respiratory challenge model was suitable to discriminate between different 
Pa, based on their protective ability and induction o f appropriate immune responses, 
and to assess the consistency o f the model between different laboratories. Mice 
were immunized with SB Pa2, SB Pa3, CLL Pa5, JNIH-3, PM Pa2 (composition 
and efficacy outlined in Table 3.1), and boosted 4 weeks later. T-cell cytokine and 
antibody responses were evaluated 2 weeks after secondary immunization. Mice
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were then infected with B. pertussis and CFU counts were performed on individual 
lungs at intervals after challenge to examine the protective ability o f each vaccine.
The Pa in this study provided a significant level o f protection against 
respiratory challenge (Fig. 3.3). Non-immunized control mice showed a 
progressive increase in the numbers o f viable bacteria in the lungs, up to 10 days 
post-infection, after which time bacterial numbers begin to decline (Fig. 3.3). In 
contrast, all immunized groups showed a sharp reduction in bacterial load 3 days 
post challenge, and the lungs were almost completely free from bacteria at day 14. 
All immunized groups displayed very similar clearance, and there was no significant 
difference between the numbers o f  viable bacteria in the lungs o f  mice immunized 
with the different vaccines. All vaccines provided a significant degree o f protection 
against B. pertussis challenge, despite differences in the their composition (Fig 3.3).
Analysis o f spleen cell cytokine production showed that mice immunized 
with the different Pa displayed a polarized but not particularly potent Th2-type 
cytokine profile, with very little IFN-y production, low levels o f IL-4 and moderate 
levels o f IL-5 in response to B. pertussis antigens (Fig. 3.4). Although there was 
small differences in the estimated efficacies o f the vaccines, the polarized Th2 
response observed was consistent, and cytokine levels did not differ significantly 
between each vaccine (Fig. 3.4).
Total IgG levels in the serum o f mice immunized with the different Pa were 
also examined. There was no antibody detected in mice immunized with alum alone 
(Control) (Fig. 3.5). All Pa induced potent antibody responses to the antigens in 
the vaccine, but the levels o f B. pertussis-specific antibody varied considerably 
between vaccines, even in those that had the same component antigens (Fig. 3.5). 
The 5-component CLL Pa induced lower levels o f antigen-specific antibody in 
general, compared to other Pa, except in response to FFLA. JN1H-3 and the 2- 
component PM Pa, induced the most potent antibody responses to all antigens 
tested. Overall, the strongest responses induced were those to PT and FHA, levels 
o f which were high in all vaccines tested. As expected, PRN-specific antibodies 
were detected only in mice immunized with either the Connaught 5-component Pa 
or SB Pa3, with considerably higher levels o f PRN-specific antibody induced with 
the SB Pa3. Antibodies to BP were detected at high levels in vaccines JNIH 3 and
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PM Pa2, but were significantly lower in all other vaccines tested. (SB Pa2, CLL 
Pa5, SB Pa3).
3 .2 .3  U s e  o f  t h e  m u r i n e  m o d e l  t o  d e t e r m i n e  c o n s i s t e n c y  b e t w e e n  
DIFFERENT BATCHES OF P w
The protective efficacy o f different clinical lots o f the Pw manufactured by Pasteur 
Merieux was determined using the murine respiratory challenge model. Mice were 
immunized twice, 4 weeks apart and T-cell and antibody responses were assessed 2 
weeks after secondary immunization. Mice were then challenged and lungs were 
taken at intervals after challenge to assess the numbers o f viable bacteria in the 
lungs. The PM Pw has been previously shown to have an estimated efficacy o f 95% 
in clinical trials. However, difficulties had recently been experienced with this 
vaccine in it’s ability to pass the Kendrick test. Although the clinical lots o f the 
vaccines used in this study were not the same lots used in clinical trials, this vaccine 
was found to provide highly effective protection against B. pertussis infection in the 
murine model (Fig. 3.6). Three clinical lots o f this vaccine were tested and there 
was good reproducibility between batches.
Examination o f the cytokine responses o f Pw-immunized mice, revealed that 
each o f the clinical lots o f this vaccine induced a polarized Thl response. Splenic 
T-cells secreted high levels o f TFN-y in particular to killed B. pertussis, and no IL-4 
or IL-5 upon restimulation in vitro (Fig. 3.7). Surprisingly, cytokine responses to 
PT were absent; an unusual observation given that previous studies examining 
cytokine responses post-immunization with Pw have demonstrated that PT is 
capable o f inducing appreciable amounts o f IFN-y (Mahon et al., 1996, Barnard et 
al., 1996, Ausiello et al., 1997, Ausiello et al., 1999).
Serum antibody levels induced following immunization with the Pasteur 
Merieux Pw were also examined. The antibody response to whole bacteria was the 
strongest response, but high levels o f FHA- and PRN-specific antibodies were also 
detected (Fig. 3.8). Consistent with the data on T-cell responses, immunization 
with these vaccines did not induce antibodies specific for PT. The absence o f an 
immune response to PT may suggest that the bacteria used to prepare these batches 
o f Pw have lost this virulence factor. This may explain their failure to pass the
6 7
Kendrick test, where an immune response to PT is considered to play a major role. 
The antibody responses observed were consistent between different batches.
3 .2 .4  U s e  o f  t h e  m u r i n e  m o d e l  t o  d e t e r m i n e  c o n s i s t e n c y  b e t w e e n
DIFFERENT BATCHES OF PA
The 2-component Pa manufactured by Pasteur Merieux has been previously shown 
to have an estimated efficacy o f 85% in the Senegal trial (Simondon et al., 1997). 
In this study the protective efficacy o f different clinical lots o f the Pasteur Merieux
2-component vaccine, formulated with the Haemophilus influenzae type B (Hib) 
vaccine (also manufactured by Pasteur Merieux), was evaluated in the mouse 
model. Mice were immunized at 0 and 4 weeks and then infected with B. pertussis 
2 weeks post secondary immunization. The course o f infection in immunized mice 
was examined through the analysis o f the numbers o f viable bacteria in the lungs at 
intervals post-challenge. This vaccine provided effective protection against 
respiratory challenge with B. pertussis (Fig. 3.9), although the level o f protection 
was not as good as that observed with Pw (Fig. 3.6). The numbers o f viable 
bacteria in the lungs o f immunized mice decline rapidly within 3 days post-infection. 
Despite an occasional rebound in CFU numbers recovered from infected mice, the 
lungs are almost completely free from bacteria by day 14. Evaluation o f the 
protective efficacy o f this 2-component Pa without the addition of the Hib vaccine, 
was carried out in a previous study (Mills et al., 1998a). Compared to this 
previous evaluation in the murine model, formulation with Hib does not appear to 
affect the protective efficacy o f the vaccine.
Cytokine responses following immunization with different lots o f PM Pa2, 
were measured 2 weeks after secondary immunization, on the day o f challenge. 
These vaccines induced a polarized Th2 cytokine profile from spleen cells 
restimulated in vitro with the relevant B. pertussis antigens (Fig. 3.10). Splenic T- 
cells secreted high levels o f IL-5 and moderate levels o f IL-4. High levels o f IFN-y 
were produced to heat-killed B. pertussis and PT. However, the potent induction 
o f IFN-y by heat-killed B. pertussis, is most likely due to the presence o f residual 
LPS in the bacterial preparation, which induces IL-12 production from innate cells. 
The high levels o f IFN-y produced in response to PT, are due to a mitogenic effect
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o f the toxin, as a result o f insufficient inactivation o f this batch o f the toxin prior to 
spleen cell stimulation.
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D i s c u s s i o n
Effective vaccines against disease caused by B. pertussis infection have been 
available and used for over 50 years (Cherry, 1996). Although Pw have been
shown to be very effective at inducing protective immunity against whooping
cough, they have been associated with a variety o f adverse reactions (Cherry et al., 
1998, Sidley et al., 1989, Löscher et al., 1998). Consequently, concern about 
safety, rather than efficacy has been the major impetus for the development o f new 
less reactogenic Pa vaccines. A major obstacle in the development o f new pertussis 
vaccines, is that there is no serologic marker that correlates with clinical efficacy, 
and it is unclear which B. pertussis antigen (or antigens) induces protective 
immunity. This means that any candidate pertussis vaccine must undergo expensive 
trials involving a large number o f participants to show that the vaccine is 
efficacious. Ideally, laboratory tests should enable us to predict the protective
efficacy o f new or modified Pa vaccines without large and costly efficacy trials.
Currently, there is an urgent need for such tests, because the traditional Kendrick 
mouse protection assay for potency is o f little or no value for the new Pa (Corbel & 
Xing, 1997), although it has been used to assess the potency o f Pw (Kendrick, 
1947).
A candidate model o f infection which may be able to overcome some o f the 
limitations of current vaccine assessment protocols, is the murine respiratory 
challenge model. This model provides a means by which we can assess pertussis 
vaccine potency, and allows us to investigate the mechanisms o f protective 
immunity to B. pertussis. Data obtained from studies in the murine model (Mills et 
al., 1998a, Mills et al., 1998b, Mahon et al., 1996, Mahon et al., 1997, Barbie et 
al., 1997, Redhead et al., 1993, Barnard et al., 1996), is consistent with the failure 
to identify a single correlate o f protection in clinical trials, and suggest that 
immunogenicity studies against individual B. pertussis antigens in mice are unlikely 
to predict vaccine efficacy in children. This can be explained in part by the fact that 
protection is multifactorial and is mediated by both humoral and cellular 
mechanisms (Mills et al., 1998a). In addition, there has been a lack o f standardized 
functional assays for the various putative protective vaccine-induced antibodies 
(Corbel & Xing, 1997, Siber, 1997). The highly significant correlation between
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bacterial clearance in immunized mice, and vaccine efficacy in children (Mills et al., 
1998a, Mills et al., 1998b), suggests that the murine respiratory challenge model 
may have valuable applications in the evaluation and development o f future vaccines 
prior to licensure. Comparisons o f the clearance o f bacteria in mice immunized with 
an experimental vaccine, to a standard vaccine o f known efficacy, may allow a 
reliable prediction o f the efficacy o f this vaccine in children.
The murine respiratory challenge model has been successfully used as a 
method for assessing the protective efficacy o f both Pa and Pw (Mills et al., 1998a, 
Mills et al., 1998b). In this study, the murine model has been utilized to evaluate 
the protective efficacy o f a range o f Pa, and one Pw, and to investigate the relative 
contributions o f humoral and cellular immunity to protection. The acellular 
vaccines tested in the WHO study were either two component (Pasteur Merieux, 
SmithKline Beecham, JNIH-3 - PT, FHA), three component (SmithKline Beecham, 
- PT, FHA, PRN), or five component (Connaught - PT, FHA, PRN, FIM 2, 3). 
The contribution o f different B. pertussis antigens to protection has been 
investigated both in the mouse model and in clinical trials. Results o f active and 
passive immunization experiments with individual antigens in mice have 
demonstrated that either PT or PRN can confer relatively high levels o f protection 
(Mills et al., 1998a). FHA is less protective, but does augment the protective 
efficacy o f PT. The findings from clinical trials indicate that a monocomponent 
pertussis toxoid vaccine, comprised o f chemically detoxified PT, can provide 71% 
protection against WHO-defined pertussis (Taranger et al., 1997, Trollfers et al., 
1995). Further studies from clinical efficacy trials have shown that 3-component, 5- 
component and most 2-component vaccines have higher estimated efficacies (84- 
85%) when compared to the protective efficacy o f the monocomponent vaccine 
(Gustaffson et al., 1996, Simondon et al., 1997, Olin et al., 1997). Although, a 
direct comparison o f the efficacies o f these vaccines is difficult, as they were tested 
in different clinical trials, contained different doses o f antigen and had different 
inactivation procedures, it does appear that vaccine efficacy increases with the 
number o f antigenic components included (CDC, 1997, Gustaffson et al., 1996, 
Simondon et al., 1997, Miller et al., 1997, Olin et al., 1997). However the benefit
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o f addition o f more than 2 component antigens in the vaccine formulation is not so 
significant (Mills et al., 1998a).
The findings from this study are consistent with previous observations. The 
five different vaccines from the WHO study showed that inclusion o f five antigens 
to the vaccine formulation, did not increase the efficacy o f the 2-component 
vaccines in the mouse model. The three 2-component vaccines (SB Pa2, JNIH-3, 
and PM Pa2) showed significant protection against aerosol challenge (Fig. 3.4). 
Surprisingly, immunization with the three-component SB Pa3 or the 5-component 
CLI Pa5, afforded very similar degrees o f protection to the 2-component vaccines; 
the addition o f PRN or FIM did not enhance their protective ability. However, 
estimations o f the efficacy of these vaccines in clinical trials showed that they all 
provided a high degree o f protection (Table 3.1), and without the inclusion o f a low 
efficacy vaccine in the experimental design, discrimination between vaccines was 
difficult. The efficacies o f the 2-component vaccines SB Pa2 and PM Pa2 were 
previously evaluated in clinical trials and shown to have efficacies o f 59% and 85% 
respectively (Greco et al., 1996, Simondon et al., 1997). The differences in their 
efficacy was an unusual observation, given that both vaccines contained the same 
components. Because o f this, it has been speculated that SB Pa2 may have been 
over-toxoided, which reduced it’s immunogenicity and protective ability. Hence, 
the observation that both SB Pa2 and PM Pa2 showed similar protection in the 
mouse model, may be a reflection o f the fact that the vaccines tested in the present 
study were not the same clinical lots used in the efficacy trials, and hence displayed 
comparable protective ability.
Because the numbers o f vaccines included in childhood immunization 
schedules are increasing, it has become impractical to deliver these vaccines 
individually, and has lead to an increased interest in the development o f combination 
vaccines. Combination vaccines have the advantage o f reducing the need for 
multiple injections in children, but an important consideration is the effect that one 
vaccine may have on the responses to another vaccine when delivered 
simultaneously. Immunization with three clinical lots o f the Pasteur Merieux 2- 
component Pa, formulated with the Hib vaccine was associated with a slight delay 
in bacterial clearance from the lungs, and an occasional rebound in bacterial load,
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when compared to immunization with the Pasteur Merieux Pw. However, it is 
unlikely that this is due to formulation with Hib, as is has been previously 
demonstrated that immunization o f mice with Pa is associated with protracted 
bacterial clearance from the lungs, when compared with Pw (Mills et al., 1998a, 
Mahon et al., 1996). The protective efficacy o f the same Pasteur Merieux Pa 
without the inclusion o f Hib has been previously evaluated in the mouse model 
(Mills et al., 1998a). Compared to this evaluation, the efficacy o f PM Pa2 does not 
appear to be affected when Hib is administered in the same injection. Furthermore, 
the demonstration that immunization with these Pa induce a polarized Th2 cytokine 
response is consistent with previous reports in mice (Mahon et al., 1996, Mills et 
al., 1998a, Mills et al., 1998b). Therefore, the slight delay in bacterial clearance 
observed in Pa-immunized mice is more likely due to the lack o f stimulation o f  Thl 
cells, as has been suggested by others (Mahon et al., 1996). The examination of 
antibody responses to different formulations o f the Pasteur Merieux (PM) 2- 
component Pa, either combined with Hepatitis-B, Hib and IPY vaccines as a full 
liquid formulation (PM 94) or reconstituted before injection (PM 181), did not have 
any obvious effect on the induction o f antigen-specific antibody. However, this is 
not surprising as both vaccines have the same antigenic composition and 
inactivation procedures. Furthermore, previous studies in mice have demonstrated 
that there is no significant difference in the level o f T-cell activation post-challenge 
(Ryan, 2000), or in the level o f protection conferred by immunization with either 
PM 94 or PM 181 (Mills et al., 1998a).
In addition to their role in the evaluation o f  vaccine efficacy, animal models 
may also have important applications in the quality control o f pertussis vaccines, to 
ensure there is minimum variation in protective efficacy between batches o f the 
same vaccine. In this study, three clinical lots o f the Pasteur Merieux Pw (PM Pw) 
were evaluated for protective efficacy in the mouse model. These vaccines induced 
a significant level o f protection against bacterial challenge, that correlated well with 
the estimated efficacy o f 96% for the vaccine from clinical trials. There was also 
good reproducibility between batches. All clinical lots o f the vaccine induced a 
polarized Thl response, which is consistent with previous reports that immunization 
with Pw results in the generation o f Thl response both in mice and children (Mills
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et al., 1993, Redhead et al., 1993, Ryan et al., 1997). Furthermore, immunization 
o f mice with different clinical lots o f the PM Pw vaccine induced very similar 
antibody levels to the constituent antigens. However, although these results would 
be expected, due to the fact that inactivation procedures, vaccine composition and 
antigen dose are all the same for the clinical lots tested, the findings from this study 
further validate the murine respiratory challenge model for the assessment of 
pertussis vaccine potency.
Despite the fact that no serologic marker in pertussis vaccination or disease 
correlates with immunity, one would expect that antibody production would be 
important for immunity to B. pertussis. Passive and active immunization 
experiments in mice have demonstrated that antibody can induce varying degrees of 
protection against either intracerebral or aerosol challenge (Oda et al., 1984, 
Robinson et al., 1985a, Kimura et al., 1990, Sato et al., 1981, Sato & Sato, 1984, 
Storsaeter et al., 1998). However, despite this, the exact contribution o f antibody 
to vaccine-induced protection remains to be elucidated. Furthermore, in clinical 
trials o f Pa and Pw it has been difficult to define quantitative correlations between 
specific anti-pertussis antibody levels and protection. In general, Pa induce more 
potent antibody responses to B. pertussis antigens than Pw. The clinical importance 
o f these antibody differences is unknown, but it has been shown that Pa-immunized 
mice develop a polarized Th2 response post-immunization (Mahon et al., 1996), 
and a mixed Thl/Th2 response in children (Ryan et al., 1997, Ryan et al., 1998). 
Some have suggested that this may be due to formulation o f component proteins 
with alum (Barnard et al., 1996, Moore et al., 1995). Th2 responses are classically 
associated with the induction o f humoral immunity, and perhaps the induction o f 
type 2 responses after immunization with Pa formulated with alum, is responsible 
for the induction o f higher levels o f antibody than the Thl-inducing Pw vaccines.
Analysis o f serum antibody responses to several Pa and Pw, the efficacy of 
which were previously evaluated in clinical trials (Greco et al., 1996, Gustafsson et 
al., 1996, Simondon et al., 1997), and in mice (Mills et al., 1998a), are consistent 
with the findings from clinical trials, which have failed to demonstrate an 
immunological correlate o f protection in children based on monotypic antibody 
responses against putative protective antigens (Ad Hoc group for the study of
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pertussis vaccines, 1998, Greco et al„ 1996, Simondon et ah, 1997, Gustafsson et 
ah, 1996, Olin et ah, 1997). Immunization o f mice with Pa induced high antibody 
titres against each o f the components in the vaccine, whereas Pw was not as 
efficient at inducing anti-PT and anti-FIM antibodies. All the Pa, including the 
lower efficacy SB Pa2 induced potent antibody responses against each o f the 
antigens in the vaccine. In general the strongest response was detected against PT. 
In contrast, the antibody response was weak in mice immunized with PM Pw, 
indicating that there was no clear relationship between the antibody response to 
either PT, FHA, PRN or FIM and vaccine efficacy. Similarly, an examination o f 
antibody responses in mice immunized with the Pa from the WHO study, revealed 
an inconsistency between the levels o f anti-pertussis antibodies and vaccine efficacy. 
In general high levels o f anti-PT and anti-FHA antibodies were induced after 
immunization with all Pa, even the low efficacy SB Pa2. In contrast, the high 
efficacy 5-component CLI Pa5 induced weaker antibody responses overall, when 
compared with the other Pa. However, these observations do not argue against a 
role for antibody in protection. The results o f  passive immunization experiments 
have demonstrated that antibodies raised against PT and one or more additional 
antigens can confer a good level o f protection against respiratory challenge (Mills et 
ah, 1998a). However, an active immunization schedule which resulted in the same 
levels o f antibody in the circulation at the time o f challenge, conferred higher levels 
o f protection, especially with the Pw vaccine. Furthermore, it has been shown that 
B-cells are required to confer immune mediated protection (Mahon et ah, 1997, 
Mills et ah, 1998a, Leef et ah, 2000). Nevertheless, the results o f this study 
suggest that although each o f the vaccines differs in its antigenic composition, 
antigen dose and method o f inactivation and formulation, the monitoring o f the 
potency o f  Pa based on ELISA-detected antibody levels, is insufficient and does not 
take into account the complex multi-antigen, dual T-cell and antibody mechanism of 
protection.
Results from this and other studies in the murine model have demonstrated a 
highly significant correlation between bacterial clearance in immunized mice, and 
vaccine efficacy in children (Mills et ah, 1998a, Mills et ah, 1998b). Furthermore, 
the lack o f  correlation between antibody responses and protection against infection
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shown in this study, is consistent with the findings from clinical trials, which failed 
to demonstrate an immunological correlate o f protection in children based on 
monotypic antibody responses against B. pertussis antigens (Trollfers et ah, 1995, 
Greco et al., 1996, Gustafsson et al., 1996). These results suggest that pertussis 
vaccine potency cannot be predicted solely on the basis o f analysis o f antibody 
responses to the putative protective antigens o f B. pertussis, and suggest that 
evaluation o f protection in the mouse model may offer a less complicated and more 
efficient method o f evaluating pertussis vaccine potency, compared to large and 
costly clinical trials in humans. Furthermore, the murine respiratory challenge 
model is a valuable tool, not only in the prediction o f pertussis vaccine efficacy, but 
may also be important in the regulatory control o f pertussis vaccines, to ensure 
minimum variation in the protective efficacy between batches, and for the 
assessment o f combined vaccine formulations.
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T a b l e  3.1 V a c c i n e  c o m p o s i t i o n ,  e s t i m a t e d  e f f i c a c i e s ,  a n d  T - c e l l  r e s p o n s e s  i n  m i c e  a n d  c h i l d r e n .
Vaccine Composition Trial/Study Estimated 
E fficacy in  
Children (% )
P otency index 
in  m ice
T-cells in mice T-cells in children
Thl Th2 Thl Th2
PM Pw Killed bacteria Senegal 95 84 ++++ - nt nt
CLIPw Killed bacteria Italy/Sweden 36-48 44 nt nt + -
SB Pa2 f  PTd/FHA Sweden 59 47 nt nt + -
SB Pa3 PTd/FHA/PRN Italy 84 75 + +++ +++ ++
CB Pa3 JrPT/FHA/PRN Italy 84 77 ++ ++ +++ ++
JNIH-3 PTd, FHA N/T N/T N/T + ++ nt nt
CLL Pa5 PTd/FHA/PRN/FIM Sweden 85 75 + +++ ++ -H -
PM Pa2 PTd/FHA Senegal 84 73 + +++ ++ ++
Estimated efficacies for children are based on published data from clinical trials (Greco et al., 1996, Gustaffson et al, 1996, 
Simondon et al., 1997). T-cell responses in mice are reproduced from a study by Mills et al, 1998a. Thl/Th2 responses are 
arbitrarily designated - to ++++ on the basis o f secretion o f IFN-y or IL-5 in response to antigen stimulation o f spleen cells. T-cell 
responses were assessed in children as described (Ryan et al., 1997, Ryan et al., 1998).
fPTd Chemically detoxified pertussis toxin, JrPT, Genetically detoxified pertussis toxin.
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Figure 3.3
Kinetics o f  B. pertussis clearance from the lungs after respiratory challenge of 
mice immunized with different Pa. Groups BALB/c mice were immunized 
intraperitoneally with 0.2 human dose o f  Pa at 0 and 4 weeks. Control mice 
were immunized with alum only. Two weeks after secondary immunization, 
mice were challenged by aerosol inoculation with B. pertussis, and CFU counts 
were performed on individual lung homogenates at intervals after challenge. 
Results are mean (± SE) viable B. pertussis counts from four mice per group at 
each time point. Vaccine composition and estimated efficacies in children are 
outlined in Table 3.1.
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Figure 3.4
T-cell cytokine responses in mice immunized with Pa vaccines. Groups of 
BALB/c mice were immunized as described in the legend to Fig. 3.3. Two 
weeks after the second immunization spleen cells were isolated from immunized 
mice and restimulated in vitro with B. pertussis antigens. Supernatants were 
collected after 72 hours and levels of IFN-y, IL-4 and IL-5 were determined by 
specific immunoassay. Results are representative o f  the mean responses (± SE) 
for four mice assessed individually in triplicate.
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Figure 3.5
Serum antibody responses in mice immunized with Pa vaccines. BALB/c mice 
were immunized as described in the legend to Fig. 3.3. Two weeks after the 
second immunization antibody responses to killed B. pertussis (B.P), PT, FHA, 
and PRN were evaluated. Results are presented as the mean antibody titres 
from four mice per group. Vaccine composition and estimated efficacies in 
children are outlined in Table 3.1.
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Figure 3.6
Kinetics of B. pertussis clearance from the lungs after respiratory challenge of 
mice immunized with different clinical lots (A, B and C) o f the Pasteur Merieux 
Pw, or alum only as control. Mice were challenged by aerosol exposure to B. 
pertussis two weeks after secondary immunization, and CFU counts were 
performed on individual lung homogenates at intervals after challenge. Results 
are mean (± SE) viable B. pertussis counts from four mice per group at each 
time point.
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Figure 3.7
T-cell cytokine responses in mice immunized with different batches (A,B and C) 
of the same PM Pw. BALB/c mice were immunized intraperitoneally with 0.2 
human dose at 0 and 4 weeks with Pw, or alum only as contol. Two weeks 
after the second immunization, spleen cells were isolated from immunized mice 
and were stimulated with B. pertussis antigens in vitro for 72 hours. Levels of 
IFN-y, IL-4 and IL-5 in supernatants were determined by specific immunoassay. 
Results are representative o f  the mean responses (± SE) for four mice assessed 
individually in triplicate.
CD
>%"Oo£*3
C
<o
T -D>o
7 n
6 -
5 -
3 -
2 -
1
O B .P  
□ PT  
a FHA  
•  PR N
▲ ▲ A
1
A B C ontro l
Figure 3.8
Serum antibody responses in mice immunized with different clinical lots (A, B 
and C) o f PM Pw. BALB/c mice were immunized intraperitoneally at 0 and 4 
weeks with 0.2 human dose of each vaccine. Control mice were immunized 
with alum only. Two weeks after the second immunization antibody responses 
to killed B. pertussis (B.P), PT, FHA, and PRN were evaluated. Results are 
presented as the mean antibody titres from four mice per group. Vaccine 
composition and estimated efficacy in children is outlined in Table 3.1.
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Figure 3.9
Kinetics of B. pertussis clearance from the lungs after respiratory challenge of 
mice immunized with different clinical tots (A, B and C) o f PM Pa or alum as 
control. Two weeks after secondary immunization, mice were challenged by 
aerosol exposure to B. pertussis, and CFU counts were performed on individual 
lung homogenates at intervals after challenge. Results are mean (± SE) viable 
B. pertussis counts from four mice per group at each time point.
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Figure 3.10
T-cell cytokine responses in mice immunized with different batches o f  the same 
PM Pa (A, B or C). BALB/c mice were immunized intraperitoneally with 0.2 
human dose at 0 and 4 weeks with Pa, or alum only as a control. Two weeks 
after the second immunization, spleen cells were isolated from immunized mice 
and were restimulated with B. pertussis antigens in vitro for 72 hours. Levels 
o f IFN-y, IL-4 and IL-5 in supernatants were determined by specific 
immunoassay. Results are representative o f the mean responses (± SE) for four 
mice assessed individually in triplicate.
❖  C h a p t e r  4  ❖
P r o t e c t i o n  a g a i n s t  bord etella  per tu ssis in  m ic e
IN THE ABSENCE OF DETECTABLE CIRCULATING 
ANTIBODY : A  ROLE FOR IMMUNOLOGICAL MEMORY
4 .1  I n t r o d u c t i o n
Immunological memory develops in response to primary antigenic exposure, and is 
a defining feature o f the adaptive immune response. It is widely accepted that once 
infected and therefore having mounted and immune response and survived the 
infection, the host is protected more efficiently against secondary infections through 
the induction o f immunological memory. This memory response to previously 
encountered antigen surpasses that induced by an initial encounter both 
quantitatively and qualitatively, and is the rationale behind contemporary 
immunization strategies. The basic premise o f vaccinology is that, by mimicking the 
effects o f a primary exposure to a pathogen, immunization can induce protective 
immunity against a subsequent encounter with the same organism. Thus the 
generation o f immunological memory and protective immunity are thought to be 
closely related (Ahmed et al., 1996). Convincing evidence for the existence o f 
identifiable T or B cells with specialized memory characteristics still remains 
ambiguous, and so, the phenotype o f immunological memory correlates best with 
antigen-driven activation o f low frequency effector T cells and plasma cells. 
Although the ability to maintain memory after an encounter with an antigen is one 
of the central features o f the immune system, the mechanisms that generate and 
maintain a memory response, or the relative contributions o f memory T- and B-cells 
to protection against certain infectious disease have still to be elucidated.
Long term antibody production is one of the hallmarks o f effective 
vaccination and is an important characteristic o f immunological memory. The 
identification of levels o f circulating antibodies that are critical for protection 
induced with certain vaccines such as Haemophilus influenzae type b (Hib), 
tetanus, diphtheria and polio (Robbins el al., 1995, Kayhty et al., 1998), has led to 
the belief that it may be possible to define a level o f protective antibody against B. 
pertussis. However, results from clinical trials have not provided definitive 
information on a relationship between antibody levels against a putative protective 
antigen and immune protection (Greco et al., 1996, Simondon et al., 1997, 
Gustafsson et al., 1996, Olin et al., 1997).
A paradox exists with regard to the role o f circulating antibody and immune 
protection. For most vaccines in human use, the induction o f humoral immunity has
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been considered to be the major effector mechanism mediating protection against 
viral and bacterial pathogens, and that this protection can be attributed to a critical 
level o f specific serum IgG. However, certain vaccines appear to protect with low 
or undetectable pathogen-specific circulating antibody. It has been difficult to 
identify a serological correlate o f protection induced with group B meningococcal 
vaccines (Goldschneider et al., 1969, Kayhty et al., 1998). Protection against 
poliovirus is primarily mediated via specific antibody supported by a CD4+ T cell 
response (Mahon et al., 1995), and yet protection can be conferred by very low 
antibody titres (McHammond et al., 1953). There emerges a similar scenario with 
Bordetella pertussis vaccination. Recent reports from household contact studies 
have indicated that antibody responses to PT, FHA and fimbriae may correlate with 
absence o f severe disease (Storsaeter et al., 1998, Cherry et ah, 1998). However, 
results from phase 3 clinical trials have failed to demonstrate an immunological 
correlate o f protection in children based on monotypic antibody responses against 
putative protective antigens (Ad hoc group for the study o f pertussis vaccines, 1998, 
Greco et al., 1996, Simondon et al., 1997, Gustafsson et al., 1996, Olin et al., 
1997).
The clinical studies are supported by experiments in a murine model where 
pertussis vaccine efficacy could not be predicted on the basis o f ELISA antibody 
responses against individual components o f the vaccine (Mills et al., 1998b). 
Furthermore bacterial clearance during primary infection o f mice occurs prior to the 
development o f IgG responses (Mills et al., 1993), revealing a role for cell-mediated 
mechanisms in protection against B. pertussis. Paradoxically B cells are required to 
confer immune mediated protection (Mahon et al., 1997, Mills et al., 1998a, Leef et 
al., 2000). For example, B. pertussis challenge o f naive Ig' mice (which do not 
make mature B-cells) results in the development o f a chronic infection that does not 
clear for at least 6 months post-challenge, compared to wild-type mice which clear 
the infection after 8 -10 weeks (Mahon et al., 1997). Nevertheless vaccination 
strategies have focused on the induction o f short term responses following 
immunization and the generation o f high titer antibody in serum. However, other 
factors are more relevant to our understanding o f the mechanisms o f protective 
immunity and the rational design o f efficacious vaccines. These include the
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definition o f correlates o f immunity, and the persistence or longevity o f the 
protective immune response.
It has been assumed that natural infection with B. pertussis confers long- 
lived protection against subsequent infection. Furthermore, the traditional pertussis 
whole cell vaccines also appear to induce long-lived immunity against severe disease 
in children and young adults. However exposure to sub-clinical infection, especially 
in countries with a high incidence o f disease, may contribute to persistence o f 
protection by periodic boosting o f immune responses (Isacson et ah, 1995, Rota et 
al., 1998). Concern about the safety o f these traditional vaccines has resulted in the 
development o f acellular pertussis vaccines (Pa) prepared from highly purified 
components of B. pertussis (Rappuoli et ah, 1997) and these vaccines, which have a 
higher safety profile, have now replaced Pw in many developed countries. Results 
from clinical trials indicated that Pa conferred a level o f protection against severe 
disease, which approached that o f the European Pw (Greco et ah, 1996, Simondon, 
et ah, 1997, Gustafsson et ah, 1996, Olin et ah, 1997). However recent follow up 
studies from the clinical trials have indicated that antibody responses in immunized 
children decline to almost undetectable levels 15-33 months after a complete course 
o f vaccination (Giuliano et ah, 1998, Salmaso et ah, 1998). Although it appears 
that these children are not developing overt disease, without a history o f exposure 
and sensitive indicators o f infection, in large post-immunization surveillance 
programs, it is impossible to determine if they are immune to infection or to 
establish the mechanisms mediating protection.
With the utilization o f  a well-established murine respiratory challenge model 
o f B. pertussis infection where protection correlates with vaccine efficacy in human 
clinical trials (Mills et al., 1998, Mills et al., 1993, Mahon et ah, 1997, Mills and 
Ryan et al., 1998), together with gene knockout mice, active and passive 
immunization and adoptive transfer techniques, complementary roles for cellular 
and humoral immunity in protection against B. pertussis have been identified (Mills 
et ah, 1998, Mills et al., 1993, Mahon et ah, 1997, Redhead et ah, 1993). In this 
chapter, the relationship between the persistence o f the immune response and the 
development o f immunological memory and protection against respiratory infection 
have been examined using this murine model o f infection. The results demonstrate
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that protective immunity persists in the absence o f a detectable antibody response 
and imply that the induction o f memory T and B cells may be more significant to 
vaccine efficacy than the initial serum IgG response.
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WITH ACELLULAR OR WHOLE CELL PERTUSSIS VACCINES 
In pertussis vaccine clinical trials evaluation o f antibody levels in the serum of 
immunized children, revealed high levels o f antibody against the antigen 
components o f the vaccine early after vaccination. This was true for both the 
acellular vaccines even those o f low efficacy (Simondon et al., 1997, Olin et al., 
1997, Greco et al., 1996, Gustafsson et al., 1996, Trollofers et al., 1995) and for 
the whole cells vaccines (Simondon et al., 1997, Olin et al., 1997, Greco et al., 
1996, Gustafsson et al., 1996, Miller et al., 1997), although these were more 
variable, due to differences in concentrations o f individual antigens in the 
preparations. However, antibody responses decline rapidly after a complete course 
o f vaccination (Giuliano et al., 1998, Salmaso et al., 1998), yet immunized children 
appear to remain protected against severe disease. In order to quantify the 
contribution o f circulating antibody to immune-mediated protection against B. 
pertussis, we exploited the well-characterized murine respiratory challenge model 
(Mills et al., 1993, Mills et al., 1998a). Mice received two immunizations with low 
doses o f either a traditional Pw or a new generation Pa, equivalent to 0.1-0.2 pg 
recombinant pertussis toxin (PT), filamentous haemaggluttinin (FHA) and pertactin 
(PRN), and the persistence o f the serum antibody response was measured by 
ELISA. Both Pw and Pa induce strong antibody responses against the B. pertussis 
antigens, PT, FHA and PRN (Fig. 4.1 A, 4.IB). Anti-5, pertussis antibody 
responses were undetectable in control mice, immunized with adjuvant only (not 
shown). Serum antibody responses are particularly strong 6 weeks after 
immunization with Pa (Fig. 4. IB), but decline rapidly in both groups o f mice after 
three months (Fig. 4.1 A, 4.IB). Six to nine months after immunization, specific 
antibody can not be detected in the serum o f immunized mice. So, in the murine 
model, which correlates with that in children, serum antibody responses do not 
persist following immunization with pertussis vaccines.
4 .2  R e s u l t s
4 .2 .1  A n a l y s i s  o f  s e r u m  a n t i b o d y  r e s p o n s e s  i n  m i c e  i m m u n i z e d
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4 .2 .2  P a  a n d  P w  p r o t e c t  a g a i n s t  B . p e r t u s s is  in  t h e  a b s e n c e  o f
CIRCULATING ANTIBODY
Mice immunized twice with 0.04 human doses o f Pw or Pa were aerosol challenged 
with B. pertussis either at the peak o f the antibody response 6 weeks after primary 
immunization or once circulating antibody titers had waned, 44 weeks after primary 
immunization. Although both vaccines conferred a high level o f protection, the rate 
o f bacterial clearance was marginally slower with this low dose o f vaccine when 
compared with that induced with a higher dose (0.2 of human dose) o f the same 
vaccines in earlier studies (Mills et ah, 1998). Following challenge o f mice at week 
6 the numbers o f CFU recovered from the lungs declined to low levels 7-10 days 
later, and after a small rebound on day 14, were undetectable 21 days after 
challenge (Fig. 4.2A). In contrast, the numbers o f viable bacteria in the lungs were
3-5 logs higher 7, 10 and 21 days after challenge in unimmunized control mice. 
Despite the decline in B. pertussis-spectRc circulating antibody to undetectable 
levels, both vaccines conferred protection against B. pertussis when challenged 44 
weeks after immunization (Fig. 4.2B). In particular mice immunized with Pw 
displayed a high level o f protection, which approached that observed at the peak of 
the antibody response 6 weeks after immunization. Thus while antibody declined, 
immunity persisted for at least 9 months after immunization.
4 .2 .3  Im m u n iz a t io n  in d u c e s  l o n g - l iv e d  T -c e l l  r e c a l l  r e s p o n s e s
In contrast to the circulating antibody response, recall T-cell responses to B. 
pertussis antigens persisted in Pw and Pa immunized mice for long periods 
following immunization. Spleen cells from immunized or control mice were 
prepared at varying times post immunization or challenge and cytokine responses to 
B. pertussis antigens examined (Fig. 4.3, Fig. 4.4, Fig. 4.5, Fig. 4.6, Fig. 4.7, Fig.
4.8). The results demonstrate that recall T-cell responses persist for long periods 
following immunization. There is a clear dichotomy in the nature o f the T-cell 
response induced either by Pw or Pa. Pw induces a Thl dominated response, 
whereas Pa induces a Th2 dominated response and these patterns o f cytokine 
secretion persist with time (Fig. 4.3-4.8). Forty six weeks after immunization with 
Pa or Pw, 3 weeks after challenge, B. pertussis-specific cytokine responses are
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clearly detectable in immunized mice (Fig. 4.7). Furthermore, memory T-cells 
secreting IFN-y and IL-5 were detected by ELISPOT in the spleen at 18 and 32 
weeks post-immunization (Fig. 4.9, Fig. 4.10). 400-600 memory Th2 cells per 106 
cells were detected in Pa immunized mice at 18 weeks (Fig. 4.9), and this had 
declined to 100-200 per 106 cells by week 32 (Fig. 4.10). The levels o f memory 
Thl cells induced by Pw appeared to increase from 100-150 per 106 cells (Fig. 4.9) 
to 350-400 per 106 at week 32 (Fig. 4.10). It has been previously reported that the 
Thl population confers optimal protection against B. pertussis (Mills el al., 1993, 
Brady et al., 1998, Barnard el al., 1996, Mahon el al., 1996). The polarized Th2 
response induced by Pa may result in impaired bacterial clearance particularly in the 
absence o f a persisting antibody response early after challenge, as seen in Fig. 4.2. 
However, whilst these patterns o f cytokine secretion are stable, they are not 
immutable or “locked in” . Following bacterial challenge, there is a broadening o f the 
pattern o f cytokine responses observed in immunized mice, from a Th2 response at 
7 days after challenge to a mixed Thl/Th2 or ThO response thereafter (Fig. 4.7, Fig.
4.8). However, the initial immunization is not without influence, because challenge 
o f Pa immunized animals does not result in the polarized Thl responses normally 
observed after immunization with Pw or B. pertussis challenge o f control animals.
4.2.4 Im m u n iz a t io n  i n d u c e s  p e r s is t e n t  m e m o r y  B -c e l l s  
Although B. pertussis-specific T cells persist after immunization and CD4+ T cells 
are critical to vaccine-mediated immunity against B. pertussis, the long-term 
protection observed is not necessarily an exclusively cell-mediated phenomenon. 
Memory B cells specific for B. pertussis are also induced by immunization with Pw 
and Pa and persist for at least 44 weeks after vaccination. Using an ELISPOT 
technique (Czerkinsky et al., 1983), specific antibody forming cells were detected in 
peripheral blood mononuclear cells and spleen cells following stimulation with PT 
or B. pertussis sonicate, and in the bone marrow following stimulation with BP, PT, 
FHA or PRN, (Fig. 4.11, Fig. 4.12). Significantly greater numbers o f B. pertussis- 
specific B cells could be detected from the blood, spleens and bone marrow of 
immunized mice when compared to controls. The importance o f memory induction 
is confirmed by the observation o f an anamnestic antibody response to B. pertussis
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antigens in immunized mice post challenge (Fig. 4.13). As previously reported 
(Mills et al., 1993), IgG responses against B. pertussis could not be detected in 
unimmunized control mice for at least 21 days after challenge. In contrast, 7 days 
after challenge, circulating antibodies were detected against PRN and B. pertussis 
sonicate in Pw-immunized mice and against PRN and PT in Pa-immunized mice.
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4.3 D is c u s s io n
The majority o f the studies on the mechanisms o f protective immunity against B. 
pertussis in both mice and humans have focused on the evaluation o f immune 
responses early after immunization. However, the effector mechanisms controlling 
infection at the peak o f the immune response are most likely to be different to those 
that maintain long term protection. The present study demonstrates that persistent 
circulating antibody need not be detectable at the time o f exposure for the 
maintenance o f vaccine-induced protective immunity against a bacterial pathogen of 
humans. The results from a murine model show that immunity against B. pertussis 
induced with Pw or Pa was maintained for a prolonged period after immunization, 
when serum antibody responses had declined to undetectable levels. The findings 
point to a role for immunological memory, at the T and B cell level, in the 
maintenance o f long term protective immunity against B. pertussis.
Antibody has been considered to be the major effector mechanism mediating 
vaccine-induced immunity against viral and bacterial pathogens. Protective levels o f 
circulating antibody have been identified for certain pathogens, such as poliovirus, 
diphtheria, tetanus and Haemophilis influenzae (Robbins et al., 1995, 
Goldschneider et al., 1969, Kayhty et al., 1998, McHammond et ah, 1953). 
However there is some uncertainty about the accuracy or indeed relevance o f these 
markers, and certain individuals with antibody levels below these threshold values 
appear to be protected. It has been more difficult to establish an immunological 
correlate o f immunity against other pathogens, including B. pertussis. The clinical 
trials o f pertussis vaccines could not establish a critical level o f antibody against 
putative protective antigens that would confer protection (Ad hoc group for the 
study o f pertussis vaccines, 1998, Greco et al., 1996, Simondon et al., 1997, 
Gustafsson et al., 1996, Olin et al., 1997). However two recent reports from 
household contact studies indicated that antibody responses against PT, PRN and 
fimbriae may correlate with absence o f severe disease (Storsaeter et al., 1998, 
Cherry et al., 1998). Although these studies suggested that antibodies against PRN 
and fimbriae are the most important, a monocomponent pertussis toxoid vaccine 
conferred 71% protection against severe disease in the Goteburg trial (Taranger et 
al., 1997). Investigations in mice have demonstrated that passive transfer o f a
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combination o f antibodies against two or more o f the antigens can confer a high 
level o f  protection (Mills et al., 1998a). However the mouse studies also 
demonstrated that T cell responses, in particular Thl cells also play a critical role in 
protective immunity, especially that induced by natural infection or immunization 
with Pw (Mills et al., 1993, Mahon et al., 1997, Mills et al., 1998a, Redhead et al., 
1993, Mahon et al., 1996). Furthermore, follow up studies from the clinical trials 
have demonstrated that antibody levels decline quite rapidly after vaccination, yet 
these children still appear to be protected against whooping cough (Giuliano et al., 
1998, Salmaso et al., 1998, Storaseter et al., 1998). However in the clinical setting 
it is difficult to establish the level o f exposure to infection and it is not clear whether 
these children would remain free from disease if exposed to B. pertussis in the 
future.
Animal models provide an alternative approach to dissecting mechanisms o f 
immunity and allow us to address fundamental questions that cannot be answered 
from clinical studies. Protection against intracerebral (i.e.) challenge in immunized 
mice has been used as an indication o f the potency o f Pw (Kendrick et al., 1947). 
However, most Pa do not protect mice against lethal i.e. challenge (Corbel & Xing, 
1997). In contrast, it has been demonstrated that Pw and Pa can protect mice 
against respiratory challenge and that the rate o f bacterial clearance from the lungs 
o f immunized mice correlates with vaccine efficacy in clinical trials (Mills et al., 
1998a). In the present study we have demonstrated that protection against B. 
pertussis in mice is possible in the absence o f circulating antibody. Following 
immunization with two low doses o f either Pw or Pa, the serum IgG level specific 
for PT, FHA, PRN and B. pertussis lysate declined rapidly and had reached 
undetectable levels 6-9 months after immunization. However despite the waning 
antibody response, mice were still protected against respiratory infection when 
challenged 44 weeks after immunization. The course o f infection in immunized 
compared with control naive mice indicated persistence o f vaccine-induced 
protection, especially with Pw.
There are a number o f explanations for the maintenance o f protection after 
the decline in circulating anti-5. pertussis antibodies. It is possible that antibody 
does not pay a role in protection and that immunity is conferred exclusively by
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cellular mechanisms. Alternatively the vaccine may have induced immunological 
memory at the B and/or T cell level, which is recalled after B. pertussis challenge. 
Analysis o f  cell mediated immunity demonstrated that specific T cell responses were 
maintained up to 3 weeks post-challenge, 46 weeks after immunization. As 
previously reported for short-term immunization, Pw selectively induced B. 
pertussis-specific Thl cells, whereas Pa induced T cells more polarized to the Th2 
subtype (Barnard et al., 1996, Mills et al., 1993). Although this dichotomy in the 
cytokine profile was maintained up to 46 weeks after immunization, the response 
with the Pa broadened to a mixed Thl/Th2 after challenge and this is consistent 
with observations in immunized children (Ausiello et al., 1997, Ryan et al., 1998, 
Ryan et ah, 1997). The results suggest that the Thl/Th2 dichotomy does not 
impinge on memory induction. It has been previously reported that the Thl sub­
population confers optimal protection against B. pertussis (Mills et ah, 1998a, 
Redhead et ah, 1993, Mills et ah, 1993, Mahon et ah, 1996). The polarized Th2 
response induced by Pa may result in impaired bacterial clearance particularly in the 
absence o f a persisting antibody early after challenge. However, whilst these 
patterns o f cytokine secretion are stable, they are not permanently fixed. Following 
bacterial challenge, there is a broadening o f the pattern o f cytokine responses 
observed in Pa immunized mice, from a Th2 response at 7 days after challenge to a 
mixed Thl/Th2 or ThO-type response thereafter.
The selective induction and maintenance of the Thl response with Pw, 
together with their superior protection against B. pertussis infection, is consistent 
with previous reports that Thl cells play an important role in protective immunity 
(Redhead et ah, 1993, Mills et ah, 1998a, Mills et ah, 1993, Mahon et ah, 1997). 
Although activation o f cellular mechanisms against intracellular B. pertussis (1997, 
Mahon et ah, 1999, Friedman et ah, 1992), including the stimulation o f bacterial 
uptake and killing by macrophages and PMN, may be one mechanism whereby Thl 
cells mediate their protective function, we cannot rule out their role in stimulating 
protective humoral immunity. Thl cells provide such a function in immunity to 
certain viral infections (Mahon et ah, 1995). Indeed studies with Ig defective mice 
and passive transfer o f IgG have indicated that antibody can play a crucial role in 
protection against B. pertussis (Mahon et ah, 1997, Mills et ah, 1998a). In the
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present study, an analysis o f serological responses after challenge demonstrated 
anamnestic antibody responses against each o f the B. pertussis antigens examined. 
Furthermore antibody forming cells specific for B. pertussis antigens were detected 
in the bone marrow, spleen and circulation at the time o f challenge. These results 
demonstrate that immunological memory is maintained despite the decline in 
circulating antibodies and suggest that memory B and T cells are responsible for the 
maintenance o f long term protection against B. pertussis.
Our findings are not incompatible with recent suggestions that antibodies 
against multiple antigens can mediate protection against B. pertussis (Olin et al., 
1997, Mills et al., 1998a, Storsaeter et al., 1998, Taranger et al., 1997). However 
it appears that current pertussis vaccines do not confer sterilizing immunity. 
Vaccine efficacy data from clinical trials was largely based on the WHO case 
definition o f whooping cough based on 21 or more days o f  paroxysmal cough. 
However with a less stringent case definition o f 7 or more days o f non-paroxysmal 
cough, the pertussis vaccine efficacy was lower (Gustafsson et al., 1996, Olin et al., 
1997). Thus pertussis vaccines are capable o f preventing severe disease, but are 
less efficient when judged on the criteria o f preventing infection or mild disease, 
even in the presence o f high levels o f circulating antibody at the time o f infection.
The results o f this present study have important implications for pertussis 
vaccination policy in relation to the level o f protection in the face o f waning 
antibody levels following vaccination and the need for booster immunization. The 
data from the mouse model suggest that persistence o f circulating antibody is not a 
prerequisite for the maintenance o f protective immunity. These findings have 
substantial ramifications for the evaluation and development o f vaccines against a 
range o f infectious diseases and demonstrate that a simple quantification of 
circulating antibodies may be a misleading correlate o f immunity against B. 
pertussis and other pathogens. Although circulating neutralizing antibodies are 
clearly important in sterilizing immunity, especially against viral infections, it is also 
evident that certain vaccines can protect by non-humoral mechanisms or by the 
recall o f immunological memory at the T and B cell level.
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Figure 4.1
Decline in antibody responses to antigens of B. pertussis following immunization with whole cell (Pw) or 
acellular (Pa) pertussis vaccines. Mice were immunized at week 0 and 4 with 0.04 human dose of Pw or Pa 
(indicated by arrows), and the circulatory antibody responses to B. pertussis (BP) sonicate, PT, FHA and 
PRN were detected by ELISA at intervals after immunization.
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Figure 4.2
Persistence o f protection against B. pertussis respiratory infection in long term 
immunized mice. Mice were immunized at week 0 and 4 with 0.04 human dose 
o f  Pw, Pa, or adjuvant only as control, and were exposed to an aerosol 
challenge o f  B. pertussis 6 weeks (A) or 44 weeks (B) after the primary 
immunization.
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Figure 4.9
Detection o f  B. pertussis-s^Qciiic memory T-cells 18 weeks after immunization 
with Pa or Pw. Spleen cells were stimulated with heat-inactivated PT, FHA or 
PRN (5.0(_ig/ml), heat killed B. pertussis (BP) (lx l0 6cells/ml), and PMA/CD3 
or medium as positive and negative controls respectively. The numbers o f  IFN- 
y and IL-5 secreting cells were determined by ELISPOT. Results are the mean 
numbers o f  cytokine secreting cells (±SE), after subtraction o f  background 
control values with medium only (IFN-y, 464-641 x 106 cells, IL-5, 359-424 x 
106 cells) for 4 mice per group assayed in triplicate.
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Figure 4.10
Detection o f  B. pertussis-specific memory T-cells 32 weeks after immunization 
with Pa or Pw. Spleen cells were stimulated with heat-inactivated PT, FHA or 
PRN (5.0pg/ml), heat killed B. pertussis (BP) ( lx l0 6cells/ml), and PMA/CD3 
or medium as positive and negative controls respectively. The numbers o f  IFN- 
y and IL-5 secreting cells were determined by ELISPOT. Results are the mean 
numbers o f  cytokine secreting cells (±SE), after subtraction o f  background 
control values with medium only (IFN^y, 12-19 x 106 cells, IL-5, 3-6 x 106 cells) 
for 4 mice per group assayed in triplicate.
300 i
250 -
=  200 0)
O
toO
O
LL
<
150
100
Spleen Blood 
BP-specific
□  Control 
a  Pw 
■  Pa
Spleen Blood 
PT-specific
Figure 4.11
Detection of B. Pertussis-specific memory B-cells 44 weeks after immunization. 
Mice were immunized at week 0 and 4 with 0.04 human dose o f Pw, Pa or adjuvant 
only (control). Peripheral blood mononuclear cells and spleen cells were incubated in 
plates coated with B. pertussis lysate (BP) or inactivated PT and the numbers of 
specific AFC determined by ELISPOT. Results are mean values for 4-6 mice per 
group. *, P < 0.05 versus mice immunized with alum only; **, P < 0.01 versus mice 
immunized with alum only; ***, P < 0.001 versus mice immunized with alum only.
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Figure 4.12
B. Pertussis-specific memory B-cells are detectable in bone marrow, up to 44 
weeks after immunization with Pa or Pw. Mice were immunized at week 0 and 
4 with 0.04 human dose o f Pw, Pa or adjuvant only (control). Cells isolated 
from the bone marrow o f  immunized mice were incubated in plates coated with 
B. pertussis lysate (BP), inactivated PT, FHA or PRN, at a concentration of 
lx l0 6/ml The numbers o f  specific AFC were determined by ELI SPOT. Results 
are mean values for 4 mice per group, after subtraction o f  background values 
(72-90 AFC/106).
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Figure 4.13
Long-term immunized mice develop an anamnestic antibody response on exposure 
to B. pertussis. Mice were immunized at week 0 and 4 with 0.04 human dose of 
Pw, Pa or adjuvant only as control, and were challenged with B. pertussis 44 weeks 
after the primary immunization. Antibody responses to B. pertussis, PT, FHA and 
PRN were determined by ELISA at days 7, 14 and 21 after challenge.
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T h e  ro le  o f  IL -12  a n d  IL -18  in  t h e  in d u c t io n  o f  a
PROTECTIVE T H l RESPONSE TO BORDETELLA PERTUSSIS
The generation o f Thl responses and IFN-y production are important in promoting 
immunity to a number o f infectious pathogens, particularly those which occupy an 
intracellular niche. Optimal immunity to Bordetella pertussis is associated with the 
induction o f  cell-mediated immunity. Cheers and colleagues demonstrated more 
than 30 years ago that B. pertussis had an intracellular phase and suggested that 
cellular immunity may be required to eliminate intracellular bacteria (Cheers et ah, 
1969, Gray et ah, 1969). These observations have been confirmed by the 
demonstration that B. pertussis has the ability to survive within macrophages, 
polymorphonuclear leukocytes and respiratory epithelial cells (Saukkonen et ah, 
1991, Steed et ah, 1992, Friedman et ah, 1992, Bassinet et ah, 2000, Weingart et 
ah, 2000, Hellwig et ah, 1999). Although there is a large body o f evidence that 
antibody plays a role in protection against B. pertussis (Mills et ah, 1998, 
Storsaeter et ah, 1998), it’s dual extra- and intra-cellular location is congruous with 
a role for cellular as well as humoral mechanisms for the resolution o f infection.
It has been shown that B. pertussis-specific T-cells induced by infection in 
mice are largely confined to IFN-y and IL-2 secreting CD4+ T-cells and that these 
cells play a critical role in the clearance o f bacteria after a primary infection and in 
the development o f protective immunity against subsequent challenge (Mills et ah, 
1993). Similarly, infection in children or immunization with whole cell pertussis 
vaccine is associated with the induction o f antigen-specific Thl cells, which are 
critical in host resistance to infection (Redhead et ah, 1993, Ryan et ah, 1997). In 
particular, the Thl cytokine IFN-y plays a major role in controlling B. pertussis 
infection and in containing the bacteria to the mucosal site (Barbie et ah, 1997, 
Mahon et ah, 1997). Given the importance o f  IFN-y and the induction o f  Thl cells 
in immunity to B. pertussis, the factors which control the induction o f  IFN-y and 
Thl responses are worthy o f investigation; namely IL-I2 and IL-18. Indeed, it has 
already been shown that IL-12 is produced following exposure to live or killed B. 
pertussis, and that the addition o f IL-12 to an acellular vaccine enhances it’s 
protective efficacy by promoting type 1 cytokine production (Mahon et ah, 1996).
IL-12 was first described in 1989 (Kobayashi et ah, 1989) and was initially 
called natural killer cell stimulatory factor (NKSF) or cytotoxic lymphocyte
5 .1  I n t r o d u c t i o n
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maturation factor. Since then, IL-12 has been shown to be produced primarily by 
activated macrophages, but also by monocytes, neutrophils, dendritic cells and 
antibody-producing B-cells. (Hall, 1995). IFN-y and IL-12 are thought to be major 
cytokines governing the promotion o f Thl differentiation. IL-12 is a 70- to 75- 
kDa heterodimeric protein consisting o f disulphide-bonded 35-kDa (p35) and 40 
kDa (p40) subunits. In vivo, IL-12 acts primarily at three stages during the innate 
resistance/adaptive immune response (Gately et al., 1998). Firstly, IL-12 is 
produced early in infection, and activates NK and T-cells to produce IFN-y, which 
contributes to phagocytic cell activation and inflammation. Secondly, IL-12 
promotes the generation o f Thl cells by priming CD4+ T-cells for high IFN-y 
production and by favouring the expansion o f Thl cells. In doing so, IL-12 acts in 
antagonistic equilibrium with IL-4 which stimulates the development o f Th2 cells. 
Thirdly, IL-12 determines optimal IFN-y production and proliferation o f Thl cells, 
in association with other stimuli. Thus IL-12 represents a functional bridge between 
early non-specific innate immunity and the subsequent antigen specific adaptive 
immunity. In the case o f IFN-y, it’s effect may be to prevent the outgrowth o f Th2 
cells rather than to promote directly the selective development o f Thl cells. In 
contrast, the presence o f IL-12 during priming directly augments Thl 
differentiation.
In addition to IL-12, IL-18 may have important relevance in the induction of 
Thl cells, and in protection against intracellular pathogens. IL-18 was originally 
identified as IFN-y inducing factor (IGIF) that was induced in the sera o f mice 
treated with heat-killed Propionibacterium acnes, followed by lipopolysaccharide 
(LPS) challenge (Nakamura et al., 1989, Okamura et al., 1995a). IL-18 is a 24- 
kDa, non-glycosylated polypeptide and is structurally similar to IL-1 p. Like IL-1 p, 
IL-18 is first synthesised as a bio inactive propeptide, requiring the IL-1 p converting 
enzyme (ICE) for cleavage into a bioactive 18-kDa molecule (Gu et al., 1997). IL- 
18 shares many biological properties with IL-12 such as stimulation o f IFN-y 
production, enhancement o f natural killer (NK) cell cytotoxicity and stimulation of 
Thl cell differentiation, and is produced by a variety o f different cell types including 
macrophages and T-cells. Although IL-18 is a stimulator o f the induction o f IFN-y
93
production by T-cells, IL-12 is a prerequisite to exert the action o f IL-18 on these 
cells (Okamura et al., 1995b, Ushio et al., 1996, Okamura et al., 1998, Micallef et 
al., 1996, Ahn et al., 1997). This is because naïve T-cells do not express IL-18 
receptor (IL-18R) but only begin to express IL-18R after IL-12 stimulation. (Akira 
et al., 2000). Thus the fiinction o f IL-18 on T-cells completely depends on the 
presence o f IL-12. IL-18 has been shown to play a role in the generation of 
protective immunity to a number o f organisms including Mycobacterium 
tuberculosis, Yersinia enterocolitica (a gram negative bacterium which causes 
enteritis and enterocolitis), Leishmania major and Salmonella typhimurium 
(Sugawara et al., 1999, Bohn el al., 1998, Ohkusu el al., 2000, Mastroeni el al., 
1999). Since Thl cells play a pivotal role in host defence against infection with B. 
pertussis, we investigated whether these two major cytokines involved in Thl 
induction, namely IL-12 and IL-18, play a role in the mechanism o f protective 
immunity.
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5 .2  R e s u l t s
5.2.1 B. PERTUSSIS INDUCES IL-12 AND IL-18 PRODUCTION FROM 
MACROPHAGES IN  VITRO
It has previously been reported that murine macrophages produce IL-12 after 
stimulation with live or killed B. pertussis (Mahon et a l ., 1996). The results o f this 
study are in agreement with these findings. B. pertussis induced the production o f 
IL-12 from J774 macrophages in vitro. J774 cells were incubated with killed B. 
pertussis in the range o f lxlO5 CFU/ml to lxlO8 CFU/ml, and IL-12 levels 
measured after 24hrs. J774 macrophages produced high levels o f IL-12 in response 
to stimulation with heat-killed B. pertussis in a dose dependent manner (Fig. 5.1).
To examine whether B. pertussis could induce production o f IL-18 a 
modification o f the technique employed by Mastroeni et al., 1999 was utilized. A 
spleen cell suspension was prepared from naïve mice and incubated for 4hrs in petri 
dishes to allow macrophages to adhere. To assess whether IL-18 acts via IFN-y 
induction, adherent cells were washed once and cultured overnight with medium 
alone or in the presence o f IFN-y. The cells were then infected with B. pertussis at 
a bacteria to cell ratio o f  5:1 (0 hrs) and supernatants were collected for 
measurement o f IL-18, for up to 4 hours post-infection. B. pertussis infection 
induced the release o f high levels o f IL-18 (Fig. 5.2) from both untreated (no IFN- 
y) and treated splenic macrophages lh after infection and IL-18 levels remained 
high throughout the course o f the experiment. Treatment with IFN-y significantly 
enhanced IL-18 production (Fig. 5.2).
5.2.2 B l o c k i n g  IL-12 i n  v it r o  a b r o g a t e s  B. p e r t u s s is -in d u c e d  
IFN-y PRODUCTION
It has previously been reported that murine macrophages produce IL-12 after 
stimulation with live or killed B. pertussis (Mahon et al., 1996). Therefore, it was 
important to assertain whether the generation o f IL-12 was responsible for 
stimulating the production o f B. pertussis-induced IFN-y. Spleen cells from naïve 
mice were prepared and stimulated with a range o f concentrations o f killed B. 
pertussis alone, or together with either a neutralizing anti-IL-12 or anti-IL-18
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antibody. Following incubation for 72hrs, supernatants were removed and IFN-y 
levels assessed. Spleen cells incubated with B. pertussis alone produce high levels 
o f IFN-y (Fig. 5.3A). However, following stimulation o f  cells with B. pertussis in 
the presence o f a neutralizing anti-IL-12 antibody, IFN-y production is completely 
abrogated (Fig. 5.3A). In contrast, IFN-y production in response to PMA/CD3 was 
not affected by the presence o f anti-IL-12 antibody. However, stimulation o f spleen 
cells with B. pertussis in the presence o f anti-IL-18 did not have downregulatory 
effect IFN-y production induced by killed bacteria (Fig. 5.3B), but when added 
simultaneously with anti-IL-12, diminished IFN-y production significantly (Fig. 
5.3C). The results show that at least in vitro that B. pertussis induced IFN-y 
production is dependent on IL-12.
5 .2 .3  D e c r e a s e d  T h I  a n d  e n h a n c e d  T h 2  c y t o k i n e  p r o d u c t i o n  i n  
I L - 1 2 - d e f i c i e n t  m ic e
Cytokine production by spleen cells from naive mice was used to establish the 
Thl/Th2 profile o f IL-12 deficient (IL-12“7') mice. Spleens from naive IL-12“7“ and 
wild-type BALB/c mice were prepared and stimulated with the polyclonal 
stimulator PMA and anti-CD3 or medium only. Following incubation for 72hrs 
supernatants were removed and assayed for the presence o f IFN-y and IL-4. IL-12“7' 
mice produced significantly less IFN-y compared to wild-type mice, but they also 
produce significantly higher levels o f IL-4 (Fig. 5.4).
Given that neutralizing IL-12 has the ability to block B. pertussis IFN-y 
production in vitro, it was important to determine the in vivo function o f IL-12 in 
resistance to B. pertussis infection. IL-12 defective mice were used to examine the 
role o f IL-12 in shaping T-cell responses to B. pertussis and on the outcome of 
infection. IL-12“7“ and wild-type BALB/c mice were infected with B. pertussis by 
aerosol inoculation. Spleen cells from IL-12“7“ and wild-type BALB/c mice were 
restimulated in vitro with medium or PMA and anti-CD3 as negative and positive 
controls respectively, and killed B. pertussis in the range o f lxlO5 to lxl07 CFU/ml. 
Supernatants from 72hr. cultures were collected on days 14, 21, 63 and 70 post­
challenge and analyzed for presence o f IFN-y and IL-5. An examination o f T-cell
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responses revealed that infection o f BALB/c mice with B. pertussis induced a 
predominantly Thl response with high levels o f IFN-y and little IL-5 (Fig. 5.5). IL- 
12'7' mice display a significant reduction in IFN-y production from spleen cells at all 
timepoints tested. IL-5 levels in knockout mice are slightly higher compared to 
wild-type mice (Fig. 5.5). Although, there is no evidence o f a complete switch from 
a Thl response to a Th2 response in these mice, there was a consistent move 
towards a more mixed Thl/Th2 response. Groups o f  four mice were sacrificed at 
intervals post-challenge to estimate the numbers o f viable bacteria in the lungs. 
Analysis o f bacterial counts from the lungs o f wild-type and knockout mice, during 
the course o f primary infection with B. pertussis, show that there are significantly 
higher numbers o f viable bacteria in the lungs o f  IL-12'7’ mice 7 days post-challenge 
compared with wild-type mice (Fig. 5.6). However, later in infection there is no 
significant difference between the two groups, and IL-12'7’ mice maintain the ability 
to clear the bacteria from the lungs as efficiently as wild-type mice (Fig. 5.6). Since 
it has previously been shown that IFN-y receptor defective mice have reduced 
IFN-y production and develop a disseminated infection (Mahon et al., 1997), the 
blood and livers o f wild-type and IL-12‘/’ mice were assessed for the presence o f 
viable B. pertussis bacteria. However, B. pertussis was not detected in any other 
organ other than the lung.
5 .2 .4  T h e  r o l e  o f  I L -1 2  i n  b a c t e r i a l  c l e a r a n c e  a n d  T - c e l l  
RESPONSES DURING SECONDARY INFECTION WITH B. PERTUSSIS 
In a separate experiment, the role o f IL-12 in secondary infection with B. pertussis 
was examined. IL-12"“ and wild-type BALB/c mice were infected with B. pertussis 
and allowed to recover from infection. Ten weeks after primary challenge, both 
groups o f mice were rechallenged with B. pertussis. Groups o f  four mice were 
sacrificed at intervals post-challenge to estimate the numbers o f viable bacteria in 
the lungs. Splenic T-cell responses were also assessed after restimulation in vitro 
with B. pertussis antigens. Spleen cells from IL-12'7' and wild-type BALB/c mice 
were restimulated in vitro with medium or PMA and anti-CD3 as negative and 
positive controls respectively, B. pertussis sonicate at 1 and 5pg/ml, PT (2pg/ml), 
FHA (5pg/nil) and PRN (5pg/ml). Spleen cell IFN-y and IL-5 production was
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assessed on the day o f challenge (Day 0) and 2 weeks post-challenge. Examination 
o f T-cell cytokine responses showed that rechallenge o f IL-12_/" and wild-type 
BALB/c mice previously infected with B. pertussis, induced a mixed Thl/Th2 
response with high levels o f IFN-y and IL-5 production in response to bacterial 
antigens (Fig. 5.7). Spleen cells from IL-12'' mice secreted significantly lower 
amounts o f  IFN-y compared to wild-type mice, which is similar to what is seen at 
day 70 after primary infection. However, knockout mice still displayed a mixed 
response, producing both Thl and Th2 cytokines (Fig. 5.7). 14 days after
secondary challenge, IFN-y production from spleen cells o f knockout mice is also 
significantly reduced. The complete clearance o f bacteria after secondary infection 
was delayed in IL-12_/‘ mice (Fig. 5.8). However, the difference in CFU counts 
between knockout and wild-type mice was not statistically significant.
5.2.5 IL-18 IS RAPIDLY INDUCED IN THE LUNG FOLLOWING RESPIRATORY 
CHALLENGE WITH B . PERTUSSIS
In order to determine if IL-18 was induced at the site o f infection, lungs from B. 
pertussis infected wild-type BALB/c and IL-12 /_ mice were taken at 4 hours, and at 
intervals up to 70 days post-challenge, and IL-18 levels in lung homogenates were 
determined by ELISA. The results show that IL-18 is induced within 4 hours of 
infection. The most potent IL-18 induction is observed early in infection and 
significantly higher levels were detected in IL-12 7 mice at day 7 post-challenge. 
Similar levels o f IL-18 in both wild-type and IL-12’ mice were seen at all other 
timepoints (Fig. 5.9). IL-18 levels begin to decline after day 7 and reach levels 
similar to those observed in uninfected control mice by day 70 post-infection.
5.2.6 T h e  R o l e  o f  IL-12 in  b a c t e r i a l  c l e a r a n c e  a n d  t - c e l l
RESPONSES IN PA AND PW- IMMUNIZED MICE
It has already been demonstrated that immunization with Pw, like natural infection, 
induces Thl cells, whereas Pa appear to protect by inducing antibody and Th2 cells 
(Mills et al., 1993, Mills et al., 1998a, Redhead et al., 1993). Therefore, the role o f 
IL-12 in the induction o f vaccine-induced immunity was investigated. The 
development o f systemic cell-mediated immune responses in B. pertussis-infected
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animals that had been previously immunized with Pa or Pw were evaluated. Wild- 
type BALB/c or IL-12"/_ mice were immunized with Pa or Pw and boosted 4 weeks 
later. Two weeks after the second immunization, mice were challenged with B. 
pertussis. T-cell responses in immune wild-type and gene-disrupted mice were 
assessed on the day o f challenge, and on days 7 and 14 post-challenge. Pw- 
immunized IL-12' " and wild-type mice exhibited a polarized Thl response with high 
levels o f IFN-y and little or no IL-5 in response to killed B. pertussis, PT, FHA and 
PRN (Fig. 5.11). Compared with wild-type mice, there was a reduction in antigen- 
specific IFN-y levels in Pw-immunized IL-12_/' mice at all timepoints tested, with a 
significant decrease at day 7 to killed bacteria and PT, and to FHA at day 14. A 
concomitant increase in IL-5 was not observed (Fig. 5.11). Immunization with Pa 
in knockout and wild type mice induced a T-cell response polarized to the Th2 
subtype, with low levels o f IFN-y and high levels o f IL-5 (Fig. 5.12).
An examination o f bacterial clearance from the lungs o f these mice revealed 
no significant difference between the numbers o f bacteria recovered from the lungs 
o f Pw-immunized IL-12' ' and wild-type mice (Fig. 5.10). This was particularly 
surprising for Pw-immunized mice, given that Pw selectively induces Thl cells 
(Redhead et al., 1993) and is associated with a cytokine profile o f high levels of 
IFN-y production and little IL-4 or IL-5. It might be predicted that Pw-immunized 
IL-12 ' mice would display impaired protection or somewhat protracted clearance 
o f the bacteria from the lungs, especially when B. /?ertw.v,sA-specific IFN-y 
production was reduced in these mice. Following immunization with Pa, bacterial 
clearance from the lungs remains unaffected in IL-12'1' mice (Fig. 5.10).
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5 .3  D i s c u s s i o n
Resistance or susceptibility to infection is strongly determined by the pattern o f 
cytokines produced in response to the infection (Scott et al., 1991). The 
pro inflammatory cytokine IL-12 is mandatory for the induction o f IFN-y 
production, and is important in anti-microbial defense (Trinchieri, 1995, Trinchieri,
1994, Locksley, 1993, Jouanguy et al., 1999). In a murine respiratory challenge 
model o f infection with B. pertussis, it has been demonstrated that mice with a 
defective IFN-y receptor (IFN-yR") gene, develop an atypical disseminated disease 
which is lethal in a proportion o f animals (Mahon et al., 1997). In comparison with 
wild-type 129 Sv/Ev mice that resolved the infection, gene-disrupted mice showed 
abnormal pathology characterized by pyogranulomatous inflammation and 
postnecrotic scarring in the livers, mesenteric lymph nodes and kidneys. 
Furthermore, viable virulent bacteria were detected in the blood and livers of 
diseased animals. In another study it was reported that murine macrophages 
produce IL-12 after stimulation with live or killed B. pertussis (Mahon et al., 1996).
In this study, it was demonstrated that IL-12 and IL-18 production is 
induced in vitro following stimulation with B. pertussis. IL-12 was readily 
produced at high levels from J774 macrophage stimulated with killed B. pertussis. 
Furthermore, IL-18 production was precipitately induced from splenic macrophages 
isolated from naïve mice and subsequently infected with live B. pertussis. The 
addition o f a neutralizing anti-IL-12 antibody (or a combination o f anti-IL-12 and 
anti-IL-18) to a culture o f spleen cells from naïve mice stimulated with B. pertussis, 
completely abrogated pertussis-induced IFN-y production. However, addition of 
anti-IL-18 to a similar culture did not have any effect on B. pertussis-induced 
IFN-y, indicating that at least in vitro IFN-y is induced via IL-12.
Endogenous IL-12 has been shown to be necessary for IFN-y production, 
and for the establishment o f a Thl-type response after infection with Listeria, 
Leishmania, Toxoplasma gondii and Candida albicans (Scharton-Kersten et al.,
1995, Mattner et al., 1996, Gazzinelli et al., 1993, Mencacci et al., 1998). IL-18 
has also been shown to be important in the induction o f Thl responses, through its 
synergistic action with IL-12 (Ahn et al., 1997). In other systems, lack o f  IL-12 
function results in a failure to direct immune responses towards Thl responsiveness,
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and to produce a cytokine profile characteristic o f a Th2 response (Seder et al., 
1993). Indeed, stimulation of naive spleen cells lfom IL-12'7' mice with the mitogen 
PMA/CD3 yielded significantly reduced IFN-y and increased levels o f IL-4 in 72hr 
culture supernatants, when compared with responses from wild-type animals that 
readily produced high levels of IFN-y and minimal IL-4.
In this study, the in vivo role o f IL-12 in B. pertussis infection was 
examined, to determine whether IL-12 deficiency leads to a shift from the normally 
observed Thl response to B. pertussis, to a more polarized Th2 response. It was 
important to determine the significance o f IL-12 in the regulation o f anti-bacterial 
cytokine expression, particularly when IFN-y has such an important function in the 
induction o f Thl cells and in confining the bacteria to the respiratory tract (Barbie 
et al., 1997, Mahon et al., 1997). The responses o f IL-12'7' mice infected with B. 
pertussis were examined, and compared with the responses o f wild-type BALB/c 
mice. In primary infection o f naive mice with B. pertussis, a shift from a polarized 
Thl response toward a mixed Thl/Th2 response was observed in IL-12"7' mice. 
IFN-y production was significantly reduced and IL-5 levels elevated in response to 
killed B. pertussis in knockout mice. Bacterial titres in the lung were significantly 
elevated in IL-12"7' mice early in infection (day 7), compared to wild-type mice. 
However, these mice still maintained the ability to eventually clear the bacteria from 
the lungs with the same efficiency as wild-type mice. Furthermore, IL-12'' mice did 
not exhibit an atypical disease pattern as was previously observed in IFN-yR'" mice. 
Blood and livers from IL-12“ ' infected mice were tested for the presence o f viable 
virulent bacteria and revealed that the bacteria still remained confined to the 
respiratory tract and there was no dissemination o f infection.
IL-18 was found to be rapidly induced in the lungs o f both wild-type and IL- 
12" ' mice, just hours after respiratory challenge. The reduction in IFN-y, together 
with the elevated numbers o f bacteria in the lungs o f IL-12"7' mice at day 7 post­
challenge, coincides with an increase in IL-18. A possible explanation for this is 
that in the absence o f IL-12 early in infection, an alternative pathway o f IFN-y 
induction comes into play, and this is mediated by IL-18. Lack o f endogenous IL- 
12 during infection with B. pertussis, did not have a significant effect on complete 
clearance o f bacteria from the lungs, as both wild-type and IL-12" ' mice cleared the
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bacteria at the same rate. However, IL-12-deficiency results in a significant 
enhancement o f the bacterial load in knockout mice at the early stages o f primary 
infection. Studies in IFN-y R'" mice have shown that dissemination o f infection is 
observed prior to the development o f acquired immune responses (Mahon et al., 
1997), suggesting that innate immunity plays a role in limiting early infection in the 
respiratory tract. IL-12-induced IFN-y, secreted by NK cells and y8 T-cells may 
help to contain the infection to the respiratory tract prior to the development of 
specific T-cell responses. Hence, the observation that bacterial load is elevated 
early in infection in knockout mice, may therefore reflect the influence o f IL-12 on 
IFN-y production by innate cells, rather than T-cells.
Similarly, IL-12 appears to play a role in the induction o f a protective Thl 
response during a secondary infection with B. pertussis, with a significant reduction 
in bacterial specific IFN-y production observed in knockout mice on the day o f 
challenge, and on day 14 post-challenge. This decrease in IFN-y production may 
have affected complete clearance o f the bacteria from the lungs during secondary 
infection with B. pertussis, which was slightly, but not significantly protracted in 
knockout mice. Spleen cells from wild-type and IL-1 2 "  mice consistently secreted 
both IFN-y and IL-5, indicating a mixed Thl/Th2 response. Although, natural 
infection with B, pertussis normally induces a polarized Thl response in mice and 
children (Mills et al., 1993, Ryan et al., 1997, Mahon et al., 1997), it has been 
demonstrated that a Th2 response can also be protective, although this is mediated 
through a distinct mechanism (Mills et al., 1998a, Mahon et al., 1996). This may 
explain why the lack o f IL-12-induced IFN-y production did not impact the course 
o f infection to a significant extent.
In Pa- and Pw-immunized IL-12 and wild-type mice, which were 
subsequently infected with B. pertussis, lack o f functional IL-12 mice had no effect 
on protection against infection. Knockout mice immunized with Pa or Pw cleared 
the infection within the same time span as wild-type mice, and did not have 
significantly higher numbers o f  bacteria in the lungs. Pa-immunized wild-type mice 
exhibited a polarized Th2 response, and this response was unaffected in knockout 
mice. A decrease in IFN-y levels was observed in Pw-immunized mice lacking IL-
1 02
12, without a significant concomitant increase in the levels o f the Th2 cytokine IL- 
5. Previous studies have demonstrated that immunization with Pw induces a 
protective Thl response in mice (Redhead et al., 1993), and an exacerbated 
disseminated disease in IFN-yR-deficient mice (Mahon et al., 1997). Therefore, the 
undiminished anti-bacterial resistance o f Pw-immunized mice lacking IL-12, is 
rather surprising in view o f the significant decrease in the Thl response in these 
mice, and the critical role for IL-12 in the induction o f IFN-y and Thl development. 
It has been demonstrated that immunization with Pa induces Th2 cytokine profile in 
mice (Mills et al., 1998a), and addition o f IL-12 to Pa, increases its protective 
efficacy through the induction o f Thl cells (Mahon et al., 1996). Furthermore, 
stimulation o f macrophages with FHA, detoxified PT and PRN (the components o f 
Pa) does not induce IL-12 production (Mahon et al., 1996). Therefore, the 
observation that Pa-immunized IL-12‘ " mice do not display increased susceptibility 
to B. pertussis infection is not so surprising, as it appears that IL-12 does not play a 
major role in protection in this system.
Lack o f IL-12 in this system appears only to effect protection against B. 
pertussis early in infection. This suggests that IL-12 may play a role in confining 
the bacteria to the respiratory tract through the induction o f IFN-y production by 
innate cells, during the early stages o f infection. Furthermore, these data indicate 
that during B. pertussis infection, the ability o f CD4+ T-cells to develop into Thl 
type cells is diminished, in the absence o f endogenous IL-12. The fact that the Thl 
response is not completely abrogated in knockout mice, suggests that alternative 
cytokines or host factors may compensate for the lack o f endogenous IL-12. The 
observation o f an IL-12 redundance for IFN-y production supports Schijns et al. 
1998, who reported that IL-12 is not essential for the generation o f a Thl response 
for the control o f Coronavirus-induced acute hepatitis. In another study, it was 
shown that in vivo alloreactive Thl development may occur independent o f IL-12 
(Piccotti et al., 1998). Piccotti and colleagues also suggested that in their system 
IL-18 may act as an alternative sensitizing pathway in vivo. So, in the absence o f 
IL-12, we suggest from our observations that an alternate IFN-y-inducing pathway 
may occur in vivo which is mediated by IL-18.
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Figure 5.1
J774 Macrophages produce IL-12 in response to heat-killed B. pertussis. 
Macrophages were incubated with increasing doses o f B. pertussis (105 to 108 
CFU/ml) for 24 hours, after which supernatants were collected and assessed for IL-12 
p40 by immunoassay. Results are expressed as the mean concentration o f  IL-12 from 
triplicate cultures.
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Figure 5.2
Splenic macrophages produce IL-18 in response to live B. pertussis. Macrophages 
were isolated from the spleens o f naïve mice and incubated for 24 hours with (•) or 
without (□) rmIFN-y. The cells were then infected with B. pertussis (Ohrs) at a 
bacteria to cell ratio o f 5:1. Supernatants were collected eveiy hour for 4 hours post­
infection, and IL-18 levels assessed by ELISA. Results are expressed as the mean 
(±SE) concentration o f IL-18 from triplicate cultures. **, P < 0.01 versus cells 
stimulated with IFN-y.
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Figure 5.3
B. pertuss¿s-induced IFN-y is btocked by neutralizing anti-IL-12 in vitro. 
Spleen cells from naïve mice were stimulated in vitro with killed B. pertussis 
(BP) only, (lxlO5 to 1x10s CFU/ml), or in the presence o f  a neutralizing anti- 
IL-12 antibody (A), neutralizing IL-18 (B), or a combination o f  both anti-IL-12 
and anti-IL-18 (C). Supernatants were removed after 72hrs and IFN-y levels 
measured by ELISA.
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Figure 5.4
Decreased Thl and enhanced Th2 cytokine production in IL- 12-deficient mice. 
Spleen cells were isolated from naïve IL-12"  ^and wild-type BALB/c mice, and 
stimulated with PMA and anti-CD3 or medium only. Supernatants were 
removed after 72 hours and assessed for IFN-y and IL-4. Results are the mean 
(±SE) cytokine concentrations for four mice per group assayed in triplicate. 
***, 7> < 0.001 versus wild-type mice.
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Figure 5.6
Clearance o f  B. pertussis from the lungs o f  knockout and wild-type mice during 
primary challenge. Both IL-12" ' (□) and W. T BALB/c mice (•) were infected 
with B. pertussis by aerosol challenge. Lungs were removed at intervals post­
challenge and numbers o f  viable bacteria assessed. Results represent mean (± 
SE) CFU per lung for four mice per time point.
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Figure 5.8
Clearance o f  B. pertussis from the lungs o f  BALB/c and IL-12"7" mice during 
secondary challenge. Both IL-12“7' (□) and W. T BALB/c mice (• ) were 
infected with B. pertussis by aerosol inoculation, and allowed to clear the 
infection. 10 weeks post-primary challenge, mice were rechallenged with B. 
pertussis. Lungs were removed at intervals post-challenge and numbers of 
viable bacteria assessed. Results represent mean (± SE) CFU per lung for four 
mice per time point.
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Figure 5.9
IL-18 is rapidly induced in the lung following respiratory challenge with B. 
pertussis and persists throughout the course o f infection. Lungs lfom B. 
pertussis infected wild-type BALB/c (•) and IL-12'" (□) mice, were taken at 
intervals post-primary challenge and homogenised. IL-18 levels in lung 
homogenates were then determined by ELISA Results are expressed as the 
mean concentration (±SE) o f IL-18 for four mice per experimental group.
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Figure 5.10
Absence o f  IL-12 does not affect the efficacy o f  Pa or Pw. Wild-type BALB/c 
(• ) and (□) mice were immunized with 0.2 Human dose o f  Pa or Pw and
boosted 4 weeks later. Two weeks after secondary immunization, mice were 
infected with B. pertussis. Mice were sacrificed at various times after challenge to 
assess the numbers o f  viable bacteria in the lungs. Results are reported as the 
mean numbers o f B. pertussis CFU (±SE) for individual lungs from 4 mice per 
group at each timepoint.
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DOWNREGULATION OF A PROTECTIVE T H l RESPONSE 
TO BORDETELLA PERTUSSIS BY A TH2-INDUCING 
PARASITE - FASCIOLA HEPA TICA
6 .1  In t r o d u c t io n
The identification o f Thl and Th2 cells has provided a useful model for our 
understanding the selective induction, polarization and reciprocal regulation o f 
distinct arms o f the immune response (Mossman et al., 1986, Abbas et al., 1996). 
Although immunity to infectious disease involves a complex interplay between both 
humoral and cellular immune responses against antigens on the infectious agent, 
CD4+ T-cells appear to be the key regulators o f the immune response. Thl cells are 
normally induced following infection with intracellular bacteria and viruses, whereas 
Th2 responses are generated in response to allergens and helminth parasites (Abbas 
et al., 1996, O’Garra et al., 1994). The early decision to polarize the immune 
response towards type 1 or type 2 is controlled by a number o f factors. Gram 
negative bacteria and viruses stimulate the production o f IL-12 and IL-18 by 
dendritic cells and macrophages, which favours the induction and expansion o f Thl 
cells (Trincheiri et al., 1994, Bohn et al., 1998). Conversely, early IL-4 acts as a 
potent stimulus for Th2 differentiation (Abbas et al., 1996, O’Garra et al., 1994). 
Thl and Th2 cells produce cytokines that act as their own autocrine growth factors 
and that are mutually inhibitory for the differentiation and effector functions o f the 
reciprocal subtype. Thus, once a T-cell immune response begins to develop along 
either a Thl or Th2 lineage, from a common precursor, it tends to become 
increasingly polarized in that direction.
The prevalent manifestation o f multiple infections has led to an increased 
interest in the effects that one infection, immunization or antigenic stimulus may 
have on another. Circumstantial evidence exists to suggest that cross-inhibitory 
immunomodulation occurs between Thl and Th2 cells in vivo. The incidence o f 
IgE-mediated allergies, such as eczema, hay fever and asthma, has risen steadily in 
Westernized societies, doubling in the last twenty years (Seaton et al, 1994). The 
short time over which this change has occurred and continues to occur, indicates 
that the environment plays a central role in these disorders. Children are bom with 
a tendency to show allergic-type Th2 cytokine responses, a pattern that disappears 
in the first few years o f life. However, this maturation might be delayed or absent in 
individuals predisposed to allergy. The theory is that depriving the immune system 
of the early input historically provided by Thl-inducing childhood infections might
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lead to inefficient maturation and a prevalence o f the Th2 type responses normally 
associated with allergy. This proposal is referred to as the ‘hygiene hypothesis’ or 
‘ Westernization’ (Folkerts et al., 2000, Cookson et al., 1997). Further evidence for 
this Thl/Th2 cross-regulation in vivo has emerged through the study o f the 
immunobiology o f pregnancy. Normal pregnancy is characterized by a lack o f 
strong maternal anti-fetal immunity and a bias toward Th2-type reactivity. A shift 
in this response to a Thl bias, which may be caused by infection, or by the 
preponderance o f certain cytokines in the local milieu during T-cell activation, has 
been shown to result in pregnancy loss (Raghupathy, 1997, Mellor et al., 2000, 
Chaouat et al., 1997). Furthermore, a recent study suggests that helminth infection, 
which results in highly polarized Th2 responses, can impair the immune response o f 
the host to HIV and TB, and may be a contributory factor in the spread o f these 
diseases (Bentwich et al., 1999).
This dichotomy into reciprocally regulated Thl and Th2 cell type responses 
provides a simple framework in which we categorize immune responses and their 
role in dealing with distinct pathogens that require different effector mechanisms for 
their control. However, the real situation, especially in the developing world, is one 
where individuals may be exposed to multiple infections or where vaccines may be 
administered in the face o f chronic parasitic infection. The aim o f the present 
investigation was to examine the reciprocal, cross-inhibitory influences o f  a Thl- 
inducing bacterial pathogen and a Th2-inducing parasite in vivo.
Bordetella pertussis is a gram negative coccobacillus that primarily infects 
infants and young children via inhalation o f aerosol droplets. It preferentially 
associates with ciliated respiratory epithelial cells, but can also invade and survive 
within alveolar macrophages and polymorphonuclear leucocytes (Friedman et al., 
1992). Colonization o f the upper respiratory tract results in the disease whooping 
cough, a significant cause o f morbidity and mortality worldwide. Respiratory 
infection or immunization with Pw is associated with the induction o f antigen- 
specific Thl cells, which are critical in host resistance to infection (Mills et al., 
1993, Redhead et al., 1993, Ryan et al., 1997). In particular, the type 1 cytokine 
IFN-y plays a major role in controlling B. pertussis infection, and in containing the 
bacteria to the mucosal site (Barbie et al., 1997, Mahon et al., 1997).
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The parasitic trematode Fasciola hepatica infects a wide variety o f 
mammals, including cattle, sheep and humans, causing liver fluke disease or 
fasciolosis. Infection is usually acquired by the ingestion o f encysted larvae that 
contaminate vegetation or water. The metacercariae excyst in the intestine, migrate 
through the intestinal wall into the peritoneal cavity an then migrate across the body 
cavity to the liver parenchyma, where they cause extensive tissue damage and 
haemorrhaging. After approximately eight weeks the parasites move into the biliary 
passages, become sexually mature and commence egg production. Infection with F. 
hepatica, like other helminths, is accompanied by elevated IgE levels, eosinophilia, 
immune responses associated with the Th2 subtype (Mulcahy et al., 1999, 
Finkelman et al., 1991), and it has been recently demonstrated that F. hepatica 
infection o f mice results in an early and persistently polarized Th2 response (O’Neill 
et ah, 2000). This has provided an ideal model to examine the cross-regulatory 
effect o f a Th2-inducing pathogen following prior or simultaneous exposure to Thl - 
inducing pathogen.
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6 .2  R e s u l t s
6 .2 .1  B. PER TU SSIS- A T h I-IN D U C J N G  BACTERIUM AND F. HEPATICA - A 
T h 2 - i n d u c i n g  p a r a s i t e
Previous studies have demonstrated that infection with B. pertussis induces a 
polarized Thl response in mice and children (Mills et al., 1993, Ryan et al., 1997). 
The results o f this study are in agreement with these findings. Naive mice were 
infected with B. pertussis by aerosol inoculation o f five virulent bacteria into the 
lungs. Three weeks after infection, spleen cells were prepared and incubated with 
heat-killed bacteria. B. pertussis-spQci&c T-cells secreted high levels o f IFN-y and 
IL-2, with no IL-4 or IL-5 (Fig. 6.1), indicating that B. pertussis induces a Thl 
response in mice.
Infection with the helminth parasite F. hepatica was shown to induce a Th2 
response in mice. Mice were orally infected with 10 metacercariae. 3 weeks post­
infection, spleen cells secreted IL-4 and IL-5, in the absence o f IFN-y and IL-2 
following restimulation in vitro with liver fluke homogenate (LFH) (Fig. 6.2).
6 .2 .2  F. HEPATICA  SUPPRESSES THE TYPE 1 RESPONSE INDUCED BY 
RESPIRATORY INFECTION WITH B. PERTUSSIS
To examine the effect o f F. hepatica infection on the immune response induced by 
infection with B. pertussis, BALB/c mice were co-infected with both parasite and 
bacteria on the same day. Mice infected with either F. hepatica or B. pertussis only 
served as controls. Spleen cells prepared from mice 3 weeks after infection with B. 
pertussis alone secreted high IFN-y levels, and undetectable IL-4, in response to B. 
pertussis sonicate and to the purified B. pertussis antigens filamentous 
haemagglutinin (FHA) and pertactin (PRN) (Fig. 6.3). This is consistent with 
previous reports (Mills et al., 1993, Ryan et al., 1997), that B. pertussis infection 
selectively induces Thl cell responses. The production o f B. pertussis-specific IFN- 
y production is almost completely abrogated in mice co-infected with F. hepatica. 
In contrast, infection with F. hepatica results in a polarized Th2 response, with high 
levels o f IL-4 and undetectable IFN-y produced by spleen cells in response to liver 
fluke homogenate (LFH). However, the profile o f F. hepatica-specific cytokine
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production was not altered in mice co-infected with B. pertussis (Fig. 6.3) and there 
was no effect on the severity o f fasciolosis, as determined by liver pathology.
Coincident with the suppression o f the Thl response, concurrent infection 
with F. hepática also resulted in delayed B. pertussis clearance from the lungs. 
Mice infected with B. pertussis alone began to clear the bacteria at a steady rate 
after 7 days, whereas clearance was protracted in co-infected mice; the numbers o f 
bacteria were significantly higher in the co-infected mice 14 and 21 days after 
challenge (Fig. 6.4).
6.2.3 F. HEPATICA  SUPPRESSES AN ESTABLISHED B. PERTUSSIS-SVECW IC 
ThI RESPONSE
Having established that F. hepática infection could suppress the B. pertussis- 
specific Thl response during the induction phase, it was determined whether the 
same suppressive effect could be observed on an established Thl response. 
BALB/c mice were infected with B. pertussis by aerosol challenge, and allowed to 
recover. After 6 weeks, by which time the B. pertussis-?pcc\i\c Thl response was 
established and the mice had recovered from infection (the lungs were completely 
free from bacteria), the mice were infected with F. hepática. Spleen cells from mice 
infected with B. pertussis alone secreted high levels o f IFN-y and low levels o f IL-4, 
whereas mice infected with F. hepática alone secreted IL-4 and low levels IFN-y, 
typical Thl and Th2 responses respectively (Fig. 6.5). However IFN-y production 
in response to B. pertussis antigens was markedly diminished in the mice that 
cleared the B. pertussis infection and were subsequently infected with F. hepática 
(Fig. 6.5), demonstrating suppression o f the already established bacterial-specific 
Thl response.
6.2.4 I n f e c t i o n  w i t h  F. h e p á t ic a  r e s u l t s  in  s u p p r e s s io n  o f  t h e  B.
PERTUSSIS-SPECÍFIC ThI RESPONSE IN MICE IMMUNIZED WITH Pw 
Since immunization with Pw also induces a potent Thl response and confers a high 
level o f protection against a B. pertussis respiratory challenge, we examined the 
effect o f F. hepática infection on this protective vaccination. Mice were immunized 
twice with Pw (0.8 iu, i.p. 0 and 4 weeks) and 4 weeks later were infected with 10
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metacercariae o f F. hepatica. As expected mice immunized with Pw alone or 
infected with F. hepatica only, developed Thl and Th2 responses respectively. The 
production o f IL-4 and IL-5 in response to F. hepatica was not affected by prior 
immunization with Pw. However, B. pertussis-specific IFN-y and IL-2 production 
in Pw immunized mice is completely inhibited following F. hepatica infection, 
demonstrating that infection with F. hepatica severely decreases B. pertussis- 
specific Thl cytokine production (Fig. 6.6). IFN-y, but not IL-4 production from 
cells stimulated with PMA and anti-CD3 was also suppressed in mice infected with 
F. hepatica. Moreover infection with F. hepatica reduced the protective efficacy o f 
the Pw in the respiratory challenge model. The numbers o f viable bacteria in the 
lungs 7 days after B. pertussis challenge were 40 fold higher in immunized mice 
infected with F. hepatica, compared to those that received the vaccine only (Fig. 
6.7).
6.2.5 F. //EPi477G4-INDUCED SUPPRESSION OF T h I  RESPONSES INVOLVES IL-4 
IL-4 plays a major role in directing the immune response to the Th2 subtype and has 
also been implicated in the reciprocal downregulation o f  Thl responses. Therefore, 
we examined the role o f IL-4 in the F. hepatica-induced suppression o f B. pertussis 
specific Thl responses by using IL-4 defective (IL-4_/‘) mice. IL-4'/' and wild-type 
C57BL/6 mice were immunized with Pw, and boosted 4 weeks later. Immunized 
and control naive mice were then infected with 10 F. hepatica metacercariae and T- 
cell cytokine production was assessed two weeks later. Spleen cells o f wild-type 
C57BL/6 mice immunized with Pw alone exhibited a strong Thl response, 
characterized by high levels o f IFN-y production and low IL-4 to B. pertussis 
antigens. Interestingly the levels o f B. pertussis-specific IFN-y secreted by spleen 
cells were lower in IL-4'/_ compared with the wild-type mice. However this is 
consistent with previous observations (Mahon et al., 1997) and with a recent report 
which suggested that IL-4 is required in the priming phase o f Thl-associated 
tumour immunity (Schuler et al., 1999). Following infection with F. hepatica, a 
complete switch from type 1 to a type 2 response was observed. B. pertussis- 
specific IFN-y production was markedly suppressed to undetectable levels, and 
significant levels o f IL-4 were now detected in response to B. pertussis antigens
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(Fig. 6.8). In contrast, F. hepatica infection did not suppress IFN-y or elevate IL-4 
production by B. pertussis-sçedxBc T cells from IL-4"7 mice immunized with Pw 
(Fig. 6.8).
In a separate experiment, IL -4 ’ mice were infected with B. pertussis only, 
or coinfected with B. pertussis and F. hepatica and the course o f infection was 
monitored through the enumeration o f viable bacteria in the lungs at various times 
following challenge (Fig. 6.9). In contrast to the delay in bacterial clearance 
observed in wild-type mice coinfected with B. pertussis and F. hepatica, the 
numbers o f viable bacteria recovered from the lungs o f singly infected and 
coinfected IL-4 ' mice did not differ significantly (Fig. 6.9)
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6 .3  D is c u s s io n
The results o f this study demonstrate that immune responses dominated by one T 
cell subtype, evoked at one mucosal surface in the body, can exert bystander 
modulation on the reciprocal T-cell subtype induced at another site in the body. 
Furthermore in an experimental exposure to simultaneous Thl and Th2-inducing 
stimuli, suppression o f Thl responses was observed, without a reciprocal effect on 
Th2 responses, suggesting that at least in this model system that the Th2 cell may 
have a dominant effect in Thl-Th2 cross-regulation in vivo. In addition the results 
provide the first evidence that the immunosuppressive effect o f helminth parasites 
can also operate on an established Thl response and that the immunoregulatory 
mechanism involves IL-4.
In general, parasitic infections do not cause high mortality, but counteract 
the host's immune defenses by developing a variety o f strategies to evade protective 
immune responses (Maizels et al., 1993). It has been well documented that 
parasitic infection is frequently accompanied by a downregulation in cell-mediated 
immunity (Sher et al., 1992). Inhibition o f lymphocyte proliferative responses has 
been reported during nematode (Allen et al., 1998, Lawrence et al., 1995) and 
trematode infections (Cervi et al., 1998). Parasitic infections also provide some of 
the clearest examples o f  how the nature and protective capacity o f  the host's 
immune system is dependent upon the polarized development o f T-lymphocytes o f 
either the Thl or Th2 subsets. It is well established that the emergence o f an 
immune response dominated by a Th2-type profile is characteristic o f many 
helminth infections, and it has been reported that Th2 responses are essential for 
resistance to these parasites (Finkelman et al., 1991, Grencis, 1993). However, it 
remains unclear whether these responses are protective to the host. There is 
evidence from studies with other helminth parasites that Thl stimulation may be 
associated with protection and that Th2 stimulation is associated with chronic 
disease (Scott et al., 1989, Sher and Coflfrnan, 1992). The adoptive transfer o f a 
CD4+ Thl clone, obtained from mice protectively immunized against the blood 
fluke Schistosoma mansoni, has been shown to convey protection against this 
parasite (Jankovic et al., 1996). In mice, resistance to Trichinella spiralis 
correlates with the early activation o f IFN-y secreting cells, and little activation o f
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Th2 cells (Pond et al., 1992). Although Thl or Th2 cells may play a role in 
protection against different parasites, it would be beneficial to the parasite to induce 
immune responses capable o f suppressing the host’ s immune protective 
mechanisms.
In the present investigation two infection models have been exploited, which 
have been shown to be capable o f generating highly polarized Thl or Th2 responses 
in mice, in order to examine the influence the cross regulation o f cell subtypes in 
vivo. Consistent with previous reports (Mills et al., 1993, Redhead et al., 1993, 
Ryan et al., 1997), this study has demonstrated that respiratory infection with B. 
pertussis or immunization with Pw selectively stimulated Thl responses. In 
contrast, infection with the parasitic helminth F. hepatica evoked a potent Th2 
response and was capable o f downregulating Thl responses induced either by 
respiratory infection with B. pertussis or systemic immunization with Pw. 
Downregulation o f Thl cytokine responses to both parasite and non-parasite 
antigens has also been reported during infection with S. mansoni (Kullberg et al., 
1992, Pearce et al., 1991). This Th2-inducing parasite has also been shown to 
exacerbate the outcome o f Salmonella typhi infection, in concurrent infections 
(Njunda et al., 1996). However, since the response has shifted from predominantly 
Thl to Th2 at the egg stage o f infection with S. mansoni (Finkelman et al., 1991), 
this model is limited to an examination o f the effects o f an established parasite- 
specific Th2 response on the induction o f a Thl cells to other antigens or 
pathogens. In the F. hepatica model a highly polarized Th2 response is detected 
throughout the infection (O’Neill et al., 2000), providing a model to examine the 
influence o f the Th2-inducing pathogen at different stages o f response to the Thl- 
inducing pathogen.
The data clearly indicates that the liver fluke has the ability, not only to alter 
the development o f  B. pertussis Thl response during infection and vaccination, but 
also to modulate this response after it has become polarized. The modulatory effect 
o f the parasitic infection could be observed when it was delivered either at the 
induction phase or during an established B. pertussis-specific Thl response. 
Significantly the results also demonstrate that the modulation o f  the cytokine profile 
by B. pertussis specific T cells was accompanied by a reduction in host resistance to
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the bacterial infection after challenge. The finding that protective immunity was not 
completely abrogated in the mice infected with F. hepatica can be explained by the 
fact that Th2 or a mixed Thl-Th2 response, such as that induced with an acellular 
pertussis vaccine, can also confer a level o f protection against B. pertussis challenge 
by a distinct mechanism (Mills et al., 1998a). The results suggest that the systemic 
response can influence protective effector mechanisms in the lung.
Our observations suggest that the suppression o f the anti-bacterial immunity 
during the F. hepatica infection is a consequence o f bystander down-regulation o f 
the B. pertussis-specific Thl cells by the parasite-specific Th2 cells. Nevertheless it 
is possible that the liver fluke infection may have exerted other effects on anti­
bacterial immunity, independent o f  Th2 cells. It has been suggested that S. mansoni 
may induce apoptosis o f IFN-y-producing cells (Estaquier et al., 1997). Excretory- 
secretory components o f F. hepatica may also exert direct immune suppressive 
effects through the activity o f proteinases on immunoglobulin molecules (Carmona 
et al., 1993). However the abrogation o f the modulatory effect o f the F. hepatica 
infection in IL-4 defective mice argues against these possibilities and points to an 
important role for IL-4 in Th2-mediated immunoregulation. F. hepatica infection 
o f C57BL/6 mice that had been immunized with Pw, resulted in a significant 
reduction in B. pertussis-spec\&c IFN-y production. In contrast, IFN-y production 
was not significantly altered following F. hepatica infection o f IL-4'" mice 
immunized with Pw. Furthermore, a significant difference in the bacterial load in 
IL-4 ' mice coinfected with F. hepatica was not observed, suggesting that 
abrogation o f the suppressive effect on IFN-y production translates into restoration 
o f full protection. However, interpretation o f the effect o f IL-4 on the outcome of 
infection in IL-4'/_ mice is complicated by the fact that IFN-y production in the 
absence o f F. hepatica infection is also partially suppressed in these mice (Mahon 
et al., 1997, Schuler et al., 1999, and this study).
In addition to IL-4 other inhibitory cytokines may also be involved in the 
Thl response inhibition by F. hepatica. Like IL-4, IL-10 can inhibit cytokine 
production by Thl cells (Fiorentino et al., 1991) and the ability o f IFN-y to activate 
macrophage killing o f both intracellular and extracellular parasites (Gazzinelli et al., 
1992). It has been suggested that this inhibitory cytokine may be responsible for the
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suppression o f Thl responses in S. mansoni infection (Sher et al., 1991). IL-4 and 
IL-10 can act synergistically to inhibit the production o f reactive nitrogen oxides, 
which are known to upregulate IL-12 production, and as a consequence, 
inflammatory responses (Liew, 1993). It has been shown that the excretory- 
secretory products produced during F. hepática infection can decrease nitrite 
production by rat peritoneal cells (Cervi et al., 1996). It has also been 
demonstrated that spleen cells from F. hepática infection mice secrete high levels o f 
IL-4 and IL-10 in response to liver fluke antigens in vitro (O’Neill et al., 2000). 
Thus F. hepática may, through the induction o f IL-4 and perhaps IL-10, inhibit the 
activation o f macrophages and suppress IFN-y production by Thl cells.
The present investigation demonstrated that F. hepática infection could 
downregulate B. pertussis-specific IFN-y production at both the induction and 
effector phases o f the Thl response. In C57BL/6 mice immunized with Pw and 
then infected with F. hepática, the Thl response completely switched to a Th2 
response. The appearance o f Th2 cytokines in C57BL/6 but not BALB/c mice was 
reproducable and is surprising in view o f the observations that responses tend to be 
more polarized to Thl in C57BL/6 mice. One possible explanation for this is that it 
may reflect complex differences in sensitivity to regulatory cytokines. As well as 
the recognized role for early IL-4 in directing the immune response to the Th2 
pathway, there is some evidence to suggest that IL-4 is capable o f converting 
committed Thl cells to the Th2 subtype. In one study, a highly polarized 
Leishmania-specific Thl cell population switched to a Th2 phenotype, following in 
vitro culture with IL-4, especially when added early in culture (Mocci et al., 1995). 
In another study it has been demonstrated that ectopic expression o f GATA-3 (a 
transcription factor differentially expressed on Th2 cells) converted committed Thl 
cells and a Thl clone to express Th2 cytokines (Lee et al., 2000). Signaling 
through IL-4 induces high-level expression o f GATA-3 which in turn blocks IL-12 
signaling by inhibiting expression o f IL-12R(32 (Ouyang et al., 1998). Transcripts 
for IFN-y have been shown to be dominant, in the skin-draining lymph nodes of 
mice vaccinated with irradiation-attenuated cercariae o f S. mansoni, but following a 
challenge infection IL-4 becomes dominant and IFN-y mRNA levels are barely 
detectable (Betts el al., 1998). Thus while early IL-4 production probably plays a
115
major role in driving the immune response to a Th2 phenotype, and may be 
important in the maintaining the polarization o f this response, it can also influence 
the profile o f cytokines secreted in response to unrelated antigens.
In conclusion, the results show that infection the Th2-inducing parasite F. 
hepatica, can suppress a Thl response induced by B. pertussis-infected or 
immunized mice. As well as suppressing IFN-y and IL-2 production, F. hepatica 
infection also delayed clearance o f the bacteria from the lungs following B. pertussis 
challenge. Suppression o f Thl responses was observed without a reciprocal effect 
on Th2 responses suggesting, that at least in the present model system, the Th2 cell 
may have a dominant effect in Thl/Th2 cross-regulation in vivo. Most importantly 
the demonstration o f bystander immunomodulation o f protective type 1 responses 
during infection with Th2-inducing organisms has profound implications for the 
outcome o f concurrent bacterial infections and on protective efficacy o f vaccines 
against intracellular pathogens.
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Figure 6.4
F. hepatica infection delays bacterial clearance in mice infected with B. 
pertussis. BALB/c mice were infected with either B. pertussis abne (A) or 
concurrently with F. hepatica (■). Subsequently, mice were sacrificed at 
various times, to assess the numbers o f viable bacteria in the lungs. Results are 
reported as the mean numbers o f  B. pertussis CFU for individual lungs from 4 
mice from each group at each time point. *, P  < 0.05 versus mice infected with 
B. pertussis alone; **, P < 0.01 versus mice infected with B. pertussis alone.
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Figure 6.7
F. hepatica infection reduces the protective efficacy o f  a whole cell pertussis 
vaccine in mice. BALB/c mice were immunized with Pw (0 and 4 weeks), and 
one week later a proportion o f  these was infected with 10 metacercariae o f  F. 
hepatica (FH). Respiratory infection o f  mice with B. pertussis was pa-formed 
by aerosol challenge 1 week after infection with F. hepatica. Naïve mice and 
mice that were immunized with Pw, and subsequently infected with B. pertussis, 
without a preceding F. hepatica infection served as controls. Mice were killed 
from all groups at various times after aerosol challenge to assess the numbers of 
viable bacteria in the lungs. Results are reported as the mean numbers o f B. 
pertussis CFU for individual lungs from 4 mice at each time point. *, P < 0.05 
versus mice immunized with Pw alone.
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Figure 6.9
F. hepatica does not exacerbate infection with B. pertussis in rL-4 7 coinfected 
mice. rL-4' ' mice were infected with B. pertussis alone (A ) or concurrently 
with F. hepatica (■). Subsequently, mice were sacrificed at various times to 
assess the numbers o f viable bacteria in the lungs. Results are reported as the 
mean numbers o f B. pertussis CFU for individual lungs from four mice from 
each group at each time point.
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As we enter a new millennium, infectious diseases remain a major burden on both 
industrialized and developing countries. Although the advent o f antibiotics has 
helped prevent death in individuals infected with bacteria, the greatest impact on the 
prevention o f infection has come from new developments o f vaccination (Bloom, 
1999). Vaccines have led to the eradication o f smallpox from the world and polio 
from the Northern Hemisphere. The World Health Organization has identified a 
number o f infectious diseases for global eradication, although surprisingly pertussis 
is not one o f them. Infection with B. pertussis results in whooping cough, a 
significant cause o f morbidity and mortality in human infants. The shortcomings of 
the current preventative program resides in the nature and efficacy o f current 
vaccine preparations. Immunization requires a 3-dose primary series and two 
additional boosters for continued protection. This immunization schedule is 
impractical in developing countries and difficult even where public health clinics are 
readily available. Furthermore, it has been recommended that pertussis 
immunization should be carried out every 10 years after the initial vaccination 
schedule, as pertussis does occur in older individuals, and this age group may be an 
important reservoir for the organism. Moreover, although Pa and Pw provide 
effective protection against pertussis (Lang et al., 1995), the efficacy o f pertussis 
vaccines is well below that achieved by with other vaccines, especially polio, 
tetanus, diphtheria and measles. With approximately 80% protection representing 
the maximum threshold for a fully immunized population, disease caused by B. 
pertussis is likely to continue.
Pw have been very effective in reducing the incidence o f pertussis, but are 
associated with adverse events, including fever, persistent crying, seizures and 
hypotonic-hyporesponsive episodes post-immunization. Concerns regarding the 
adverse reactions associated with Pw, together with the recommendation that the 
risk/benefit ratio o f Pw is thought to be too high for individuals over 7 years o f age, 
led to the development o f  Pa (Lang et al., 1995). The new generation Pa composed 
o f purified bacterial components, have now replaced the traditional whole cell 
vaccine against whooping cough, in most developed countries (Rappuoli, 1996). 
Although Pa have a higher safety profile when compared with the Pw (Trollfers et
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al., 1995, Greco et al., 1996, Gustafsson et al., 1996, Simondon et al., 1997, Miller 
et al., 1997), the estimated efficacy o f Pa did not rival that o f most European Pw 
(Gustaffson et al., 1996). Although considerable advances have been made in 
understanding the pathogenesis and immunological mechanisms involved in the 
prevention and control o f infection by B. pertussis, development o f a more effective 
vaccine has been hampered by the inability to identify an immunological correlate o f 
protection against B. pertussis. Further investigation o f the relative contributions o f 
T- and B-cells and their products in immunity to B. pertussis, and the mechanisms 
involved in bacterial elimination, may accelerate the development o f more 
efficacious vaccines. In this study, the role o f Thl and Th2 cells in immunity to B. 
pertussis has been examined using a murine respiratory challenge model o f 
infection.
Animal models, particularly the murine respiratory challenge model, have 
been pivotal in delineating the immunological mechanisms o f protection against B. 
pertussis. It was initially presumed that protection against B. pertussis was 
mediated entirely by antibodies, due to the fact that the bacterium was considered to 
be non-invasive, and occupied a purely extracellular niche. Although antibody does 
play a role, both in toxin neutralization and in preventing bacterial attachment, 
indirect evidence o f a role for T-cells in immunity to B. pertussis has been provided 
by the fact that specific serum antibodies do not rise to significant levels until about 
5 weeks after challenge o f mice (Mills et al., 1993), when five bacteria are no longer 
detectable in the lungs. This suggests that prior to the appearance o f serum 
antibodies, an alternative mechanism o f  immunity must mediate clearance o f the 
bacteria from the lungs. This alternative protective mechanism has been shown to 
be mediated by B. pertussis-specific T-cells, and by cells o f the innate immune 
system. Using a murine respiratory challenge model o f infection Mills et al. (1993) 
demonstrated that normal naive mice clear a respiratory infection after 
approximately 5 weeks, whereas nude mice which are deficient in T-cells, fail to 
eliminate the bacteria after aerosol inoculation, and develop a persistent infection. 
Furthermore, adoptive transfer o f immune spleen cells, or purified CD4+ T-cells into 
nude recipient mice, restored their ability to clear the bacteria. It was shown that 
these protective B. pertussis-specific T-cells induced by infection were CD4+ T-
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cells, which secreted IFN-y and IL-2, but not IL-4 or IL-5; a characteristic Thl 
response.
The use o f animal models has also played an important role in the 
elucidation o f the protective mechanisms induced following vaccination with Pa or 
Pw, and in the evaluation o f pertussis vaccine efficacy prior to clinical trials. As well 
as being an important tool for vaccine efficacy evaluation, animal models can be 
effectively used in the quality control o f pertussis vaccines, to ensure there is 
minimum variation in protective efficacy between different batches o f vaccines. The 
traditional animal model used for testing the potency o f Pw was the mouse 
protection assay devised by Kendrick (1947). This test, while sufficient for the 
evaluation o f Pw, was not suitable for assessing the efficacy o f Pa. New generation 
Pa, despite having relatively high efficacy in clinical trials, do not pass the original 
Kendrick test (Corbel & Xing, 1997). Furthermore, because the bacteria is 
delivered intracerebrally, the Kendrick test is o f little use in the investigation o f 
pathology, or protective mechanisms in acquired immunity to B. pertussis. The 
aerosol challenge model developed by Sato et al. (1980), has been important in 
dissecting the mechanisms o f protection against B. pertussis (Mills et al., 1998a, 
Mills et al., 1998b, Mahon et al., 1996, Mahon et al., 1997, Barbie et al., 1997, 
Redhead et al., 1993, Barnard et al., 1996, McGuirk et al., 1998).
In this study the murine respiratory challenge model was employed in an 
attempt to validate the model for predicting vaccine efficacy and to examine the role 
o f antibody and T-cell subtypes in protection. These studies were made possible by 
access to Pa and Pw vaccines that had been tested in the National Institute o f 
Allergy and Infectious Disease-sponsored phase 3 clinical trials in Italy (Greco et 
al., 1996), Sweden (Gustafsson et al., 1996) and Senegal (Simondon et al., 1997), 
and five vaccines tested in a WHO collaborative study on the mouse model, 
together with different clinical lots o f Pa manufactured by Chiron Corporation (CB 
Pa3(a), CB Pa3 (b)), and different formulations o f the Pasteur Merieux 2- 
component vaccine (PM 94, PM 181).
In previous studies comparing the protective efficacy o f individual antigens 
o f B. pertussis in mice, PT and PRN alone were found to be the most protective 
antigens, but also demonstrated increasing protection with two, three or five
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component vaccines (Mills et ah, 1998a). Results from clinical trials have also 
demonstrated that increasing the number o f antigens increased vaccine efficacy 
(Olin et ah, 1997, Gustafsson et al., 1996). However, examination o f the 
protective efficacy o f the different Pa from the WHO study showed that increasing 
the number o f antigens in the vaccines did not appear to have a significant effect on 
their protective ability. The 3-component SmithKline Beecham vaccine provided a 
very similar degree o f protection to the 2-component vaccine in the mouse model. 
In contrast, when evaluated in clinical trials, the SmithKline vaccine that included 
PRN was more protective than a 2-component vaccine with PT and FHA alone 
(Greco et ah, 1996, Gustafsson et ah, 1996). Similarly, the 5-component 
Connaught Pa did not appear to be significantly more protective in the mouse model 
than 2- or 3-component vaccines, although studies in children have found 5- 
component Pa to be more efficacious than Pa with lesser numbers o f antigenic 
components (Olin et ah, 1997, Gustafsson et ah, 1996). However, the vaccines 
evaluated in this study all provided a high degree o f protection when estimated in 
clinical trials, and similarly, we have shown that these vaccines provided a 
significant degree o f protection in the mouse model. Furthermore, the cytokine 
profile induced after immunization with the different Pa in this study is typical o f a 
Th2 response, and this is in agreement with previous studies which showed that 
immunization with Pa results in the generation o f T-cells that secrete Th2 cytokines 
(Barnard et ah, 1996, Mahon et ah, 1996). Similarly, Pw-immunized mice 
displayed a polarized Thl response, in agreement with previous observations 
(Redhead et ah, 1993)
Evaluation o f the antibody responses to the putative protective antigens o f 
B. pertussis in immunized mice revealed that there was no correlation between the 
antibody titres generated to the component antigens in the vaccines, and estimated 
vaccine efficacy in children. This observation was consistent in all experiments. 
Highly efficacious Pw induced low levels o f pertussis-specific antibody, and high 
antibody titres were induced by the Pa, even those o f low efficacy. These results 
are congruous with the findings from clinical trials, which have failed to 
demonstrate an immunological correlate o f  protection in children based on antibody 
responses against the putative protective antigens o f B. pertussis (Greco et ah,
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1996, Simondon et al., 1997, Gustafsson et al., 1996, Olin et al., 1997). These 
results, together with the demonstration o f a highly significant correlation between 
bacterial clearance in immunized mice, and vaccine efficacy in children (Mills et al., 
1998a, Mills et al., 1998b), suggests that the murine respiratory challenge model is 
a valuable animal model for the regulation and future development o f pertussis 
vaccines, and also for the elucidation o f protective mechanisms against B. pertussis.
The 3-component Pa manufactured by Chiron Corporation contains a 
genetically detoxified pertussis toxin (Rappuoli, 1996, Pizza et al., 1989, Rappuoli, 
1997), while the pertussis toxin present in all other vaccines is chemically 
inactivated. The genetically detoxified pertussis toxin retains conformational 
epitopes which are destroyed by chemical treatment, therefore the mutant toxin is 
more effective at generating anti-PT neutralizing antibodies than chemically treated 
toxins (Rappuoli, 1997). Furthermore, a lower dose o f the mutant PT is present in 
the final vaccine formulation which has been shown to confer effective protection in 
clinical trials (Greco et al., 1996). Analysis o f antibody responses to different 
clinical lots o f this vaccine in this study showed that immunization with CB Pa3 
induced high antibody titres to the genetically detoxified PT, which were 
comparable to those induced with other Pa, even though the concentration of rPT 
was lower (5pg versus 25pg) in this vaccine. This is in agreement with previous 
findings suggesting that recombinant PT induces more potent antibody responses 
relative to antigen content (Rappuoli, 1997).
The numbers o f vaccines included in childhood vaccination programs are 
increasing, and consequently there is much interest in increasing the number of 
vaccines administered in the same injection. However, an important consideration 
is the effect that one vaccine might have on the immune responses generated by 
other vaccines when delivered simultaneously. For example PT (Ryan et al., 1998) 
and FHA (McGuirk and Mills, 2000) have been shown to possess 
immunomodulatory properties, and it is likely that these components o f current Pa 
may effect the response to co injected antigens in a combined vaccine formulation. 
Immunization with different clinical lots o f Pasteur Merieux 2-component Pa 
combined with Hib, was associated with a slight delay in bacterial elimination and 
occasional rebound in bacterial load. This is consistent with previous studies which
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demonstrated that immunization with Pa results in protracted clearance o f  the 
bacteria from the lungs when compared with Pw (Mills et al., 1998a, Mahon et al.,
1996). The protective efficacy o f this 2-component Pa without the addition o f  Hib 
in the formulation, was previously evaluated in mice (Mills et al., 1998a). 
Compared to this evaluation in the mouse model, formulation with Hib does not 
appear to effect the efficacy o f the Pa. Therefore, the slightly impaired bacterial 
clearance in these mice is unlikely to be due to the inclusion o f Hib in the 
formulation, and is probably a result o f the lack o f induction a Thl response, which 
has been shown to confer optimal immunity to B. pertussis (Mahon et al., 1996, 
Mills et al., 1993, Redhead et al., 1993). Different formulations o f the 2- 
component PM Pa (PM 94, PM 181) did not have any obvious effect on the 
induction o f antigen-specific antibody. However, this is not surprising as both 
vaccines have the same antigenic composition and inactivation procedures. 
Furthermore, previous studies have shown that there was no difference in the level 
o f T-cell activation post-challenge, in mice immunized with either PM 94 or PM 
181 (Ryan, 2000).
The majority o f the studies on the mechanisms o f protective immunity 
against B. pertussis in both mice and humans have focused on the evaluation o f 
immune responses early after immunization. However, the principle o f effective 
vaccination in long term protection is dependent on the induction o f immunological 
memory, maintained by antigen-specific B- and T-cells (Zinkemagal et al., 1996). 
Protective levels o f circulating antibody have been identified for certain pathogens, 
such as poliovirus, diphtheria, tetanus and Haemophilis influenzae. However, 
levels o f circulating antibody that are critical for protection against B. pertussis have 
to date remained impossible to define both in children and in mice (Storsaeter et al., 
1998, Cherry et al., 1998, Taranger et al., 2000, Mills et al., 1998a, Mills et al., 
1998b). Furthermore, it has been shown that B. pertussis-specific IgG levels in 
children wane to low or undetectable levels soon after immunization with Pa 
(Giuliano et al., 1998, Storsaeter et al., 1998). The effector mechanisms that 
maintain long term protection are most likely different from those controlling 
infection at the peak o f the immune response. Anamnestic antibody production 
after exposure to the pathogen is considered to be an important characteristic o f
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immunological memory, which provides the host with the first line o f defence 
against reinfection. It has been suggested that long-lived antibody-secreting plasma 
cells play a role in the maintenance o f persistent antibody responses (McHeyzer- 
Williams & Ahmed, 1999, Sliika & Ahmed, 1998). Whether, the decline in serum 
antibody responses observed in children occurs as a result o f premature apoptosis o f 
plasma cells following immunization with Pa remains to be elucidated. 
Nevertheless, these children still appear to be protected against B. pertussis despite 
the decline o f specific antibody (Storsaeter et al., 1998). So, what are the 
mechanisms mediating protection? This study attempted to answer this question.
In this study, levels o f anti-pertussis antibodies were measured following 
immunization o f mice with low doses o f  Pw or a 3-component Pa. Serum 
antibodies to PT, FHA and PRN peaked 5-6 weeks after primary immunization, and 
in concordance with observations in immunized children, declined rapidly and 
reached undetectable levels after 6-9 months. Despite the decline in specific serum 
antibody responses, significant levels o f protection were still observed following 
bacterial challenge. When Pw-immunized mice were challenged by aerosol 
inoculation at 38 weeks post-immunization, the bacterial clearance curves were not 
significantly different to that observed at the peak o f the immune response, 6 weeks 
after immunization. Persistent protection was also observed in mice immunized 
with Pa, although the course o f infection was slightly more protracted. However, 
immunization with Pa has previously been associated with a delay in bacterial 
clearance, when compared with Pw-immunized mice (Mills et al., 1998a, Mahon et 
al., 1996), and it is has been speculated that this eifect is due to the lack o f 
induction o f Thl cells, known to play a critical role in protection (Mills et al., 1993, 
Redhead et al., 1993).
In contrast to serum antibody levels, T-cell responses were detectable using 
in vitro stimulated spleen cells for prolonged periods after immunization. As had 
been previously reported there is a clear dichotomy in the nature o f the T-cell 
responses induced by either Pa or Pw, which generate Th2 and Thl cells 
respectively. Extensive analysis o f splenic T-cell production o f characteristic Thl 
and Th2 type cytokines show that these patterns o f cytokine secretion persist with 
time, and are detectable up to 46 weeks post-immunization, suggesting that
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memory T-cells may maintain long term immunity. Following bacterial challenge, 
there was a broadening o f the pattern o f cytokine responses in Pa-immunized mice 
from a Th2 response 7 days after challenge to a mixed Thl/Th2 response thereafter. 
This indicates that although the Th phenotypes induced by pertussis immunization 
are stable, they are not immutable or “locked in” , and is consistent with 
observations in immunized children (Ryan et ah, 1997, Ryan et al., 1998).
Despite the inferior long-term protection in Pa-immunized mice, this vaccine 
still afforded a high level o f  protection, and this may reflect the switch from the Th2 
response to a more mixed Thl/Th2 cytokine profile after challenge. In addition to 
the induction o f persistent recall T-cell responses detected by cytokine secretion by 
antigen-stimulated spleen cells in vitro, B. pertussis-specific cytokine-secreting cells 
from the spleens o f immunized mice were also enumerated by ELISPOT. At 3 
months post-immunization, mice immunized with Pa and Pw had memory T-cells 
present in the spleen which secreted both the Thl cytokine (IFN-y) and the Th2 
cytokine (IL-5). However, after 6 months, Pw-immunized mice had significantly 
greater numbers o f IFN-y secreting cells compared to IL-5 producing cells, and 
mice immunized with Pa had high numbers o f IL-5 secreting cells relative to cells 
producing IFN-y. These results correlate well with the T-cell responses detected by 
cytokine ELISA on supernatants o f spleen cells stimulated with antigen in vitro.
Although B. pertussis-specific T-cells persist after immunization and CD4+ 
T-cells are critical to vaccine-mediated immunity to B. pertussis, the long term 
protection observed is not necessarily an exclusively cell mediated phenomenon. In 
addition to the detection o f memory cytokine-producing T-cells, memory B-cells 
specific for B. pertussis were also induced by immunization with Pa and Pw. These 
specific antibody-secreting cells were detected in the bone marrow at 9 months 
post-immunization, and persisted for at least 44 weeks after vaccination in 
peripheral blood and spleen. Taken together the data suggest that memory B- and 
T-cells can mediate persistent vaccine-induced protection against B. pertussis after 
the disappearance o f specific IgG in the serum, and also suggest that cellular 
immunity may contribute to long term protection induced with Pa, as well as Pw.
The selective induction and maintenance o f the Thl response after 
immunization with Pw, together with their superior protection against B. pertussis
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infection, is consistent with previous reports that Thl cells play an important role in 
protective immunity (Redhead et al., 1993). Activation o f cellular mechanisms 
against intracellular B. pertussis (Mahon et al., 1999, Friedman et al., 1992), 
including stimulation o f bacterial uptake and killing by macrophages and PMN, may 
be one mechanism whereby Thl cells mediate their protective function. The Thl 
cytokine IFN-y has particular relevance for the immune protective mechanisms 
against B. pertussis. This cytokine plays a major role in controlling B. pertussis 
infection and in confining the bacteria to the mucosal site (Barbie et al., 1997, 
Mahon et al., 1997). Given the importance o f IFN-y in host resistance to B. 
pertussis, this study examined the contributions o f two cytokines known to be 
involved in the induction o f Thl responses and IFN-y production - IL-12 and IL-18. 
A large body o f evidence has accumulated over recent years to indicate that IL-12 
is one o f the most important cytokines in the differentiation o f naive CD4+ T-cells 
to the Thl subset, and for stimulating the production o f IFN-y (Germann et al.,
1993, Schmitt et al., 1994, Manetti et al., 1993, Abbas et al., 1996, Trinchieri,
1994, Seder el al., 1993). Thl responses are considered most relevant for the 
elimination o f intracellular pathogens, and therefore it may also be assumed that IL- 
12, which favours the development o f  Thl cells would play a role in the resolution 
o f intracellular infections. Indeed, in experimental infections with intracellular 
pathogens such as Leishmania, Toxoplasma and Listeria, attenuation o f the Thl 
response through the elimination o f IL-12 has revealed an obligatory role for this 
cytokine in the production o f IFN-y, and for the establishment o f a Thl-type 
response (Mattner et al., 1996, Gazzinelli et al., 1993, Scharton-Kersten et al., 
1995). Similarly, IL-18, which is also an inducer o f IFN-y has been shown to play a 
role in the development o f protective Thl responses to a variety o f pathogens 
(Sugawara et al., 1999, Bohn et al., 1998, Ohkusu et al., 2000, Mastroeni et al., 
1999).
It has been demonstrated that IL-12 is induced following in vitro stimulation 
with live or heat-inactivated B. pertussis, and the addition o f  IL-12 to a Pa 
preparation enhances its protective efficacy by promoting the induction o f Thl cells 
and IFN-y production (Mahon et al., 1996). However, the exact role o f IL-12 in 
the induction o f immune responses responsible for the resolution o f infection with
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B. pertussis has not yet been clearly defined, and to date there is no evidence to 
suggest protection against B. pertussis involves the IFN-y-inducing cytokine IL-18. 
In this study, it has been shown that addition o f neutralizing IL-12 antibody to 
culture o f spleen cells stimulated with B. pertussis completely inhibits B. pertussis- 
induced IFN-y production. However, a similar finding was not observed with the 
addition o f a neutralizing IL-18 antibody. This preliminary evidence demonstrated 
that B. pertussis-specific IFN-y is induced via an IL-12 dependent mechanism, at 
least in vitro.
In certain systems, deficiency in IL-12 function leads to a shift from the 
normally observed Thl response, to a more polarized Th2 response (Seder et al., 
1993). Given this and the fact that anti-IL-12 has the ability to block B. pertussis- 
induced IFN-y production in vitro, we examined the role o f  IL-12 in B. pertussis 
infection in vivo, in an attempt to determine whether a lack o f endogenous IL-12 
would lead to impaired IFN-y production and hence defective Thl responses. 
During primary infection IL-12 deficient (IL-12' ') mice displayed a significant 
reduction in antigen-specific IFN-y production compared to wild-type mice, with a 
concomitant increase in IL-5 levels. Although IL-12'7' mice displayed a shift 
towards a more mixed Thl/Th2 cytokine profile, compared to the characteristic 
Thl response normally seen during infection o f wild-type mice, a complete switch 
from a Thl to a Th2 response was not observed. Lack o f IL-12 in this system 
effected the clearance o f the bacteria from the lungs, only very early in infection, 
indicating that IL-12 probably plays an important role during the induction phase o f 
the immune response. Later in infection, IL-12'7' mice maintained the ability to clear 
the bacteria from the lungs with the same efficiency as the wild-type mice. 
Furthermore, in contrast to observations in IFN-y R"7' mice, mice lacking IL-12 did 
not develop a disseminated infection, and blood and livers o f these mice remained 
free o f viable bacteria throughout the course o f infection. Aerosol challenge o f IL- 
12'7' and wild-type mice immunized with Pa or Pw demonstrated that lack o f 
functional IL-12 did not effect protection against B. pertussis infection. Although 
IFN-y production was significantly reduced in Pw-immunized IL-12'7' mice 
compared to wild-type mice, both knockout and control mice had antigen-specific
127
Thl responses and displayed similar ability to clear the bacteria from the lungs. Pa- 
immunized knockout mice showed enhanced production o f the Th2 cytokine IL-5, 
and these mice eliminated viable bacteria from the lungs, with the same efficiency as 
wild-type mice. Th2 responses have also been shown to be protective against 
respiratory challenge with B. pertussis (Mills et al., 1998a). Furthermore, the 
results o f this and other studies suggest that protection induced by Pa does not 
appear to be mediated by an IL-12-dependent mechanism (Mahon et al., 1996). 
However, the observation that knockout mice immunized with the Thl-inducing Pw 
display undiminished anti-bacterial resistance is surprising, particularly in relation to 
the critical role attributed to IL-12 in the induction o f IFN-y and Thl responses. 
The results suggest that in this system, CD4+ T-cells have the ability, although 
impaired, to develop into Thl cells and protect against challenge inlection, despite 
the lack o f IL-12.
In another series o f experiments the role o f IL-12 in clearance o f a 
secondary infection was examined. IL-12' ' and wild-type BALB/c mice were 
infected with B. pertussis and were allowed to recover from infection. 10 weeks 
after the initial challenge, both groups o f mice were rechallenged with B. pertussis, 
and then analyzed for cytokine production and their ability to clear the bacteria. 
Surprisingly, the IL-12 knockout group cleared the challenge infection at the same 
rate as wild-type mice. Although bacterial clearance was slightly delayed in the 
knockout mice, the numbers o f viable bacteria in the lungs were not significantly 
different to those in wild-type mice. Cytokine responses were evaluated on the day 
o f challenge and two weeks post-challenge. IL-12"7' mice and wild-type mice 
displayed a mixed Thl/Th2 cytokine profile on the day o f challenge and 2 weeks 
post-challenge, with responding T-cells producing both IFN-y and IL-5. However, 
knockout mice produced significantly lower levels o f IFN-y compared to BALB/c 
at these timepoints. This may account for the slight delay in bacterial clearance 
from the lungs o f knockout mice.
The results o f this study show that IL-12 does not have a significant effect 
on the protective mechanisms involved in the clearance o f a primary infection with 
B. pertussis, or in the resolution o f infection in mice primed by immunization or 
infection. This suggests that there is some degree o f redundancy for the induction
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o f Thl responsiveness, and alternative factors may function in the absence o f IL-12. 
Therefore, the production o f IL-18 by macrophages in response to B. pertussis was 
examined to assess if this cytokine played a role in IFN-y induction in this system. 
The results showed that IL-18 is rapidly produced by splenic macrophages when 
infected with pertussis. Furthermore, this cytokine rapidly produced in the lungs o f 
both BALB/c and IL-12’ ' mice following respiratory challenge. High levels o f IL- 
18 were detected in both groups o f mice 4hrs post-challenge, and these levels 
remained elevated throughout the course o f infection, up to 70 days after challenge. 
It is interesting to note that IL-18 production in the lungs o f  IL-12“7’ mice is slightly 
elevated at day 7 post-challenge when compared with wild-type mice. At day 7, the 
numbers o f viable bacteria in the lungs o f these mice are significantly higher than 
those o f wild-type mice, suggesting that in the absence o f  IL-12, IL-18 may be 
recruited for the induction o f IFN-y and the subsequent elimination o f the bacteria 
from the lungs. Studies in other systems have also suggested a redundancy for IL- 
12 in IFN-y production, and have speculated that IL-18 may act as an alternative 
sensitizing pathway in vivo (Schijns et al., 1998, Piccotti et al., 1998). Similarly, it 
appears that IL-12 is not a critical requirement for the differentiation o f naïve T- 
cells towards a polarized Thl phenotype during B. pertussis infection, and in this 
system, IL-12, although induced by the bacterium, is dispensable for the resolution 
o f challenge infection. This suggests that an alternative IFN-y inducing pathway 
occurs in vivo in the absence o f IL-12, and may be mediated by IL-18.
Further evidence for the importance o f IFN-y and Thl cells in immunity to 
B. pertussis, has been highlighted in this study through the investigation o f the 
effect o f helminth infection o f the outcome o f  infection with B. pertussis or 
immunization with Pw. Access to mouse models o f  infection with F. hepatica and 
B. pertussis, which induce Th2 and Thl responses respectively, provided an ideal 
system to examine the concept o f Thl/Th2 cross-regulation in vivo. The helminth 
parasite Fasciola hepatica has been shown to induce a potent polarized Th2 
response in this and other studies (O’Neill et al., 2000). As previously discussed, 
recovery from natural infection with B. pertussis or immunization with Pw 
selectively induces Thl cells (Mills et al., 1993, Redhead et al., 1993, Ryan et al.,
1997). Due to the prevalent occurrence o f polyparasitosis or multiple infections,
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particularly in developing countries, there has been an increased interest in the effect 
that one infection may have on another. It is well accepted that Thl and Th2 cells 
have the ability to cross-regulate each others cytokine secretion and development in 
vitro. However, whether this crossregulation occurs between these two subsets of 
cells in vivo is less clearly defined. Although circumstantial evidence exists in 
favour of the latter, studies on the reciprocal regulation o f Th subsets during 
infection in vivo have been rare both in humans and in animal models.
To examine the effect o f F. hepática infection on the immune response 
induced by infection with B. pertussis, mice were coinfected with both pathogens 
on the same day, and the course o f infection was examined. Infection with F. 
hepática resulted in delayed clearance o f B. pertussis lfom the lungs o f coinfected 
mice, and numbers o f viable bacteria were significantly higher in mice infected with 
both parasite and bacteria. Examination o f cytokine responses in these mice 
demonstrated that B-pertussis-specific IFN-y production was almost completely 
abrogated in coinfected mice compared to mice infected with B. pertussis only. 
Given the importance o f IFN-y in the resolution o f B. pertussis infection, the 
delayed bacterial clearance observed in these mice is almost certainly due to the 
downregulation o f  the protective Thl response normally seen during infection. F. 
hepática infection also has the ability to downregulate the protective Thl response 
to B. pertussis after it has already become established. Mice infected with B. 
pertussis and allowed to recover form infection, and develop a Thl response. They 
were then infected with F. hepática. Infection with F. hepática was also shown to 
significantly inhibit pertussis-specific IL-2 and IFN-y production in these mice, 
indicating that the parasite has the ability not only to impair the bacterial-specific 
Thl response at the induction phase, but can also debilitate this protective response 
after it has become established. Similarly, infection with F. hepática was capable of 
downregulating the Thl response induced by systemic immunization with Pw, and 
reducing its protective efficacy.
In IL-4 knockout mice the modulatory effect o f F. hepática infection on B. 
pertussis-specific IFN-y production is abrogated, suggesting that IL-4 plays a major 
role in Thl suppression and exacerbation o f B. pertussis infection. These findings 
suggest that the suppression o f anti-bacterial immunity during F. hepática infection
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is a result o f bystander downregulation of B. pertussis-specific Thl cells by the 
parasite-specific Th2 cells. F. hepatica has also been shown to induced the 
production o f IL-10 in vivo (O’Neill et al., 2000). This cytokine has been 
implicated in downregulation o f cell-mediated immunity in response to S. mansoni 
(Sher et al., 1991), and it is possible that IL-10 may act with IL-4 in this system in 
the suppression o f B. pertussis-specific cytokine production, and Th2 
immunomodulation. It is important to note that B. pertussis infection, or 
immunization with Pw had no effect on parasite-specific cytokine responses, or on 
the severity o f fasciolosis determined by liver pathology. This indicates that at least 
in this model system Th2 responses have a dominant effect in Thl/Th2 
crossregulation in vivo. However, protective immunity was not completely 
abrogated in mice infected with F. hepatica, and this can be explained that a mixed 
Thl/Th2 or a Th2 response may also confer protection against B. pertussis infection 
by a distinct but less effective mechanism, such as that shown by immunization with 
Pa (Mills et al., 1998a).
Parasitic infections have frequently been associated with the preturbation o f 
cell-mediated immunity and Thl responses (Kullberg el al., 1992, Pearce et al., 
1991, O’Neill et al., 200 0). This immunosuppression may be mediated by 
cytokines, but immunoevasion strategies that downregulate host cell-mediated 
immunity and prolong parasite survival may also play a role. Molecules contained 
in the excretory-secretory products o f F. hepatica, such as cysteine proteinases 
have been shown to cleave IgG at or near the hinge region, and to prevent the 
antibody-mediated attachment o f immune effector cells to the parasite (Smith et al., 
1993, Carmona et al., 1993). However, whether the excretory-secretory products 
o f F. hepatica play an additional role to IL-4 in the suppression o f Thl responses to 
B. pertussis remains to be defined. Nevertheless, the observation o f 
immunomodulation o f protective type 1 responses during infection with Th2- 
inducing parasites has important implications for the outcome o f concurrent 
infections and immunizations.
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A little learning is a dang'ro us thing; 
Drink deep, or taste not the Pierian spring: 
There shallow draughts intoxicate the brain, 
And drinking largely sobers us again
- A l e x a n d e r  Pope

